Multifunctional metallo-prodrugs

WO2026236547A1PCT designated stage Publication Date: 2026-11-12BOARD OF RGT THE UNIV OF TEXAS SYST +3
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027175
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-07
Publication Date
2026-11-12

Smart Images

  • Figure US2026027175_12112026_PF_FP_ABST
    Figure US2026027175_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure relates to compounds and methods for treating cancer, the methods comprising administering a compound of the disclosure to the subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Attorney Docket No: 206161-0078-00WO MULTIFUNCTIONAL METALLO-PRODRUGS

[0002] CROSS REFERENCE TO RELATED APPLICATIONS

[0003] The present application claims priority to U. S. Provisional Patent Application No.

[0004] 64 / 019,419, filed March 27, 2026, and U. S. Provisional Patent Application No. 63 / 801,458, filed May 7, 2025, the disclosures of which are incorporated by reference herein in their entireties.

[0005] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0006] This invention was made with government support under Grant no. R01 CA068682 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.

[0007] BACKGROUND

[0008] Cancer chemotherapy remains hampered by the narrow therapeutic index and emerging resistance of platinum-based drugs, as tumors employ enhanced efflux, nucleophile-mediated detoxification, and DNA-repair pathways to evade apoptosis, while patients suffer severe nephrotoxicity, neurotoxicity, and myelosuppression. Current platinum prodrugs release active species unpredictably and lack robust tumor targeting. Separately, metal complexes capable of inducing immunogenic cell death (ICD) have shown promise in reactivating anti-tumor immunity, yet single-agent approaches or simple mixtures of distinct metals face divergent pharmacokinetics, suboptimal intratumoral accumulation, and poor synchronization of multimodal mechanisms. Consequently, existing strategies struggle to co-deliver cytotoxic and immune-stimulating activities at effective ratios within tumors, limiting their ability to overcome resistance and achieve durable responses.

[0009] The rising prevalence of cancer — projected to increase by 47% in the next 20 years — highlights the urgent need for innovative therapies. The financial impact of cancer care is substantial. In the United States, the overall cost of cancer treatment was estimated at $208 billion in 2020, with further increases expected. Systemic toxicity from traditional chemotherapeutics can severely impact patients’ quality of life, leading to adverse effects like nausea and fatigue. The emergence of ICD, as a means to jump-start a cancer-specific immune response, represents a promising shift in cancer therapy. ICD holds the promise of both targeting cancer cells and enhancing immune surveillance.Attorney Docket No: 206161-0078-00WO Accordingly, there is a need for new cancer therapies that mitigate side effects while effectively treating cancer and lowering healthcare costs. The present invention addresses this long-felt but unmet need.

[0010] SUMMARY

[0011] In some embodiments, the present invention provides a multifunctional prodrug comprising a first activatable anticancer agent, a second activatable anticancer agent, and platinum(IV), wherein the first activatable anticancer agent is linked to the second activatable anticancer agent via the platinum(IV).

[0012] In some embodiments, reduction of the platinum(IV) to platinum(II) releases a first active anticancer agent and a second active anticancer agent.

[0013] In some embodiments, the the first activatable anticancer agent comprises a gold(I) complex. In some embodiments, the first activatable anticancer agent comprises a structure of Formula (I):

[0014]

[0015] wherein:

[0016] each instance of R1, R2, and R3is independently selected from the group consisting of hydrogen, deuterium, halogen, Ci-Cio alkyl, Ci-Cio haloalkyl, C2-C10 alkenyl, C2-C10 haloalkenyl, C2-C10 alkynyl, C2-C10 haloalkynyl, C3-C10 cycloalkyl, and combinations thereof;

[0017] n, m, and 0 are all integers from 0 to 5; and

[0018] represents a connection to the rest of the multifunctional prodrug.

[0019] In some embodiments, the the first activatable anticancer agent comprises the structure Formula (III)Attorney Docket No: 206161-0078-00WO

[0020]

[0021] Formula (III),

[0022] wherein:

[0023] "- represents a connection to the rest of the multifunctional prodrug.

[0024] In some embodiments, the first active anticancer agent comprises

[0025]

[0026] In some embodiments, the second activatable anticancer agent comprises:

[0027] a) a carboxylic acid, conjugated to the platinum(IV); or

[0028] b) a primary or secondary alcohol, which may be functionalized into a carbonate, which is conjugated to the platinum(IV); or

[0029] c) a primary or secondary amine, which may be functionalized into a carbonate, which is conjugated to the platinum(IV).

[0030] In some embodiments, the multifunctional prodrug comprises a structure of Formula (IV)Attorney Docket No: 206161-0078-00WO

[0031]

[0032] Formula (IV),

[0033] wherein:

[0034] A" represents a connection to the second activatable anticancer agent, and L1, L2, L3, and L4each represent monoanionic or monodentate ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentate ligand.

[0035] In some embodiments, the second activatable anticancer agent comprises gemcitabine, floxuridine, cytarabine, cladribine, fludarabine, and nelarabine.

[0036] In some embodiments, the second activatable anticancer agent comprises

[0037]

[0038] wherein A' represents a connection to the platinum(IV).

[0039] In some embodiments, the multifunctional prodrug comprises a structure of Formula (V) or Formula (IV)Attorney Docket No: 206161-0078-00WO

[0040]

[0041] Formula (VI),

[0042] wherein:

[0043] L1, L2, L3, and L4each represent monoanionic or monodentate ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentateAttorney Docket No: 206161-0078-00WO ligand.

[0044] In some embodiments, the second activatable anticancer agent comprises the platinum(IV). In some embodiments, the second active anticancer agent comprises cisplatin, carboplatin, or oxaliplatin.

[0045] In some embodiments, the multifunctional prodrug comprises a structure of Formula (VII):

[0046]

[0047] Formula (VII),

[0048] wherein:

[0049] represents hydroxide, halide, cyanide, azide, nitrite, thiocyanate, nitrate, formate, and acetate, or a connection to at least one additional activatable anticancer agent.

[0050] In some embodiments, the multifunctional prodrug is selected from the group consisting of:Attorney Docket No: 206161-0078-00WO

[0051]

[0052] and pharmaceutically acceptable salts and solvates thereof.

[0053] In some embodiments, the present invention provides a method of killing a cancer cell, comprising contacting the cancer cell with the multifunctional prodrug of the present invention.Attorney Docket No: 206161-0078-00WO In some embodiments, the present invention provides a method of: a) inducing immunogenic cell death (ICD) in a subject in need thereof; or b) treating cancer in a subject in need thereof; wherein the method comprises administering to the subject the multifunctional prodrug of the present invention.

[0054] In some embodiments, the present invention provides the multifunctional prodrug of the present invention, for use in a method of: a) killing a cancer cell; b) inducing ICD in a subject in need thereof; or c) treating cancer in a subject in need thereof.

[0055] In some embodiments, the present invention provides a sue of the multifunctional prodrug of the present invention for use, in the manufacture of a medicament for: a) inducing ICD in a subject in need thereof; or b) treating cancer in a subject in need thereof.

[0056] In some embodiments, the present invention provides a pharmaceutical composition comprising the multifunctional prodrug of the present invention and a pharmaceutically acceptable carrier.

[0057] BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 depicts an exemplary schematic of the mode of action of multi-action Pt(IV) prodrugs.

[0059] Figure 2 depicts an exemplary diagram showing a positive ICD effect, characterized by a substantial reduction in new tumor growth following rechallenge.

[0060] Figure 3 depicts the structures of representative Pt(II), Au(I), and Ru(II) complexes that can induce immunogenic cell death (ICD).

[0061] Figure 4 depicts the structures of representative metallo-drugs and the corresponding numbering.

[0062] Figure 5 depicts an exemplary diagram of reduction products after cellular uptake and successful activation. The three standard reduction products obtained by release of the axial position were observed, in addition to degradation of the carbamate bond between gold complex and ethylenediamine, as well as small formation of a ruthenium dimer.

[0063] Figure 6 depicts representative quantitative data on metal content and organelle distribution, demonstrating enhanced uptake and mitochondrial localization.Attorney Docket No: 206161-0078-00WO Figure 7 depicts representative data demonstrating the ability of Compound 5 to induce ICD hallmarks, including extracellular ATP release, HMGB1 secretion, and calreticulin (CRT) exposure, exceeding single metal treatment.

[0064] Figure 8 depicts representative data demonstrating the ability of Compound 5 to suppress CT26 tumor growth in vivo, achieving an 88.6% tumor growth inhibition

[0065] Figure 9 depicts a representative inductively coupled plasma-mass spectrometry (ICP-MS) analysis, which revealed that Compound 5 led to higher tumor accumulation of all three metals and lower off-target distribution than the 1:1:1 mixture.

[0066] Figure 10 comprises Figure 10A through Figure 10C. Figure 10A depicts a general mechanism of action (MOA) of ICD-induced chemotherapeutics. Figure 10B depicts examples of type I and type II metal-based ICD inducers. Figure 10C depicts a schematic illustration of Pt(IV) oxaliplatin intracellular reduction, releasing both axial ligands (LI and L2) and the FDA-approved drug Oxa.

[0067] Figure 11 depicts representative chemical structures of newly synthesized mono, bi- & tri-metallic complexes used in this study.

[0068] Figure 12 depicts synthetic routes to the bi- & tri-metal complexes of this study. Reaction conditions: A) 2-Picoline, 135 °C, overnight (ON); B) 0.3 h, room temperature (r.t); C) pH 6.6, 0.25 h, r.t.; D) acetonitrile (ACN), 1 h, r.t.; E) ACN, 0.16 h, r.t.; F) ACN / DMF, 3 h, r.t.; G) DMSO, 40 °C, O. N.; H) MeOH, 0.16 h, r.t.; J) DMF, 1 h, r.t.; K) MeOH, 0.16 h, r.t. (see Supporting Information for detailed synthesis description).

[0069] Figure 13 depicts representative reduction and stability data showing the half-life of bi- & tri-metallic complexes determined by HPLC.

[0070] Figure 14 depicts a representative illustration of the reduction of complex 5 that is thought to occur in the TME and upon entering a cancer cell. Evidence supporting the presumed reduction of 5 came from studies where the complex was treated with 10 equiv. of ascorbic acid at pH 7 at 37 °C. This resulted in the release of the constituent moieties and several other species.

[0071] Figure 15 depicts ruthenium dimer formation as inferred from an LC-HRMS analysis -Plecstatin-1 dissolved in water or complex 5 reduction mixture after 4 h incubation at 37 °C.

[0072] Figure 16 depicts a representative lipoate reduction assay. HCT-116 cells were incubated with the indicated complexes at 1 pM concentrations for 24 h.

[0073] Figure 17 comprises Figure 17A and Figure 17B. Figure 17A depicts total cellular metal uptake of various complexes and mixtures. Figure 17B depicts organelle metal accumulation of aAttorney Docket No: 206161-0078-00WO 1:1:1 mixture of 1 + Oxa + 2 versus complex 5. The metal levels shown in both A & B were determined by ICP-MS after a 24 h period of incubation of HCT-116 cells at a 1 pM concentration of the indicated complexes. **p < 0.01, ****p < 0.0001 (two-way ANOVA).

[0074] Figure 18 depicts confocal microscopy studies of ROS generation after a 24 h incubation at IC50 concentrations. CM-H2DCFDA dye was used as a general oxidative stress marker.

[0075] Figure 19, comprising Figure 19A through Figure 19D, depicts ICD DAMPs released after 24 h incubation of CT26 cells with IC50 concentrations of the indicated species. Figure 19A depicts extracellular ATP release data. Data were normalized to the untreated control, set to 100%. Figure 19B depicts extracellular HMGB1 release data. Figure 19C depicts data relating to externalized calreticulin (CRT) on the cell membrane of live versus dead CT26 cells. Figure 19D depicts data relating to the early apoptotic phase percentage of CT26 cells as determined from the Annexin-V quadrant Q3. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (one-way ANOVA).

[0076] Figure 20 depicts a representative Annexin-V / PI FACS Analysis. CT26 cells were incubated with the indicated complexes at their respective IC50 concentrations for 24 h.

[0077] Figure 21 depicts a visual comparison of the tumor size. Mice were euthanized on day 16, and tumors were resected.

[0078] Figure 22 comprises Figure 22A through Figure 22D. Figure 22A depicts in vivo tumorinhibition efficacy studies in a CT26 colorectal cancer model involving i.p. injection of the indicated treatments (Created in BioRender; Babu, T., 2025). Figure 22B depicts dosages and percentage of solid tumor growth reduction produced by the test compounds Figure 22C depicts tumor volume changes over time. Figure 22D depicts body weight as a function of time.

[0079] ***p < 0.001, ****p < 0.0001 compared to control.

[0080] Figure 23 depicts in vivo biodistribution profiles of complex 5 (left) and a 1:1:1 combination of 1 + Oxa + 2 (right) in BALB / c mice (n = 5), as monitored by ICP-MS on day 16 post-administration.

[0081] Figure 24 comprises Figure 24A through Figure 24D. Figure 24A depicts an exemplary protocol used for ICD challenge in vivo with blood samples collected on days -7, 0, and 7.

[0082] Figure 24B depicts percent tumor-free mice (n = 5) following challenge (created in BioRender, Babu, T., 2025). Figure 24C depicts total WBC count determined on different days and WBC differential percentage of monocytes (Figure 24D) and lymphocytes (Figure 24E). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.Attorney Docket No: 206161-0078-00WO Figure 25 depicts the chemical structures of compounds used in Example 3.

[0083] Figure 26 depicts a representative synthetic route to Oxali(Gem)(Au(I)) - Gen 2.

[0084] Figure 27 comprises Figure 27A through Figure 27C. Figure 27A depicts Pt(IV)-Au(I) Gen 2 reduction products - Reduction of prodrug incubated for 75 min with 10 equiv. Asc. at pH 7 and 37 °C as monitored via LC-MS. Figure 27B depicts the half-life of Pt(I V)- Au(I) Gen 2 in the presence of excess GSH. Figure 27C depicts the half-life of Pt(IV)-Au(I) Gen 2 in the presence of excess GSH and ascorbic acid.

[0085] Figure 28, comprising Figure 28A and Figure 28B, depicts representative data for a stability study of Pt(IV)-Au(I) Gen 2. Figure 28A depicts an HPLC chromatogram over time. Figure 28B depicts a linear fitting of ln(At / Ao) vs time ( / ) for / 1 / 2 calculation.

[0086] Figure 29 depicts representative dose-response proliferation data of CT26 cells seen upon incubation with monometallic and multimetallic complexes (t = 72 h). Data represent the mean ± SD from 3 independent experiments.

[0087] Figure 30 depicts total cellular metal uptake of various complexes (top) and organelle metal accumulation of a 1:1:1 mixture of oxaliplatin: Au(I)-amine: gemcitabine versus Gen 2 (bottom). **p<0.01 (two-way ANO V A).

[0088] Figure 31 depicts representative HMGB1 release data.

[0089] Figure 32 depicts a representative Ingenuity Pathway Analysis of selected canonical signaling pathways in Gen 2 vs. untreated CT26 cells. Color is based on Z-score, with orange and blue colors indicating upregulated and downregulated pathways, respectively.

[0090] Figure 33 depicts representative extracellular ATP release data.

[0091] Figure 34 depicts representative confocal microscopy studies of CRT translocation after 4 h incubation.

[0092] DETAILED DESCRIPTION

[0093] The present invention is based, in part, on the discovery of synergistic activity between multiple anticancer agents when simultaneously delivered to a cancer cell. Accordingly, in some embodiments, the present invention provides multifunctional prodrugs that release multiple anticancer agents when internalized by a cancer cell. In some embodiments, the multifunctional prodrug comprises a first activatable anticancer agent, a second activatable anticancer agent, and platinum(IV), wherein the first activatable anticancer agent is linked to the second activatable anti cancer agent via the platinum (IV), and reduction of the platinum(IV) to platinum(II) releasesAttorney Docket No: 206161-0078-00WO a first active anticancer agent and a second active anticancer agent. In some embodiments, the first activatable anticancer agent is an immunogenic cell death (ICD) inducer. In some embodiments, the first activatable anticancer agent comprises gold(I). In some embodiments, the second active anticancer agent is a metal-based anticancer agent. In some embodiments, the second active anticancer agent comprises a nucleoside analog.

[0094] In some embodiments, the second activatable anticancer agent comprises the platinum(IV). In some embodiments, the second active anticancer agent comprises oxaliplatin. In some embodiments, the multifunctional prodrug comprises at least one additional activatable anticancer agent. In some embodiments, the at least one additional active anticancer agent is a metal-based anticancer agent. In some embodiments, at least one additional active anticancer agent comprises a nucleoside analog.

[0095] In another embodiment, the present invention provides methods of killing a cancer cell comprising contacting the cancer cell with a multifunctional prodrug of the present invention. In some embodiments, the present invention provides methods of inducing ICD in a subject in need thereof, comprising administering to the subject a multifunctional prodrug of the present invention. In some embodiments, the present invention provides methods of treating cancer in a subject in need thereof, comprising administering to the subject a multifunctional prodrug of the present invention.

[0096] Definitions

[0097] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, exemplary materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used.

[0098] It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0099] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0100] “About” as used herein when referring to a measurable value, such as an amount, aAttorney Docket No: 206161-0078-00WO temporal duration, and the like, is meant to encompass variations of ±20%, ±10%, ±5%, ±1%, or ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.

[0101] A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated, then the animal’s health continues to deteriorate.

[0102] In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.

[0103] A disease or disorder is “alleviated” if the severity of a sign or symptom of the disease or disorder, the frequency with which such a sign or symptom is experienced by a patient, or both, is reduced.

[0104] The terms “patient,” “subject,” or “individual” are used interchangeably herein and refer to any animal, or cells thereof, whether in vitro or in situ, amenable to the methods described herein. In a non-limiting embodiment, the patient, subject, or individual is a human. In another non-limiting embodiment, the patient, subject, or individual is a dog. In another non-limiting embodiment, the patient, subject, or individual is a cat.

[0105] As used herein, the term “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates the administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art, including, but not limited to, intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

[0106] A “therapeutic” treatment is a treatment administered to a subject who exhibits signs or symptoms of pathological disease or disorder, for the purpose of diminishing or eliminating those signs or symptoms.

[0107] As used herein, the term “treatment” or “treating” is defined as the application or administration of a therapeutic agent, i.e., a compound of the invention (alone or in combination with another pharmaceutical agent), to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell from a patient (e.g., for diagnosis or ex vivo applications), who has a disease or disorder contemplated herein, a sign or symptom of a disease or disorderAttorney Docket No: 206161-0078-00WO contemplated herein or the potential to develop a disease or disorder contemplated herein, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect a disease or disorder contemplated herein, the signs or symptoms of a disease or disorder contemplated herein or the potential to develop a disease or disorder contemplated herein. Such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics.

[0108] As used herein, the terms “effective amount,” “pharmaceutically effective amount,” and “therapeutically effective amount” refer to a sufficient amount of an agent to provide the desired biological or physiologic result. That result may be reduction and / or alleviation of a sign, a symptom, or a cause of a disease or disorder, or any other desired alteration of a biological system. An appropriate, effective amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.

[0109] As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing an undesirable biological effect or interacting in a deleterious manner with any of the components of the composition in which it is contained.

[0110] As used herein, the language “pharmaceutically acceptable salt” refers to a salt of the administered compound prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, hexafluorophosphoric, citric, gluconic, benzoic, propionic, butyric, sulfosalicylic, maleic, lauric, malic, fumaric, succinic, tartaric, amsonic, pamoic, p-tolunenesulfonic, and mesylic. Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, camphorsulfonic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, paratoluenesulfonic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic (besylate), stearic, sulfanilic, alginic, galacturonic, and the like. Furthermore, pharmaceutically acceptable salts include, by way of non-limiting example, alkaline earth metal salts (e.g., calcium or magnesium), alkali metal salts (e.g., sodium-dependent or potassium), and ammonium salts.Attorney Docket No: 206161-0078-00WO As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ or portion of the body to another organ or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example, in Remington's Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.

[0111] As used herein, the term “potency” refers to the dose needed to produce half the maximal response (EDso).

[0112] As used herein, the term “efficacy” refers to the maximal effect (Emax) achieved within an assay.

[0113] As used herein, “activity” includes physiological activity, binding affinity, and / or theAttorney Docket No: 206161-0078-00WO enzymatic activity of a molecule.

[0114] As used herein, “associated” refers to coincidence with the development or manifestation of a disease, condition, or phenotype. Association may be due to, but is not limited to, genes responsible for housekeeping functions, those involved in pathways associated with a specific disease, condition, or phenotype, and those that indirectly contribute to the manifestation of a disease, condition, or phenotype.

[0115] As used herein, the term “cancer” refers to any of various types of malignant neoplasms, most of which invade surrounding tissues, may metastasize to several sites, and are likely to recur after attempted removal and to cause death of the patient unless adequately treated. As used herein, neoplasia comprises cancer. Representative cancers include, for example, squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, and renal cell carcinomas, cancer of the bladder, bowel, breast, cervix, colon, esophagus, head, kidney, liver, lung, neck, ovary, pancreas, prostate, and stomach; leukemias, including non-acute and acute leukemias, such as acute myelogenous leukemia, acute lymphocytic leukemia, acute promyelocytic leukemia (APL), acute T-cell lymphoblastic leukemia, T-lineage acute lymphoblastic leukemia (T-ALL), adult T-cell leukemia, basophilic leukemia, eosinophilic leukemia, granulocytic leukemia, hairy cell leukemia, leukopenic leukemia, lymphatic leukemia, lymphoblastic leukemia, lymphocytic leukemia, megakaryocytic leukemia, micromyeloblastic leukemia, monocytic leukemia, neutrophilic leukemia and stem cell leukemia; benign and malignant lymphomas, particularly Burkitt's lymphoma and Non-Hodgkin's lymphoma; benign and malignant melanomas; myeloproliferative diseases; sarcomas, including Ewing's sarcoma, hemangiosarcoma, Kaposi's sarcoma, liposarcoma, myosarcomas, peripheral neuroepithelioma, synovial sarcoma, gliomas, astrocytomas, oligodendrogliomas, ependymomas, gliobastomas, neuroblastomas, ganglioneuromas, gangliogliomas, medulloblastomas, pineal cell tumors, meningiomas, meningeal sarcomas, neurofibromas, and Schwannomas; bowel cancer, breast cancer, prostate cancer, cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, esophageal cancer, pancreatic cancer, stomach cancer, liver cancer, colon cancer, melanoma; carcinosarcoma, Hodgkin's disease, Wilms' tumor and teratocarcinomas, among others, which may be treated by one or more compounds of the present invention.

[0116] As used herein, the term “alkyl,” by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon having the number of carbon atomsAttorney Docket No: 206161-0078-00WO designated (i.e., Ci-6 means one to six carbon atoms) and including straight, branched chain, or cyclic substituent groups. Examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, and cyclopropylmethyl.

[0117] As used herein, the term “substituted alkyl” means alkyl as defined above, substituted by one, two or three substituents selected from the group consisting of halogen, -OH, alkoxy, -NH2, amino, azido, -N(CH3)2, -C(=O)OH, trifluoromethyl, -CN, -C(=O)O(Ci-C4)alkyl, -C(=O)NH2, -SO2NH2, -C(=NH)NH2, and -NO2. Examples of substituted alkyls include, but are not limited to, 2,2-difluoropropyl, 2-carboxy cyclopentyl and 3 -chloropropyl.

[0118] As used herein, the term “heteroalkyl” by itself or in combination with another term means, unless otherwise stated, a stable straight or branched chain alkyl group consisting of the stated number of carbon atoms and one or two heteroatoms selected from the group consisting of O, N, and S, and wherein the nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quatemized. The heteroatom(s) may be placed at any position of the heteroalkyl group, including between the rest of the heteroalkyl group and the fragment to which it is attached, as well as attached to the most distal carbon atom in the heteroalkyl group. Examples include -O-CH2-CH2-CH3, -CH2-CH2-CH2-OH,

[0119] -CH2-CH2-NH-CH3, -CH2-S-CH2-CH3, -CH2-CH2-S(=O)-CH3, and -CH2-CH2-S(=O)2-CH3Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-O-CH3 or

[0120] -CH2-CH2-S-S-CH3.

[0121] As used herein, the term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1 -propoxy, 2-propoxy (isopropoxy), and the higher homologs and isomers.

[0122] As used herein, the term “halo” or “halogen” alone or as part of another substituent means, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.

[0123] As used herein, the term “cycloalkyl” refers to a monocyclic or polycyclic non-aromatic radical, wherein each of the atoms forming the ring (i.e., skeletal atoms) is a carbon atom. In some embodiments, the cycloalkyl group is saturated or partially unsaturated. In another embodiment, the cycloalkyl group is fused with an aromatic ring. Cycloalkyl groups include groups having from 3 to 10 ring atoms. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:Attorney Docket No: 206161-0078-00WO

[0124]

[0125] Monocyclic cycloalkyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Dicyclic cycloalkyls include, but are not limited to, tetrahydronaphthyl, indanyl, and tetrahydropentalene. Polycyclic cycloalkyls include adamantine and norbornane. The term cycloalkyl includes “unsaturated nonaromatic carbocyclyl” or “nonaromatic unsaturated carbocyclyl” groups, both of which refer to a nonaromatic carbocycle as defined herein, which contains at least one carbon double bond or one carbon triple bond.

[0126] As used herein, the term “heterocycloalkyl” or “heterocyclyl” refers to a heteroalicyclic group containing one to four ring heteroatoms, each selected from O, S, and N. In some embodiments, each heterocycloalkyl group has from 4 to 10 atoms in its ring system, with the proviso that the ring of said group does not contain two adjacent O or S atoms. In another embodiment, the heterocycloalkyl group is fused with an aromatic ring. In some embodiments, the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic system may be attached, unless otherwise stated, at any heteroatom or carbon atom that affords a stable structure. A heterocycle may be aromatic or nonaromatic in nature. In some embodiments, the heterocycle is a heteroaryl.

[0127] An example of a 3-membered heterocycloalkyl group includes, and is not limited to, aziridine. Examples of 4-membered heterocycloalkyl groups include, and are not limited to, azetidine and a P-lactam. Examples of 5-membered heterocycloalkyl groups include, and are not limited to, pyrrolidine, oxazolidine, and thiazolidinedione. Examples of 6-membered heterocycloalkyl groups include, and are not limited to, piperidine, morpholine, and piperazine. Other non-limiting examples of heterocycloalkyl groups are:Attorney Docket No: 206161-0078-00WO

[0128]

[0129] Examples of non-aromatic heterocycles include monocyclic groups such as aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, pyrazolidine, imidazoline, dioxolane, sulfolane, 2, 3 -dihydrofuran, 2, 5 -dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydropyridine, 1,4-dihydropyridine, piperazine, morpholine, thiomorpholine, pyran, 2.3-dihydropyran, tetrahydropyran, 1,4-dioxane, 1,3-dioxane, homopiperazine, homopiperidine, 1.3-dioxepane, 4,7-dihydro-l,3-dioxepin, and hexamethyleneoxide.

[0130] As used herein, the term “aromatic” refers to a carbocycle or heterocycle with one or more polyunsaturated rings and having aromatic character, i.e., having (4n + 2) delocalized it (pi) electrons, where n is an integer.

[0131] As used herein, the term “aryl,” employed alone or in combination with other terms, means, unless otherwise stated, a carbocyclic aromatic system containing one or more rings (typically one, two, or three rings), wherein such rings may be attached together in a pendent manner, such as a biphenyl, or may be fused, such as naphthalene. Examples of aryl groups include phenyl, anthracyl, and naphthyl.

[0132] As used herein, the term “aryl-(Ci-C3)alkyl” means a functional group wherein a one- to three-carbon alkylene chain is attached to an aryl group, e.g., -CH₂CH₂-phenyl. In some embodiments, aryl-(Ci-C3)alkyl is aryl-CHz- or aryl-CH(CH3)-. The term “substituted aryl-(Ci-C3)alkyl” means an aryl-(Ci-C3)alkyl functional group in which the aryl group is substituted. Similarly, the term “heteroaryl-(Ci-C3)alkyl” means a functional group wherein a one to three carbon alkylene chain is attached to a heteroaryl group, e.g., -CH₂CH₂-pyridyl. TheAttorney Docket No: 206161-0078-00WO term “substituted heteroaryl-(Ci-C3)alkyl” means a heteroaryl -(Ci-C3)alkyl functional group in which the heteroaryl group is substituted.

[0133] As used herein, the term “heteroaryl” or “heteroaromatic” refers to a heterocycle having aromatic character. A polycyclic heteroaryl may include one or more rings that are partially saturated. Examples include the following moieties:

[0134]

[0135] Examples of heteroaryl groups also include pyridyl, pyrazinyl, pyrimidinyl (particularly 2- and 4-pyrimidinyl), pyridazinyl, thienyl, furyl, pyrrolyl (particularly 2-pyrrolyl), imidazolyl, thiazolyl, oxazolyl, pyrazolyl (particularly 3- and 5-pyrazolyl), isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl.

[0136] Examples of polycyclic heterocycles and heteroaryls include indolyl (particularly 3-, 4-, 5-, 6- and 7-indolyl), indolinyl, quinolyl, tetrahydroquinolyl, isoquinolyl (particularly 1- and 5 -isoquinolyl), 1,2,3,4-tetrahydroisoquinolyl, cinnolinyl, quinoxalinyl (particularly 2- and 5-quinoxalinyl), quinazolinyl, phthalazinyl, 1,8-naphthyridinyl, 1,4-benzodioxanyl, coumarin, dihydrocoumarin, 1,5-naphthyridinyl, benzofuryl (particularly 3-, 4-, 5-, 6- and 7-benzofuryl), 2,3-dihydrobenzofuryl, 1,2-benzisoxazolyl, benzothienyl (particularly 3-, 4-, 5-, 6-, and

[0137] 7-benzothienyl), benzoxazolyl, benzothiazolyl (particularly 2-benzothiazolyl and

[0138] 5-benzothiazolyl), purinyl, benzimidazolyl (particularly 2-benzimidazolyl), benzotriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrrolizidinyl, and quinolizidinyl.

[0139] As used herein, the term “substituted” means that an atom or group of atoms has replaced hydrogen as the substituent attached to another group. The term “substituted” further refers to any level of substitution, namely mono-, di-, tri-, tetra-, or penta-substitution, where such substitution is permitted. The substituents are independently selected, and substitution may be at any chemically accessible position. In some embodiments, the substituents vary in number fromAttorney Docket No: 206161-0078-00WO 1 to 4. In another embodiment, the substituents vary in number from 1 to 3. In yet another embodiment, the substituents vary in number between one and two.

[0140] As used herein, the term “optionally substituted” means that the referenced group may be substituted or unsubstituted. In some embodiments, the referenced group is optionally substituted with zero substituents, i.e., the referenced group is unsubstituted. In another embodiment, the referenced group is optionally substituted with one or more additional group(s) individually and independently selected from groups described herein.

[0141] In some embodiments, the substituents are independently selected from the group consisting of oxo, halogen, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, alkyl (including straight chain, branched and / or unsaturated alkyl), substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, fluoro alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, fluoroalkoxy, -S-alkyl, S(=O)2alkyl, -C(=O)NH[substituted or unsubstituted alkyl, or substituted or unsubstituted phenyl], -C(=O)N[H or alkyl]2, -OC(=O)N[substituted or unsubstituted alkyl]2, -NHC(=O)NH[substituted or unsubstituted alkyl, or substituted or unsubstituted phenyl], -NHC(=O)alkyl, -N[substituted or unsubstituted alkyl]C(=O)[substituted or unsubstituted alkyl], -NHC(=O)[substituted or unsubstituted alkyl], -C(OH)[substituted or unsubstituted alkyl]2, and -C(NH2)[substituted or unsubstituted alkyl]2. In another embodiment, by way of example, an optional substituent is selected from oxo, fluorine, chlorine, bromine, iodine, -CN, -NH2, -OH, -NH(CH3), -N(CH3)2, -CH3, -CH2CH3, -CH(CH3)2, -CF3, -CH2CF3, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCF3, - OCH2CF3, -S(=O)2-CH3, -C(=O)NH2, -C(=O)-NHCH3, -NHC(=O)NHCH3, -C(=O)CH3, -ON(O)2, and -C(=O)OH. In yet one embodiment, the substituents are independently selected from the group consisting of C1-6 alkyl, -OH, C1-6 alkoxy, halo, amino, acetamido, oxo, and nitro. In yet another embodiment, the substituents are independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, acetamido, and nitro. As used herein, where a substituent is an alkyl or alkoxy group, the carbon chain may be branched, straight, or cyclic.

[0142] Ranges: Throughout this disclosure, various aspects of the invention may be presented in ranges. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosedAttorney Docket No: 206161-0078-00WO subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the range's breadth.

[0143] Compounds

[0144] The compounds of the present disclosure may be synthesized using techniques well-known in the art of organic synthesis. The starting materials and intermediates required for the synthesis may be obtained from commercial sources or synthesized according to methods known to those skilled in the art.

[0145] In one aspect, the present disclosure provides novel multifunctional prodrugs. In some embodiments, the multifunctional prodrug comprises a first activatable anticancer agent, a second activatable anticancer agent, and platinum(IV), In some embodiments, the first activatable anticancer agent is linked to the second activatable anticancer agent via the platinum(IV). In some embodiments, reduction of the platinum(IV) to platinum(II) releases a first active anticancer agent and a second active anticancer agent.

[0146] In some embodiments, the first activatable anticancer agent comprises a gold(I) complex. In some embodiments, the first active anticancer drug comprises a gold(I) ICD inducer. In some embodiments, the first activatable anticancer drug comprises a structure of Formula (I):

[0147]

[0148] wherein:

[0149] each instance of R1, R2, and R3is independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C10 alkyl, C1-C10 haloalkyl, C2-C10 alkenyl, C2-C10 haloalkenyl, C2-C10 alkynyl, C2-C10 haloalkynyl, C3-C10 cycloalkyl, and combinations thereof;Attorney Docket No: 206161-0078-00WO wherein n, m, and o are all independently integers from 0 to 5; and wherein A"- represents a connection to the rest of the multifunctional prodrug. In some embodiments, n, m, and o are independently 2 or 3.

[0150] In some embodiments, all instances of R1are 2-propyl. In some embodiments, all instances of R2are 2-propyl. In some embodiments, all instances of R3are methyl. In some embodiments, all instances of R1and R2are 2-propyl. In some embodiments, all instances of R1and R2are propyl and all instances of R3are methyl.

[0151] In some embodiments, the first activatable anticancer agent of Formula (I) comprises a structure of Formula (II):

[0152]

[0153] Formula (II).

[0154] In some embodiments, the anticancer agent of Formula (II) comprises a structure of Formula (III):

[0155]

[0156] Formula (III).

[0157] In some embodiments, the first active anticancer agent comprisesAttorney Docket No: 206161-0078-00WO

[0158]

[0159] In some embodiments, the multifunctional prodrug comprises a structure of Formula (IV):

[0160]

[0161] Formula (IV),

[0162] wherein:

[0163] represents a connection to the second activatable anticancer agent, and

[0164] L1, L2, L3, and L4each represent monodentate or monoanionic ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentate ligand.

[0165] Suitable monodentate and monoanionic ligands include, but are not limited to, alcohols, halides, cyanides, azides, nitrites, thiocyanates, nitrates, carboxylic acids, amines, and combinations thereof.

[0166] Suitable bidentate ligands include, but are not limited to, 1,2-diaminoethane, 1,3-diaminopropane, 1,2-diaminocyclobutane, 1,2-diaminocyclopentane, 1,2-diaminocyclohexane,Attorney Docket No: 206161-0078-00WO oxalic acid, glycolic acid, malonic acid, 3-hydroxypropanoic acid, lactic acid, succinic acid, glutaric acid, and cyclobutene- 1,1 -di carboxylic acid.

[0167] In some embodiments, the second activatable anticancer agent is linked to platinum(IV). In some embodiments, the second activatable anticancer agent comprises:

[0168] a) a carboxylic acid, which may coordinate with the platinum(IV); or b) a primary or secondary alcohol, which may be functionalized into a carbonate, which may coordinate with the platinum(IV); or

[0169] c) a primary or secondary amine, which may be functionalized into a carbonate, which may coordinate with the platinum(IV).

[0170] Suitable classes of anti cancer agent agents include, but are not limited to, alkylating agents, anthracyclines, antifolates, histone deacetylase (HDAC) inhibitors, immunomodulatory agents, metal-based anticancer agents, mTOR inhibitors, podophyllotoxins, retinoids, taxanes, topoisomerase inhibitors, tyrosine kinase inhibitors, vinca alkaloids, and uncategorized anti cancer agents.

[0171] Suitable alkylating agents include, but are not limited to, bendamustine, chlorambucil, dacarbazine, lurbinectedin, melphalan, streptozotocin, trabectedin.

[0172] Suitable anthracyclines include, but are not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.

[0173] Suitable antifolates include, but are not limited to, methotrexate, pemetrexed, pralatrexate, raltitrexed, and trimetrexate.

[0174] Suitable HDAC inhibitors include, but are not limited to, Panobinostat and valproate. Suitable immunomodulatory agents include, but are not limited to, lenalidomide and pomalidomide.

[0175] Suitable mTOR inhibitors include, but are not limited to, everolimus and temsirolimus. Suitable podophyllotoxins include, but are not limited to, etoposide and teniposide. Suitable retinoids include, but are not limited to, alitretinoin, bexarotene, isotretinoin, tamibarotene, and tretinoin.

[0176] Suitable taxanes include, but are not limited to, cabazitaxel, docetaxel, and paclitaxel. Suitable topoisomerase inhibitors include, but are not limited to, irinotecan and topotecan.

[0177] Suitable TKIs include, but are not limited to, afatinib, bosutinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, ruxolitinib, sunitinib, and vandetanib.Attorney Docket No: 206161-0078-00WO Suitable vinca alkaloids include, but are not limited to, vinblastine, vincristine, vindesine, vinflunine, and vinorelbine.

[0178] Other suitable anticancer agents include, but are not limited to, bleomycin, dactinomycin, estramustine, ixabepilone, mitomycin, plicamycin, and vemurafenib.

[0179] In some embodiments, the second activatable anticancer agent is a metal-based anticancer agent. In some embodiments, the metal-based anticancer agent comprises ruthenium. In some embodiments, the metal-based anti cancer agent comprises:

[0180]

[0181] wherein:

[0182] Rxrepresents Ci-Ce alkyl,

[0183] p is an integer from 0 to 6, and

[0184] represents connection to the platinum(IV).

[0185] In some embodiments, the metal-based anticancer agent comprises:

[0186]

[0187] In some embodiments, the second activatable anticancer agent comprises a nucleoside analog. Suitable nucleoside analogs include, but are not limited to, azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, gemcitabine, mercaptopurine, nelarabine, pentostatin, and thioguanine.

[0188] In some embodiments, the multifunctional prodrug of Formula (IV) comprises a structure of Formula (V) or Formula (IV)Attorney Docket No: 206161-0078-00WO

[0189]

[0190] Formula (VI).

[0191] In some embodiments, the second activatable anticancer agent comprises the platinum(IV). In some embodiments, the second active anticancer agent comprises cisplatin,Attorney Docket No: 206161-0078-00WO carboplatin, or oxaliplatin. In some embodiments, the second active anticancer agent is oxaliplatin.

[0192] In some embodiments, the multifunctional prodrug comprises a structure of Formula (VII):

[0193]

[0194] Formula (VII),

[0195] represents hydroxide, halide, cyanide, azide, nitrite, thiocyanate, nitrate, formate, and acetate, or a connection to at least one additional activatable anticancer agent.

[0196] In some embodiments, the multifunctional prodrug comprises at least three activatable anti cancer agents. In some embodiments, the multifunctional prodrug comprises a structure selected from the group consisting of:Attorney Docket No: 206161-0078-00WO

[0197]

[0198] Attorney Docket No: 206161-0078-00WO

[0199]

[0200] and pharmaceutically acceptable salts and solvates thereof.

[0201] In some embodiments, the multifunctional prodrug is selected from the group consisting of:

[0202]

[0203] Attorney Docket No: 206161-0078-00WO

[0204]

[0205] and pharmaceutically acceptable salts and solvates thereof.

[0206] In some embodiments, the compound comprises a first activatable anticancer drug and a second activatable anticancer drug, wherein the first activatable anticancer drug is linked to the second activatable anticancer drug through a linker. In some embodiments, the linker comprises platinum(IV). In some embodiments, the second activatable anticancer drug comprises the linker. In some embodiments, the second activatable anticancer drug comprises a linker comprising platinum(IV).

[0207] The compounds of the invention may possess one or more stereocenters, and each stereocenter may exist independently in either the R or S configuration. In some embodiments, compounds described herein are present in optically active or racemic forms. It is to be understood that the compounds described herein encompass racemic, optically-active, regioisomeric, and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active starting materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. In some embodiments, a mixture of one or more isomers is utilized as the therapeutic compound described herein. In another embodiment, compounds described herein contain one or more chiral centers. TheseAttorney Docket No: 206161-0078-00WO compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis, and / or separation of a mixture of enantiomers and / or diastereomers. Resolution of compounds and isomers thereof is achieved by any means, including, by way of non-limiting example, chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.

[0208] The compounds described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), solvates, amorphous phases, and / or pharmaceutically acceptable salts of compounds having the structure of any compound of the invention, as well as metabolites and active metabolites of these compounds having the same type of activity. Solvates include water, ether (e.g., tetrahydrofuran, methyl tert-butyl ether) or alcohol (e g., ethanol) solvates, acetates, and the like. In some embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water and ethanol. In another embodiment, the compounds described herein exist in unsolvated form.

[0209] In some embodiments, the compounds of the invention may exist as tautomers. All tautomers are included within the scope of the compounds presented herein.

[0210] In some embodiments, sites on, for example, the aromatic ring portion of compounds of the invention are susceptible to various metabolic reactions. Incorporation of appropriate substituents on the aromatic ring structures may reduce, minimize, or eliminate this metabolic pathway. In some embodiments, the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a deuterium, a halogen, or an alkyl group.

[0211] Compounds described herein also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds described herein include and are not limited to2H,3H,nC,13C,14C,36Cl,18F,123I,125I,13N,15N,15O,17O,18O,32P, and35S. In some embodiments, isotopically labeled compounds are useful for drug and / or substrate tissue distribution studies. In another embodiment, substitution with heavier isotopes, such as deuterium, affords greater metabolic stability (for example, an increased in vivo half-life or reduced dosage requirements). In yet another embodiment, substitution with positron-emitting isotopes, such asnC,18F,15O, and13N, is useful in Positron Emission Tomography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds areAttorney Docket No: 206161-0078-00WO prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.

[0212] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.

[0213] The compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein and as described, for example, in Fieser & Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Suppiementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4thEd., (Wiley 1992); Carey & Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green & Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference in their entirety). General methods for the preparation of compounds as described herein are modified by the use of appropriate reagents and conditions for the introduction of the various moieties found in the formula as provided herein.

[0214] Compounds described herein are synthesized using any suitable procedures starting from compounds that are available from commercial sources, or are prepared using procedures described herein.

[0215] In some embodiments, reactive functional groups, such as hydroxyl, amino, imino, thio, or carboxy groups, are protected to avoid their unwanted participation in reactions. Protecting groups are used to block some or all of the reactive moieties, preventing them from participating in chemical reactions until the protective group is removed. In another embodiment, each protective group is removable by a different means. Protecting groups that are cleaved under totally disparate reaction conditions fulfill the requirement of differential removal.

[0216] In some embodiments, protective groups are removed by acid, base, reducing conditions (e g., hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal, and t-butyldimethylsilyl are acid-labile and are used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base-labile. Carboxylic acid and hydroxy reactive moieties are blocked with base labile groups, including, but not limited to, methyl, ethyl, andAttorney Docket No: 206161-0078-00WO acetyl, in the presence of amines that are blocked with acid labile groups, such as t-butyl carbamate, or with carbamates that are both acid and base stable but hydrolytically removable.

[0217] In some embodiments, carboxylic acid and hydroxy-reactive moieties are blocked with hydrolytically removable protective groups, such as benzyl, while amine groups capable of hydrogen bonding with acids are blocked with base-labile groups, such as Fmoc. Carboxylic acid reactive moieties are protected by conversion to simple ester compounds as exemplified herein, which include conversion to alkyl esters, or are blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while co-existing amino groups are blocked with fluoride-labile silyl carbamates.

[0218] Allyl blocking groups are useful in the presence of acid- and base-protecting groups, since the former are stable and can be removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid is deprotected with a palladium-catalyzed reaction in the presence of acid-labile t-butyl carbamate or base-labile acetate amine protecting groups. Yet another form of protecting group is a resin to which a compound or intermediate is attached. As long as the residue is attached to the resin, that functional group is blocked and does not react. Once released from the resin, the functional group is available to react.

[0219] Typically, blocking / protecting groups may be selected from:

[0220]

[0221] Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal, are described in Greene & Wuts, ProtectiveAttorney Docket No: 206161-0078-00WO Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994, which are incorporated herein by reference for such disclosure.

[0222] Methods

[0223] In some embodiments, the present invention provides methods of killing a cancer cell. In some embodiments, the method comprises contacting a cancer cell with a multifunctional prodrug of the present invention. In some embodiments, the multifunctional prodrug is selectively internalized by the cancer cell.

[0224] In some embodiments, the cancer cell is from a cancer selected from the group consisting of bladder cancer, brain tumors, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer, head and neck cancer, leukemia, lung cancer, lymphoma, mesothelioma, neuroblastoma, ovarian cancer, prostate cancer, pancreatic cancer, sarcoma, and uterine cancer.

[0225] In some embodiments, internalization of the multifunctional prodrug concurrently liberates a first active anti cancer agent and a second active anticancer agent. In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent and at least one additional active anticancer agent.

[0226] In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent and an active a metal-based anticancer agent. In some embodiments, the metal-based anticancer agent comprises a ruthenium(II) based anticancer agent. In some embodiments, the ruthenium(II) anticancer agent binds DNA and disrupts the cytoskeleton. In some embodiments, the gold(I) anticancer agent is a thioredoxin reductase inhibitor.

[0227] In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent and an active nucleoside analog. In some embodiments, the nucleoside analog inhibits DNA synthesis.

[0228] In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent, an active a platinum(II) anticancer agent. In some embodiments, the platinum(II) anti cancer agent is a DNA crosslinker.

[0229] In some embodiments, the multifunctional prodrug concurrently liberates three or more active anticancer agents. In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent, an active a platinum(II) anticancer agent, and at leastAttorney Docket No: 206161-0078-00WO one additional active anticancer agent.

[0230] In some embodiments, the at least one additional active anti cancer agent is a metal-based anticancer agent. In some embodiments, the at least one additional active anticancer agent is an active ruthenium(II) anticancer agent. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anticancer agent, an active gold(I) anticancer agent, and an active ruthenium(II) anticancer agent. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anticancer agent that crosslinks DNA, an active gold(I) anti cancer agent that inhibits thioredoxin reductase, and an active ruthenium(II) anticancer agent that binds DNA and disrupts the cytoskeleton.

[0231] In some embodiments, the at least one additional active anticancer agent is an active nucleoside analog. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anti cancer agent, an active gold(I) anti cancer agent, and an active nucleoside analog anticancer agent. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anti cancer agent that crosslinks DNA, an active gold(I) anticancer agent that inhibits thioredoxin reductase, and an active nucleoside analog anticancer agent that inhibits DNA synthesis.

[0232] In some embodiments, the methods of the present invention induce three complementary mechanisms to overcome cisplatin resistance in the cancer cell and drive mitochondrial reactive oxygen species (ROS) generation. In some embodiments, the methods overcome cisplatin resistance in the cancer cell by combining reductive activation of platinum(IV), gold-mediated inhibition of thioredoxin reductase, and ruthenium-induced cytoskeletal disruption to bypass efflux, nucleophile inactivation, and DNA repair mechanisms. In some embodiments, the method overcomes cisplatin resistance by combining reductive activation of platinum(IV), gold-mediated inhibition of thioredoxin reductase, and nucleoside analog-mediated inhibition of DNA synthesis to bypass efflux, nucleophile inactivation, and DNA repair mechanisms.

[0233] In some embodiments, the present invention provides methods comprising administering a multifunctional prodrug of the present invention to a subject. In some embodiments, the subject has a disease or disorder. In some embodiments, the subject has cancer. In some embodiments, the cancer is selected from the group consisting of bladder cancer, brain tumors, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer,Attorney Docket No: 206161-0078-00WO head and neck cancer, leukemia, lung cancer, lymphoma, mast cell tumors, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, prostate cancer, pancreatic cancer, sarcoma, and uterine cancer.

[0234] In some embodiments, the present invention provides methods of inducing ICD in a cancer cell of a subject in need thereof. In some embodiments, the method comprises administering to the subject a multifunctional prodrug of the present invention. In some embodiments, the method triggers ICD via combined Type I / II pathways. In some embodiments, the method promotes immune memory and activation of peripheral leukocytes. In some embodiments, the method induces ATP release, HMGB1 release, and external presentation of calreticulin.

[0235] In some embodiments, the method increases ATP release by at least about 2-fold compared to untreated cancer cells. In some embodiments, the method increases ATP release by at least about 3-fold compared to untreated cancer cells. In some embodiments, the method increases ATP release by at least about 4-fold compared to untreated cancer cells. In some embodiments, the method increases ATP release by at least about 5-fold compared to untreated cancer cells.

[0236] In some embodiments, the method increases ATP release by at least about 2-fold compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 3 -fold compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone.

[0237] In some embodiments, the method increases HMGB1 release by at least about 2-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 3-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 4-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 5-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 6-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 7-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 8-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 9-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 10-fold compared to untreated cancer cells.Attorney Docket No: 206161-0078-00WO In some embodiments, the method increases ATP release by at least about 10% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 20% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 30% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 40% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 50% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 60% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone.

[0238] In some embodiments, the method increases calreticulin display by at least about 2-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 3-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 4-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 5-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 6-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 7-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 8-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 9-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 10-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 11 -fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 12-fold compared to untreated cancer cells. In some embodiments, the method increases calreticulin display by at least about 13-fold compared to untreated cancer cells.

[0239] In some embodiments, the method increases calreticulin display by at least about 50% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases calreticulin display by at least about 60% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, theAttorney Docket No: 206161-0078-00WO method increases calreticulin display by at least about 70% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases calreticulin display by at least about 80% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases calreticulin display by at least about 90% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone.

[0240] In some embodiments, the method induces three complementary mechanisms to overcome cisplatin resistance, drive mitochondrial reactive oxygen species (ROS) generation, and trigger immunogenic cell death.

[0241] In some embodiments, the cancer cell is from a cancer selected from the group consisting of bladder cancer, brain tumors, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer, head and neck cancer, leukemia, lung cancer, lymphoma, mast cell tumors, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, prostate cancer, pancreatic cancer, sarcoma, and uterine cancer.

[0242] In some embodiments, the present invention provides methods of treating cancer in a subject in need thereof. In some embodiments, the method comprises administering to the subject a multifunctional prodrug of the present invention. In some embodiments, the multifunctional prodrug is selectively internalized by cancer cells. In some embodiments, internalization of the multifunctional prodrug by a cancer cell concurrently liberates a first active anticancer agent and a second active anticancer agent. In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent and at least one additional active anticancer agent.

[0243] In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent and an active a metal-based anticancer agent. In some embodiments, the metal-based anticancer agent comprises a ruthenium(II) based anticancer agent. In some embodiments, the ruthenium(II) anticancer agent binds DNA and disrupts the cytoskeleton. In some embodiments, the gold(I) anticancer agent is a thioredoxin reductase inhibitor.

[0244] In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent and an active nucleoside analog. In some embodiments, the nucleoside analog inhibits DNA synthesis.

[0245] In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent, an active a platinum(II) anticancer agent. In some embodiments, theAttorney Docket No: 206161-0078-00WO platinum(II) anticancer agent is a DNA crosslinker.

[0246] In some embodiments, the multifunctional prodrug concurrently liberates three or more active anticancer agents. In some embodiments, the multifunctional prodrug concurrently liberates an active gold(I) anticancer agent, an active a platinum(II) anticancer agent, and at least one additional active anticancer agent.

[0247] In some embodiments, the at least one additional active anticancer agent is a metal-based anticancer agent. In some embodiments, the at least one additional active anticancer agent is an active ruthenium(II) anticancer agent. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anticancer agent, an active gold(I) anticancer agent, and an active ruthenium(II) anticancer agent. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anticancer agent that crosslinks DNA, an active gold(I) anti cancer agent that inhibits thioredoxin reductase, and an active ruthenium(II) anticancer agent that binds DNA and disrupts the cytoskeleton.

[0248] In some embodiments, the at least one additional active anticancer agent is an active nucleoside analog. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anti cancer agent, an active gold(I) anti cancer agent, and an active nucleoside analog anticancer agent. In some embodiments, upon cellular uptake, the multifunctional prodrug concurrently liberates an active platinum(II) anticancer agent that crosslinks DNA, an active gold(I) anticancer agent that inhibits thioredoxin reductase, and an active nucleoside analog anticancer agent that inhibits DNA synthesis.

[0249] In some embodiments, the methods of the present invention induce three complementary mechanisms to overcome cisplatin resistance in the cancer cell and drive mitochondrial reactive oxygen species (ROS) generation. In some embodiments, the methods overcome cisplatin resistance in the cancer cell by combining reductive activation of platinum(IV), gold-mediated inhibition of thioredoxin reductase, and ruthenium-induced cytoskeletal disruption to bypass efflux, nucleophile inactivation, and DNA repair mechanisms. In some embodiments, the method overcomes cisplatin resistance by combining reductive activation of platinum(IV), gold-mediated inhibition of thioredoxin reductase, and nucleoside analog-mediated inhibition of DNA synthesis to bypass efflux, nucleophile inactivation, and DNA repair mechanisms.

[0250] In some embodiments, administering the multifunctional prodrug promotes tumor inhibition, immune memory, and activation of peripheral leukocytes. In some embodiments, theAttorney Docket No: 206161-0078-00WO method triggers ICD and activates immune responses for long-term protection against tumor recurrence and metastasis.

[0251] In some embodiments, the administration of the multifunctional prodrug results in targeted tumor localization. In some embodiments, targeted tumor localization results in greater drug accumulation at the tumor site. In some embodiments, targeted tumor localization minimizes systemic toxicity.

[0252] The methods of the present invention for treating cancer are suitable for a wide range of cancers. In some embodiments, the cancer is selected from the group consisting of bladder cancer, brain tumors, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer, head and neck cancer, leukemia, lung cancer, lymphoma, mast cell tumors, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, prostate cancer, pancreatic cancer, sarcoma, and uterine cancer.

[0253] In some embodiments, the method induces strong immunogenic cell death (ATP release, HMGB1, calreticulin). In some embodiments, the strong immunogenic cell death converts the tumor microenvironment into a “hot” state, improving response rates to subsequent immunotherapies.

[0254] In some embodiments, the method comprises administering a multifunctional prodrug as a single-agent replacement for cisplatin in subjects whose cancer has acquired platinum resistance. Exemplary cancers which may acquire platinum resistance include, but are not limited to, ovarian, lung, bladder, and head-and-neck cancers. In some embodiments, the method overcomes resistance mechanisms, reduces systemic toxicity, and eliminates the need for combination-drug regimens. In some embodiments, the method overcomes cisplatin resistance by combining reductive activation of platinum(IV) with gold-mediated inhibition of thioredoxin reductase and ruthenium-induced cytoskeletal disruption to bypass efflux, nucleophile inactivation, and DNA repair mechanisms that limit the efficacy of normal platinum(II) anticancer agents. In some embodiments, the multifunctional prodrug induces immunogenic cell death and elicits robust ATP release, HMGB1 secretion, and calreticulin display in tumor cells.

[0255] In some embodiments, the method increases ATP release by at least about 2-fold compared to untreated cancer cells. In some embodiments, the method increases ATP release by at least about 3-fold compared to untreated cancer cells. In some embodiments, the method increases ATP release by at least about 4-fold compared to untreated cancer cells. In some embodiments, the method increases ATP release by at least about 5-fold compared to untreatedAttorney Docket No: 206161-0078-00WO cancer cells.

[0256] In some embodiments, the method increases ATP release by at least about 2-fold compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 3 -fold compared to cancer cells of patients treated with only oxaliplatin or gemcitabine.

[0257] In some embodiments, the method increases HMGB1 release by at least about 2-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 3-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 4-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 5-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 6-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 7-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB 1 release by at least about 8-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 9-fold compared to untreated cancer cells. In some embodiments, the method increases HMGB1 release by at least about 10-fold compared to untreated cancer cells.

[0258] In some embodiments, the method increases ATP release by at least about 10% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 20% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 30% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 40% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 50% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone. In some embodiments, the method increases ATP release by at least about 60% compared to cancer cells of patients treated with oxaliplatin or gemcitabine alone.

[0259] In some embodiments, the method enhances tumor selectivity compared with administering the corresponding anticancer agents individually. In some embodiments, the method reduces toxicity compared with administering the corresponding anticancer agents individually.Attorney Docket No: 206161-0078-00WO In some embodiments, the methods inhibit tumor growth. In some embodiments, the methods inhibit tumor growth by at least about 10%. In some embodiments, the methods inhibit tumor growth by at least about 25%. In some embodiments, the methods inhibit tumor growth by at least about 50%. In some embodiments, the methods inhibit tumor growth by at least about 10%. In some embodiments, the methods inhibit tumor growth by at least about 75%. In some embodiments, the methods inhibit tumor growth by at least about 90%. In some embodiments, the methods inhibit tumor growth by about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%.

[0260] In some embodiments, the methods result in reduced off-target metal accumulation compared to a 1:1:1 mixture of individual Pt, Au, and Ru complexes. In some embodiments, the methods reduce gold accumulation in the liver by at least about 10%. In some embodiments, the methods reduce gold accumulation in the liver by at least about 20%. In some embodiments, the methods reduce gold accumulation in the liver by at least about 30%. In some embodiments, the methods reduce gold accumulation in the liver by at least about 40%. In some embodiments, the methods reduce gold accumulation in the liver by at least about 50%. In some embodiments, the methods reduce gold accumulation in the liver by at least about 60%. In some embodiments, the methods reduce gold accumulation in the liver by at least about 70%. In some embodiments, the methods reduce platinum accumulation in the kidneys by at least about 10%. In some embodiments, the methods reduce platinum accumulation in the kidneys by at least about 20%. In some embodiments, the methods reduce platinum accumulation in the kidneys by at least about 30%. In some embodiments, the methods reduce platinum accumulation in the kidneys by at least about 40%. In some embodiments, the methods reduce platinum accumulation in the kidneys by at least about 50%. In some embodiments, the methods reduce platinum accumulation in the kidneys by at least about 60%.

[0261] In some embodiments, methods of the present invention that comprise administering a multifunctional prodrug of the present invention to a subject comprise orally administering the multifunctional prodrug to the subject. In some embodiments, the methods compriseAttorney Docket No: 206161-0078-00WO administering the multifunctional prodrug pre-surgically. In some embodiments, the methods comprise administering the multifunctional prodrug in combination with a checkpoint inhibitor. In some embodiments, the multifunctional prodrug is administered in combination with a checkpoint inhibitor for immunologically cold tumors. Examples of immunologically cold tumors include, but are not limited to, pancreatic cancer and triple-negative breast cancer.

[0262] In some embodiments, the therapy comprises one or more immune checkpoint inhibitors. Immune checkpoint inhibitors are agents that, in a statistically significant manner, block or inhibit the inhibitory pathways of the immune system. Immune checkpoint inhibitors include antibodies or antigen-binding fragments thereof, other binding proteins, biologic therapeutics, and small molecules that bind to and block or inhibit the activity of a target. Examples of immune checkpoint targets for blocking or inhibition include, but are not limited to, CTLA-4, PD-L1, PD-L2, PD-1, BTLA, HVEM, GAL9, LAG3, TIM3, VISTA, KIR, 2B4, CD 160 (also referred to as BY55), CGEN-15049, CHK1 kinase, CHK2 kinase, A2aR, and various B-7 family ligands. Examples of B-7 family ligands include, but are not limited to, B7-1, B7-2, B7-DC, B7H1, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6, and B7-H7. Examples of immune checkpoint inhibitors include, but are not limited to, tremelimumab, anti-OX40, anti-B7-Hl, MEDI4736, MK-3475, nivolumab, CT-011, BY55, AMP224, BMS-936559, MPLDL3280A, MSB0010718C, ipilimumab, pembrolizumab, cemiplimab, spartalizumab, camrelizumab, sintilimab, tislelizumab, toripalimab, AMP-224, AMP-514, atezolizumab, avelumab, durvalumab, KN035, CK-301, AUNP12, CA-170, and BMS-986189.

[0263] Administration, dosages, and formulations

[0264] The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations may be administered to the subject either before or after the onset of a disease or infection. Further, several divided doses may be administered daily or sequentially, or the dose may be continuously infused or given as a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.

[0265] Administration of the compositions of the present invention to a patient or subject, such as a mammal (e.g., human, dog, cat, etc.), may be carried out using known procedures, at dosages and for periods of time effective to treat the disease or infection in the patient. The effective amount of the therapeutic compound necessary to achieve a therapeutic effect may varyAttorney Docket No: 206161-0078-00WO based on factors such as the state of the disease or disorder in the subject; the subject's age, sex, and weight; and the compound's ability to treat the disease in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily. In another example, the dose may be proportionally reduced in response to the exigencies of the therapeutic situation. A non-limiting example of an effective dose range for a therapeutic compound of the invention is from about 1 mg / kg to about 5,000 mg / kg of body weight / per day. One of ordinary skill in the art would be able to assess the relevant factors and determine the effective amount of the therapeutic compound without undue experimentation.

[0266] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular subject, composition, and mode of administration, without generating excessive side effects in the subject.

[0267] In particular, the selected dosage level depends upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the subject being treated, and like factors well, known in the medical arts.

[0268] A medical professional, e.g., a physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start with a dosage of the compound of the invention in the pharmaceutical composition at a level below that required to achieve the desired therapeutic effect, and then increase the dosage over time until the desired effect is achieved.

[0269] In particular embodiments, it is advantageous to formulate the compound in dosage unit form to facilitate administration and ensure uniformity of dosage. “Dosage unit form” as used herein refers to a physically discrete unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect, in association with the required pharmaceutical vehicle. The dosage unit forms of the invention can be selected based upon (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such a therapeutic compound for the treatment of a disease or infection in a patient.Attorney Docket No: 206161-0078-00WO In some embodiments, the compositions of the invention are formulated using one or more pharmaceutically acceptable excipients or carriers. In some embodiments, the pharmaceutical compositions of the invention comprise a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier.

[0270] The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, and suitable mixtures thereof. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. Prevention of microorganism activity may be achieved using various antibacterial and antifungal agents. Exemplary agents include, but are not limited to, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In some embodiments, it is useful to include isotonic agents, for example, sugars, sodium chloride, or polyalcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions can be achieved by including an agent that delays absorption, such as aluminum monostearate or gelatin. In some embodiments, the pharmaceutically acceptable carrier is DMSO, alone or in combination with other carriers.

[0271] The therapeutically effective amount or dose of a compound of the present invention depends on the age, sex, and weight of the subject, the current medical condition of the subject, and the severity of the disease in the subject being treated. The skilled artisan can determine appropriate doses based on these and other factors.

[0272] The dose may be administered as a single dose or in multiple doses, for example, 1 to 4 or more times per day. When multiple doses are used, the amounts of each dose may be the same or different. For example, a dose of 1 mg per day may be administered as two 0.5 mg doses, with about a 12-hour interval between doses.

[0273] Doses of the compound of the invention for administration may be in the range of from about 1 pg to about 10,000 mg, from about 20 pg to about 9,500 mg, from about 40 pg to about 9,000 mg, from about 75 pg to about 8,500 mg, from about 150 pg to about 7,500 mg, from about 200 pg to about 7,000 mg, from about 3050 pg to about 6,000 mg, from about 500 pg to about 5,000 mg, from about 750 pg to about 4,000 mg, from about 1 mg to about 3,000 mg, from about 10 mg to about 2,500 mg, from about 20 mg to about 2,000 mg, from about 25 mg to about 1,500 mg, from about 30 mg to about 1,000 mg, from about 40 mg to about 900 mg, from about 50 mg to about 800 mg, from about 60 mg to about 750 mg, from about 70 mg to about 600 mg,Attorney Docket No: 206161-0078-00WO from about 80 mg to about 500 mg, and any and all whole or partial increments therebetween.

[0274] In some embodiments, the dose of a compound of the invention is from about 1 mg to about 2,500 mg. In some embodiments, a dose of a compound of the invention used in compositions described herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, the dosage of a second compound as described elsewhere herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than about 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg, or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.

[0275] The compounds for use in the method of the invention may be formulated in unit dosage form. The term “unit dosage form” refers to physically discrete units suitable as unitary dosage for patients undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form may be for a single daily dose or one of multiple daily doses (e.g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.

[0276] In some embodiments, the compositions of the invention are administered to the subject from about one to about five times per day or more. In various embodiments, the compositions of the invention are administered to the subject 1-7 times per day, 1-7 times every two days, 1-7 times every 3 days, 1-7 times every week, 1-7 times every two weeks, and 1-7 times per month. It is readily apparent to one skilled in the art that the frequency of administration of the various combination compositions of the invention will vary from individual to individual, depending on many factors, including, but not limited to, age, the disease or disorder to be treated, the severity of the disease or disorder to be treated, gender, overall health, and other factors. Thus, the invention should not be construed as limited to any particular dosing regimen, and the precise dosage and composition to be administered to any subject are determined by the medical professional, taking all other factors about the subject into account.

[0277] In the case wherein the subject’s status does improve, upon the doctor’s discretion, theAttorney Docket No: 206161-0078-00WO administration of the inhibitor of the invention is optionally given continuously; alternatively, the dose of the drug being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0278] Once the subject’s condition improves, a maintenance dose is administered if necessary. Subsequently, the dosage, the frequency of administration, or both may be reduced to a level at which the improved disease is maintained. In some embodiments, a subject may require intermittent treatment on a long-term basis, or upon any recurrence of the disease or disorder.

[0279] Toxicity and therapeutic efficacy of such regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, LDso (the dose lethal to 50% of the population) and EDso (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index, defined as the ratio of LDso to EDso. Data obtained from cell culture assays and animal studies are optionally used to formulate a range of dosages for use in humans or other animals. The dosage of such compounds lies preferably within a range of circulating concentrations that includes the ED50 with minimal toxicity. The dosage optionally varies within this range depending on the dosage form and route of administration.

[0280] In some embodiments, the present invention is directed to a packaged pharmaceutical composition comprising a container that holds a therapeutically effective amount of a compound of the invention, alone or in combination with a second pharmaceutical agent, and instructions for using the compound to treat or prevent a disease or infection in a patient.

[0281] Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring, and / or aromatic substances, and theAttorney Docket No: 206161-0078-00WO like. They may also be combined where desired with other active agents, e.g., other analgesic agents.

[0282] Routes of administration of any of the compositions of the invention include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual, or topical. The compounds for use in the invention may be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intratumoral, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.

[0283] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry powder or aerosolized formulations for inhalation, compositions and formulations for parenteral administration and the like. It should be understood that the formulations and compositions that would be useful in the present invention are not limited to the particular formulations and compositions that are described herein.

[0284] Oral Administration

[0285] For oral administration, suitable forms include tablets, dragees, liquids, drops, suppositories, or capsules, caplets, and gel caps. The compositions formulated for oral use may be prepared according to any method known in the art, and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets. Such excipients include, for example, an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or coated using known techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules, in which the active ingredient is mixed with an inert diluent.

[0286] For oral administration, the compounds of the invention may be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., polyvinylpyrrolidone, hydroxypropyl cellulose orAttorney Docket No: 206161-0078-00WO hydroxypropylmethylcellulose); fillers (e.g., cornstarch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc, or silica); disintegrates (e.g., sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). If desired, the tablets may be coated using suitable methods and coating materials such as OPADRY™ film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY™ OY Type, OYC Type, Organic Enteric OY-P Type, Aqueous Enteric OY-A Type, OY-PM Type and OPADRY™ White, 32K 18400). Liquid preparation for oral administration may be in the form of solutions, syrups, or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose, or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxy benzoates or sorbic acid).

[0287] Granulating techniques are well known in the pharmaceutical art for modifying starting powders or other particulate materials of an active ingredient. The powders are typically mixed with a binder to form larger, permanent, free-flowing agglomerates or granules, referred to as a “granulation.” For example, solvent-using “wet” granulation processes are generally characterized by combining powders with a binder and moistening them with water or an organic solvent under conditions that result in the formation of a wet granulated mass, from which the solvent must then be evaporated.

[0288] Melt granulation involves using materials that are solid or semi-solid at room temperature (i.e., with a relatively low softening or melting point range) to promote granulation of powdered or other materials, essentially in the absence of added water or other liquid solvents. The low-melting solids, when heated to a temperature within the melting point range, liquefy and act as a binder or granulating medium. The liquefied solid spreads itself over the surface of powdered materials with which it is contacted, and on cooling, forms a solid granulated mass in which the initial materials are bound together. The resulting melt granulation may then be fed to a tablet press or encapsulated to prepare the oral dosage form. Melt granulation improves the dissolution rate and bioavailability of an active (i.e., drug) by forming a solid dispersion or solid solution.

[0289] U. S. Patent No. 5,169,645 discloses directly compressible wax-containing granules having improved flow properties. The granules are obtained by admixing waxes in the melt with certain flow-improving additives, followed by cooling and granulation of the admixture. In certain embodiments, only the wax itself melts in the melt combination of the wax(es) andAttorney Docket No: 206161-0078-00WO additives(s), and in other cases, both the wax(es) and the additives(s) melt.

[0290] The present invention also includes a multi-layer tablet comprising a layer providing for the delayed release of one or more compounds of the invention, and a further layer providing for the immediate release of a medication for treatment of G-protein receptor-related diseases or disorders. Using a wax / pH-sensitive polymer mix, a gastric-insoluble composition may be obtained in which the active ingredient is entrapped, ensuring delayed release.

[0291] Parenteral Administration

[0292] For parenteral administration, the compounds of the invention may be formulated for injection or infusion, for example, intravenous, intramuscular, or subcutaneous injection or infusion, or for bolus dosing and / or continuous infusion. Suspensions, solutions, or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing, and / or dispersing agents, may be used.

[0293] Controlled Release Formulations

[0294] In some embodiments, the formulations of the present invention may be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained, delayed, and pulsatile release formulations.

[0295] The term sustained release refers to a drug formulation that provides for the gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a day, a week, or a month or more, and should be a release longer than the same amount of agent administered as a bolus. The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration, and that may, although not necessarily, include a delay of from about 10 minutes up to about 12 hours.

[0296] For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material to provide sustained-release properties. As such, the compounds for use in the method of the invention may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.

[0297] In some embodiments of the invention, the compounds of the invention are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation.

[0298] The term pulsatile release refers to a drug formulation that provides release of the drug inAttorney Docket No: 206161-0078-00WO such a way as to produce pulsed plasma profiles of the drug after drug administration.

[0299] The term immediate release refers to a drug formulation that provides for the drug's release immediately after administration.

[0300] As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.

[0301] As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.

[0302] Those skilled in the art recognize, or are able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents were considered within the scope of this invention and covered by the appended claims. For example, it should be understood that modifications in reaction conditions, including but not limited to reaction times, reaction size / volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing / oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.

[0303] Additional dosage forms of this invention include those described in U. S. Patents Nos.

[0304] 6,340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790. Additional dosage forms of this invention also include dosage forms as described in U. S. Patent Applications Nos.

[0305] 20030147952; 20030104062; 20030104053; 20030044466; 20030039688; and 20020051820. Additional dosage forms of this invention also include those described in PCT Applications Nos. WO 03 / 35041; WO 03 / 35040; WO 03 / 35029; WO 03 / 35177; WO 03 / 35039; WO 02 / 96404; WO 02 / 32416; WO 01 / 97783; WO 01 / 56544; WO 01 / 32217; WO 98 / 55107; WO 98 / 11879; WO 97 / 47285; WO 93 / 18755; and WO 90 / 11757.

[0306] EMBODIMENTS

[0307] Embodiment 1 is a multifunctional prodrug comprising a first activatable anticancer agent, a second activatable anticancer agent, and platinum(IV), wherein the first activatable anti cancer agent is linked to the second activatable anticancer agent anticancer agent via theAttorney Docket No: 206161-0078-00WO platinum (IV).

[0308] Embodiment 2 is the multifunctional prodrug of Embodiment 1, wherein reduction of the platinum(IV) to platinum(II) releases a first active anticancer agent and a second active anticancer agent.

[0309] Embodiment 3 is the multifunctional prodrug of Embodiment 1 or 2, wherein the first activatable anticancer agent comprises a gold(I) complex.

[0310] Embodiment 4 is the multifunctional prodrug of any one of Embodiments 1-3, wherein the first activatable anticancer agent comprises a gold(I) immunogenic cell death (ICD) inducer.

[0311] Embodiment 5 is the multifunctional prodrug of any one of Embodiments 1-4, wherein the first activatable anti cancer agent comprises a structure of Formula (I):

[0312]

[0313] wherein:

[0314] each instance of R1, R2, and R3is independently selected from the group consisting of hydrogen, deuterium, halogen, Ci-Cio alkyl, Ci-Cio haloalkyl, C2-C10 alkenyl, C2-C10 haloalkenyl, C2-C10 alkynyl, C2-C10 haloalkynyl, C3-C10 cycloalkyl, and combinations thereof;

[0315] wherein n, m, and o are all integers from 0 to 5; and

[0316] wherein

[0317]

[0318] represents a connection to the rest of the multifunctional prodrug. Embodiment 6 is the multifunctional prodrug of any one of Embodiments 1-5, wherein the first activatable anticancer agent comprises the structure of Formula (II):Attorney Docket No: 206161-0078-00WO

[0319]

[0320] Formula (II)

[0321] wherein '" represents a connection to the rest of the multifunctional prodrug.

[0322] Embodiment 7 is the multifunctional prodrug of any one of Embodiments 1-6, wherein the first activatable anti cancer comprises the structure Formula (III)

[0323]

[0324] Formula (III)

[0325] wherein

[0326]

[0327] represents a connection to the rest of the multifunctional prodrug.

[0328] Embodiment 8 is the multifunctional prodrug of any one of Embodiments 1-7, wherein the first active anticancer agent comprisesAttorney Docket No: 206161-0078-00WO

[0329]

[0330] Embodiment 9 is the multifunctional prodrug of any one of Embodiments 1-8, wherein the second activatable anticancer agent comprises:

[0331] a) a carboxylic acid, conjugated to the platinum(IV); or

[0332] b) a primary or secondary alcohol, which may be functionalized into a carbonate, which is conjugated to the platinum(IV); or

[0333] c) a primary or secondary amine, which may be functionalized into a carbonate, which is conjugated to the platinum(IV).

[0334] Embodiment 10 is the multifunctional prodrug of any one of Embodiments 1-9, wherein the multifunctional prodrug comprises a structure of Formula (IV)

[0335]

[0336] Formula (IV),

[0337] wherein:

[0338] " represents a connection to the second activatable anticancer agent, andAttorney Docket No: 206161-0078-00WO L1, L2, L3, and L4each represent monoanionic or monodentate ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentate ligand. Embodiment 11 is the multifunctional prodrug of any one of Embodiments 1-10, wherein the second activatable anticancer agent comprises a nucleoside analog.

[0339] Embodiment 12 is the multifunctional prodrug of any one of Embodiments 1-11, wherein the second activatable anticancer agent comprises gemcitabine, floxuridine, cytarabine, cladribine, fludarabine, and nelarabine.

[0340] Embodiment 13 is the multifunctional prodrug of any one of Embodiments 1-12, wherein the second activatable anticancer agent comprises a metal-based anticancer agent.

[0341] Embodiment 14 is the multifunctional prodrug of any one of Embodiments 1-13, wherein the second activatable anticancer agent comprises:

[0342]

[0343] wherein:

[0344] Rxrepresents Ci-Ce alkyl,

[0345] p is an integer from 0 to 6, and

[0346] represents connection to the platinum(IV).

[0347] Embodiment 15 is the multifunctional prodrug of any one of claims 1-14, wherein the second activatable anticancer agent comprises:

[0348]

[0349] wherein A"'- represents a connection to the platinum(IV).

[0350] Embodiment 16 is the multifunctional prodrug of any one of Embodiments 1-15, wherein the second activatable anticancer agent comprises at least one selected form the group consistingAttorney Docket No: 206161-0078-00WO of alkylating agents, anthracyclines, antifolates, histone deacetylase (HDAC) inhibitors, immunomodulatory agents, metal-based anticancer agents, mTOR inhibitors, podophyllotoxins, retinoids, taxanes, topoisomerase inhibitors, tyrosine kinase inhibitors, vinca alkaloids, and uncategorized anticancer agents.

[0351] Embodiment 17 is the multifunctional prodrug of any one of Embodiments 1-16, wherein the second activatable anticancer agent comprises at least one selected from the group consisting of bendamustine, chlorambucil, dacarbazine, lurbinectedin, melphalan, streptozotocin, trabectedin, daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, methotrexate, pemetrexed, pralatrexate, raltitrexed, trimetrexate, Panobinostat, valproate, lenalidomide, pomalidomide, everolimus, temsirolimus, etoposide, teniposide, alitretinoin, bexarotene, isotretinoin, tamibarotene, tretinoin, cabazitaxel, docetaxel, paclitaxel, irinotecan, topotecan, afatinib, bosutinib, crizotinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, ruxolitinib, sunitinib, vandetanib, vinblastine, vincristine, vindesine, vinflunine, vinorelbine, bleomycin, dactinomycin, estramustine, ixabepilone, mitomycin, plicamycin, and vemurafenib.

[0352] Embodiment 18 is the multifunctional prodrug of any one of Embodiments 1-17, wherein the multifunctional prodrug comprises a structure of Formula (V) or Formula (IV)

[0353]

[0354] Attorney Docket No: 206161-0078-00WO

[0355]

[0356] Formula (VI),

[0357] wherein:

[0358] L1, L2, L3, and L4each represent monoanionic or monodentate ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentate ligand.

[0359] Embodiment 19 is the multifunctional prodrug of any one of Embodiments 1-18, wherein the second activatable anticancer agent comprises the platinum(lV).

[0360] Embodiment 20 is the multifunctional prodrug of any one of Embodiments 1-19, wherein the second active anticancer agent comprises cisplatin, carboplatin, or oxaliplatin.

[0361] Embodiment 21 is the multifunctional prodrug of any one of Embodiments 1-20, wherein the multifunctional prodrug comprises a structure of Formula (VII):Attorney Docket No: 206161-0078-00WO

[0362]

[0363] Formula (VII),

[0364] wherein:

[0365] " represents hydroxide, halide, cyanide, azide, nitrite, thiocyanate, nitrate, formate, and acetate, or a connection to at least one additional activatable anticancer agent.

[0366] Embodiment 22 is the multifunctional prodrug of any one of Embodiments 1-21, wherein the multifunctional prodrug is selected from the group consisting of:

[0367]

[0368] Attorney Docket No: 206161-0078-00WO

[0369]

[0370] and pharmaceutically acceptable salts and solvates thereof.

[0371] Embodiment 23 is a method of killing a cancer cell, comprising contacting the cancer cell with the multifunctional prodrug of any one of Embodiments 1-22.

[0372] Embodiment 24 is the method of inducing ICD in a subject in need thereof, comprising administering to the subject the multifunctional prodrug of any one of Embodiments 1-22.

[0373] Embodiment 25 is the method of Embodiment 24, wherein the method increases ATP release of the cancer cell by at least about 3 -fold compared to an untreated cancer cell.

[0374] Embodiment 26 is the method of Embodiment 24 or 25, wherein the method increases ATP release of the cancer cell by at least about 2-fold compared to a cancer cell treated with only oxaliplatin or gemcitabine.

[0375] Embodiment 27 is the method of any one of Embodiments 24-26, wherein the method increases HMGB 1 release of the cancer cell by at least about 9-fold compared to an untreated cancer cell.

[0376] Embodiment 28 is the method of any one of Embodiments 24-27, wherein the method increases HMGB1 release of the cancer cell by at least about 50% compared to a cancer cell treated with only oxaliplatin or gemcitabine.

[0377] Embodiment 29 is the method of any one of Embodiments 24-28, wherein the method increases calreticulin display on the cancer cell by at least about 10-fold compared to anAttorney Docket No: 206161-0078-00WO untreated cancer cell.

[0378] Embodiment 30 is the method of any one of Embodiments 24-29, wherein the method increases calreticulin display on the cancer cell by at least about 80% compared to a cancer cell treated with only oxaliplatin or gemcitabine.

[0379] Embodiment 31 is the method of any one of Embodiments 24-30, wherein the method increases calreticulin display in the cancer cell compared to an untreated cancer cell.

[0380] Embodiment 32 is a method of treating cancer in a subject in need thereof, comprising administering to the subject the multifunctional prodrug of any one of Embodiments 1-22.

[0381] Embodiment 33 is the method of Embodiment 32, wherein the method induces ICD of cancer cells in the subject.

[0382] Embodiment 34 is the method of Embodiment 32 or 33, wherein the method increases ATP release of the cancer cell by at least about 3 -fold compared to an untreated cancer cell.

[0383] Embodiment 35 is the method of any one of Embodiments 32-34, wherein the method increases ATP release of the cancer cell by at least about 2-fold compared to a cancer cell treated with only oxaliplatin or gemcitabine.

[0384] Embodiment 36 is the method of any one of Embodiments 32-35, wherein the method increases HMGB 1 release of the cancer cell by at least about 9-fold compared to an untreated cancer cell.

[0385] Embodiment 37 is the method of any one of Embodiments 32-36, wherein the method increases HMGB1 release of the cancer cell by at least about 50% compared to a cancer cell treated with only oxaliplatin or gemcitabine.

[0386] Embodiment 38 is the method of any one of Embodiments 32-37, wherein the method increases calreticulin display on the cancer cell by at least about 10-fold compared to an untreated cancer cell.

[0387] Embodiment 39 is the method of any one of Embodiments 32-38, wherein the method increases calreticulin display on the cancer cell by at least about 80% compared to a cancer cell treated with only oxaliplatin or gemcitabine.

[0388] Embodiment 40 is the method of any one of Embodiments 32-39, wherein the method increases calreticulin display in the cancer cell compared to an untreated cancer cell.

[0389] Embodiment 41 is the method of any one of Embodiments 32-40, wherein the method comprises administering the multifunctional prodrug to the subject orally.

[0390] Embodiment 42 is the method of any one of Embodiments 32-41, wherein the methodAttorney Docket No: 206161-0078-00WO inhibits tumor growth by at least about 75%.

[0391] Embodiment 43 is the method of any one of Embodiments 32-42, wherein the cancer is at least one selected from the group consisting of bladder cancer, brain tumors, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, gastrointestinal cancer, head and neck cancer, leukemia, lung cancer, lymphoma, mast cell tumors, mesothelioma, neuroblastoma, osteosarcoma, ovarian cancer, prostate cancer, pancreatic cancer, sarcoma, and uterine cancer.

[0392] Embodiment 44 is the method of any one of Embodiments 32-43, wherein the subject was previously administered cisplatin and the cancer has acquired platinum resistance.

[0393] Embodiment 45 is the method of any one of Embodiments 32-44, wherein the cancer is immunologically cold, and wherein the method further comprises administering to the subject at least one checkpoint inhibitor.

[0394] Embodiment 46 is the method of any one of Embodiments 32-45, wherein the subject is a human.

[0395] Embodiment 47 is the method of any one of Embodiments 32-46, wherein the subject is a dog or a cat.

[0396] Embodiment 48 is the method of any one of Embodiments 32-45 and 47, wherein the subject is a dog or a cat, and the cancer is at least one selected from the group consisting of a mast cell tumor, lymphoma, and osteosarcoma.

[0397] Embodiment 49 is the multifunctional prodrug of any one of Embodiments 1-22, for use in a method of killing a cancer cell.

[0398] Embodiment 50 is the multifunctional prodrug of any one of Embodiments 1-22, for use in a method of inducing ICD in a subject in need thereof.

[0399] Embodiment 51 is the multifunctional prodrug of any one of Embodiments 1-22, for use in a method of treating cancer in a subject in need thereof.

[0400] Embodiment 52 is a use of the multifunctional prodrug of any one of Embodiments 1-22, in the manufacture of a medicament for ICD in a subject in need thereof.

[0401] Embodiment 53 is a use of the multifunctional prodrug of any one of Embodiments 1-22, in the manufacture of a medicament for treating cancer in a subject in need thereof.

[0402] Embodiment 54 is a pharmaceutical composition comprising the multifunctional prodrug of any one of Embodiments 1-22 and a pharmaceutically acceptable carrier.

[0403] Embodiment 49 is the pharmaceutical composition of claim 46, wherein the compositionAttorney Docket No: 206161-0078-00WO is formulated for oral administration.

[0404] EXPERIMENTAL EXAMPLES

[0405] The following non-limiting Examples serve to illustrate selected embodiments of the invention. It will be appreciated that variations in proportions and alternatives in elements of the components shown will be apparent to those skilled in the art and are within the scope of embodiments of the present invention.

[0406] Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the present invention and practice the claimed methods. The following working examples, therefore, point out specific embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.

[0407] Example 1: A Multifunctional Metal Prodrug Platform for Targeted, Immune-Driven Cancer Treatment

[0408] Systemic toxicity from traditional chemotherapeutics can severely impact patients’ quality of life, leading to adverse effects like nausea and fatigue. By creating metal complexes that enhance tumor localization, a goal is to target cancer cells more effectively while reducing harm to healthy tissues. This approach not only promises improved outcomes but also aims to address the complexity of current multi-drug regimens that often lead to poor patient compliance.

[0409] The emergence of ICD as a means to jump start a cancer-specific immune response represents a promising shift in cancer therapy. ICD holds the promise of both targeting cancer cells and enhancing immune surveillance. This dual benefit could significantly improve longterm treatment efficacy, especially for advanced or metastatic diseases. These positive effects will be multiplied if ICD is exerted by metal complexes thus overcoming the limitations of conventional chemotherapies.

[0410] The rising prevalence of cancer — projected to increase by 47% in the next 20 years — highlights the urgent need for innovative therapies. This work provides a new generation of cancer treatments that effectively integrate chemotherapy and immunotherapy, reducing reliance on traditional multi-drug approaches and potentially lowering healthcare costs.

[0411] The financial impact of cancer care is substantial. In the United States, the overall cost of cancer treatment was estimated at $208 billion in 2020, with expectations for further increases.Attorney Docket No: 206161-0078-00WO By reducing the reliance on multiple drugs and hospital visits, this approach can alleviate some of the economic burdens.

[0412] The present example provides both broad screening across various cancer types and explorations of mechanism of action, including in vivo studies. These results provide support for the hypothesis that the inventive approach shows promise in targeting and treating effectively a wide range of tumors, including both early-stage and advanced cancers. An expanded focus on multiple cancer types is viewed as necessary in addressing the global cancer burden.

[0413] The present example centers on the development of multifunctional metal-based prodrugs designed to combat cancer through a synergistic combination of chemotherapy and immunotherapy. These prodrugs consist of carefully engineered metal complexes that integrate platinum(IV), gold(I), and ruthenium (II) components, each contributing distinct therapeutic mechanisms. Upon administration, the tri-metallo prodrugs accumulate to tumor cells, where they undergo reductive activation. This process releases an active platinum drug along with gold complexes that inhibit the thioredoxin reductase enzyme, and ruthenium complex that interacts with DNA as well as inhibiting key proteins in the cytoskeleton. This multimodal approach not only enhances cytotoxicity against cancer cells but also stimulates an anti-tumor immune response through ICD.

[0414] Further described is the novel design of multi-targeted prodrugs that unify distinct therapeutic modalities into a single entity. Unlike traditional chemotherapy, which often results in systemic toxicity and poor patient compliance, the proposed prodrugs offer a streamlined treatment approach. The incorporation of ICD-inducing mechanisms sets this solution apart, as fewer than 1% of current cancer therapies are recognized for their immunogenic properties. By effectively bridging the gap between conventional chemotherapy and emerging immunotherapeutic strategies, this approach provides a differentiated solution that could reshape care models, enhance patient adherence, and improve clinical outcomes.

[0415] The scientific foundation of this research is based on the understanding that Pt(IV) complexes that can act as prodrugs with minimal in vivo toxicity, as well as recent reports by Dr. Sessler and myself, that showed that several metal complexes, including platinum and gold, can act as ICD inducers.

[0416] The significance and improvements associated with the proposed approach is predicated on observations and reports that a combination of chemotherapy and immunotherapy showedAttorney Docket No: 206161-0078-00WO better treatment outcomes compared to a single modality in early clinical trials. The problem with co-admini strati on of several drugs is that each has different pharmacokinetic behavior and different toxicities complicating optimization of the therapeutic protocols.

[0417] The inventive design therefore relies on an appreciation that unlike drug cocktails, multitargeted prodrugs have single molecule pharmacokinetics that ensure all components reach the tumor together. Since they are tested as a single entity, they are also free of normal concerns involving drug-drug interactions. This is expected to translate into enhanced activity and safety compared to drug cocktails. Ultimately, this will provide for better patient compliance while facilitating regulatory approvals.

[0418] Investing in the proposed combined single drug strategy will provide a tangible benefit in terms of addressing the rising global cancer burden. Cancer cases projected to increase by 47% in the next two decades. Completely new strategies can help meet the associated therapeutic need. The potential impact of the proposed work is further enhanced because it will allow for the integration of ICD into small molecule-based treatment paradigms: The invention can not only inhibit primary tumors but also promote long-term immune surveillance against metastatic disease.

[0419] Key highlights of the invention include:

[0420] • Enhanced Efficacy - Multimodal action targeting tumor cells reduces drug resistance.

[0421] • Reduced Toxicity - Improved tumor metal accumulation minimizes harm to healthy tissues.

[0422] • ICD Induction - Stimulating an anti-tumor immune response offers long-term protection.

[0423] Market Potential - With nearly 50% of cancer patients receiving platinum-based therapies and coping with recurrent tumors and severe side effects, the demand for improved treatments is substantial.

[0424] Robust preliminary biological data supports the therapeutic potential of the inventive multifunctional metal-based prodrugs. These results include:

[0425] • Demonstrating selective cytotoxicity in vitro across ovarian, lung, and colorectal cancer cell lines.

[0426] • Broad-spectrum generation of Immunogenic Cell Death (ICD) markers, including ATP, HMGB1, and calreticulin release.Attorney Docket No: 206161-0078-00WO • Confirmation of ROS generation and mechanism-specific cellular uptake using confocal microscopy and ICP-MS.

[0427] • Initial in vivo efficacy and safety data in a murine model showing enhanced tumor inhibition and lower systemic toxicity.

[0428] Long-Term ICD Re-challenge Validation

[0429] A long-term immunological memory assessment is conducted using gold-standard in vivo ICD models. Mice are inoculated with cancer cells pre-treated with the lead multifunctional prodrug. After complete tumor rejection, surviving mice will be re-challenged with untreated live tumor cells after a latency period. The ability of the host to reject the second tumor will serve as definitive evidence for immunological memory induction. Tumor-free survival will be monitored, and immune cell profiling (including T-cell subsets and memory markers) will be performed to validate sustained anti-tumor immunity.

[0430] PK / PD studies

[0431] Comprehensive pharmacokinetic and pharmacodynamic profiling was conducted to understand the in vivo behavior of the lead multifunctional metal prodrugs. These studies evaluate circulation times in murine models, while ICP-MS analyses are used to quantify the elemental signatures of the metal complexes in plasma. These data inform dose selection, administration route, and optimal scheduling for efficacy and safety studies, and are critical for future TND-enabling studies.

[0432] Mechanistic Dissection and Biomarker Discovery

[0433] To support precision oncology applications and clinical translation, the molecular mechanisms underlying the therapeutic activity of the inventive multifunctional metal prodrugs are systematically investigated. Using transcriptomic (RNA-seq) and proteomic profiling of treated tumor tissues and immune cell populations, the immune and stress-response pathways activated by the treatment are mapped. Emphasis will be placed on identifying upregulated immunogenic markers, oxidative stress responses, and DNA damage pathways that correlate with therapeutic efficacy. In parallel, biomarker discovery efforts are performed by identifying predictive markers associated with treatment responsiveness across cancer models. These insights enable rational selection of disease indications, inform combination strategies withAttorney Docket No: 206161-0078-00WO existing immunotherapies, and guide early patient stratification strategies for future clinical trials.

[0434] Scale-Up and Optimization

[0435] Synthesis methods are optimized for scalability. Formulation development for clinical applications is also performed.

[0436] Regulatory Preparation

[0437] Documentation for Investigational New Drug (IND) is prepared and a comprehensive safety and efficacy profile is developed.

[0438] Platinum complexes are used in 50% of chemotherapeutic regimens administered in the clinic. While in the cell, cisplatin undergoes hydrolysis, binds to nuclear DNA, and triggers apoptosis. Cisplatin and its similar platinum(II) complexes have severe side effects and tumors can gain resistance through enhanced efflux, inactivation by nucleophiles, or enhanced DNA repair. Example approved Pt(II) anticancer drugs for use in humans include cisplatin, carboplatin, and oxaliplatin.

[0439] Platinum(IV) complexes as prodrugs can overcome the drawbacks of existing platinum complexes. Platinum(IV) complexes are octahedral and kinetically inert and can therefore be administered per-os. Their stability results in diminished side effects and have demonstrated efficacy in cisplatin-resistant cancer cell lines. An exemplary schematic of the mode of action of multi-action Pt(IV) prodrugs is shown in Figure 1.

[0440] Traditionally, chemotherapeutics are assumed to suppress the immune system. However, studies have shown that certain anticancer drugs can actually stimulate tumor-specific immune responses and reinstate immunosurveillance. Several reports helped define in vitro damage associated molecular patterns (DAMPs), and gold standard for testing in-vivo ICD effects. A positive ICD effect is marked by a substantial reduction in new tumor growth following the rechallenge (Figure 2). Metal complexes including platinum(II) & (IV), gold(I), ruthenium(II) and iridium(III) were reported as potential ICD inducers. Currently, a derivative of Oxaliplatin, Pt-112, is under clinical trials for ICD (Figure 3).

[0441] Preliminary Results

[0442] Newly synthesized mono, bis and tri metallo-drugs were successfully prepared and wereAttorney Docket No: 206161-0078-00WO chemically characterized by NMR, HPLC, HR-MS and Elemental analysis. Representative structures and compound numbering are shown in Figure 4.

[0443] A crucial study for the understanding of any biological effect is the release of reduction products after cellular uptake and successful activation. In the case of the triple metallo-prodrug, not only the three standard reduction products obtained by release of the axial position were observed, but also degradation of the carbamate bond between gold complex and ethylenediamine as well as small formation of a ruthenium dimer (Figure 5).

[0444] The half-life time of the compounds were also monitored for reduction and stability and it was found that the compounds can act as prodrugs with higher tl / 2 in cell culture medium and rapid release by reduction in presence of ascorbic acid (Table 1).

[0445] Table 1. Half-life of select compounds for reduction and stability.

[0446]

[0447] The tri-metallic complex (Compound 5) demonstrates potent cytotoxicity across cisplatin-resistant and sensitive cancer cell lines (Table 2).

[0448] Table 2. Cytotoxicity measurements across cisplatin-resistant and sensitive cancer cell lines.

[0449]

[0450] The Au(I)-Pt(IV)-Ru(II) complex (Complex 5) shows significantly higher cellular uptake of all three metals compared to the mixture of individual components, with substantial accumulation in the mitochondria, as indicated in the quantitative metal content and organelle distribution data. This enhanced uptake and mitochondrial localization correlates with the strong oxidative stress signal observed in the imaging data, supporting a synergistic mechanism that promotes redox disruption and cellular damage through higher accumulation (Figure 6).

[0451] Compound 5 induces ICD hallmarks, including extracellular ATP release, HMGB 1Attorney Docket No: 206161-0078-00WO secretion, and calreticulin (CRT) exposure, exceeding single metal treatment. These findings highlight its strong potential as a single-agent ICD inducer, simplifying combination strategies without compromising efficacy (Figure 7).

[0452] Compound 5 significantly suppressed CT26 tumor growth in vivo, achieving an 88.6% tumor growth inhibition — outperforming both doxorubicin and the metal mixture. Importantly, this potent antitumor effect was achieved without significant body weight loss, indicating good systemic tolerability (Figure 8).

[0453] Inductively coupled plasma-mass spectrometry (ICP-MS) analysis revealed that Compound 5 led to higher tumor accumulation of all three metals with lower off-target distribution compared to the 1:1:1 mixture. This selective biodistribution likely contributes to its superior therapeutic efficacy and improved safety profile (Figure 9).

[0454] Example 2: Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death

[0455] ICD is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage-associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. The present example reports the design, synthesis, and evaluation of a tri-metallic AuIPtIV-RuIIprodrug (5) that codelivers oxaliplatin (Type I ICD inducer), RuIIarene 2-pyridinecarbothioamides (Type I), and Au(I) bis-N-heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off-target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1: 1: 1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo-immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal-based multimodal anticancer therapies.

[0456] ICD represents a unique strategy in oncology, converting dying cancer cells into aAttorney Docket No: 206161-0078-00WO vaccine-like stimulus that elicits durable antitumor immunity. During ICD, tumor cells release damage-associated molecular patterns (DAMPs), such as calreticulin (CRT), adenosine triphosphate (ATP), and high mobility group box 1 protein (HMGB1), that promote immune system activation (Figure 10), effectively transforming dying tumor cells into a source of in situ immunization (Kroemer et al., 2022, Nat. Immunol., 23, 487; Zhou et al., 2019, J. Cell. Mol. Med., 23, 4854). In recent years, metal complexes have emerged as potent and versatile ICD inducers, capable of engaging diverse cellular stress pathways while offering chemical modularity and tunable pharmacology (Zhang et al., 2023, Angew. Chem. Int. Ed., 62, e202300662; Zou etal., 2025, Ang. Chem. Sci., 16, 6160).

[0457] CD inducers are broadly categorized into two types. Type I inducers, such as oxaliplatin (Oxa) (Tesniere et al., 2010, Oncogene, 29, 482; Wong et al., 2015, Angew. Chem. Int. Ed., 54, 6483) and reports of potential ICD activity by RuIIarene 2-pyridinecarbothioamides (Wemitznig et al., 2020, Metallomics, 12, 2121) that elicit ICD by targeting non-ER structures, such as DNA or mitochondria, with endoplasmic reticulum (ER) stress arising as a downstream consequence. In contrast, Type II inducers, which include IrIIIN-heterocyclic (Lu et al., 2025, J. Am. Chem. Soc., 147, 15216) (NHC) and Au1complexes (Sen et al., 2020, J. Am. Chem. Soc., 142, 20536) directly engage the ER, typically through the localized production of reactive oxygen species (ROS), to promote immunogenic signaling (Figure 10B). While several gold NHC complexes have been reported to trigger DAMPs release, they may also exert immunosuppressive effects depending on the ligands that are coordinated to the metal center (Cheng et al., 2020, Commun. Biol., 3, 10).

[0458] Chemotherapeutics that can induce ICD are attractive in that they can both inhibit primary tumors and promote a systemic immune response that suppresses distant or metastatic tumors. This outcome can potentially be increased by combining ICD inducers with other chemotherapeutic treatments. However, achieving this in practice is not necessarily straightforward. In spite of its widespread use, the coadministration of multiple drugs faces practical and pharmacological challenges (Ramsay et al., 2018, Clin. Transl. Med., 7, e3). Differences in solubility, circulation half-lives, cellular uptake, and metabolism often lead to asynchronous delivery, unpredictable local concentrations, and diminished synergy. Moreover, drug mixtures can result in increased off-target toxicity or antagonistic interactions (Niu et al., 2019, Clin. Pharmacol. Then, 105, 1395). One approach to avoid these drawbacks involves integrating multiple drugs into a single prodrug scaffold that can release several moietiesAttorney Docket No: 206161-0078-00WO simultaneously upon activation (Starha, 2024, Coord. Chem. Rev., 501, 215578). PtIVscaffolds offer several advantages in this context (Figure 10C): They are kinetically inert under physiological conditions, chemically versatile, and selectively activated in tumor cells and in the tumor microenvironment (TME) (Wang et al., 2019, Dalton Trans., 48, 2536). This activation comes in the form of reduction to the corresponding Pt11species by endogenous reductants, such as ascorbate, glutathione (GSH), or low molecular weight antioxidents (Marotta et al., 2023, Inorg. Chim. Acta, 548, 121388; Gibson, 2016, Dalton Trans., 45, 12983). This leads to loss of the axial ligands and conversion from a six-coordinate pseudo-octahedral complex to a square planar four-coordinate species. If the axial ligands comprise a drug, this provides a mechanism for targeted drug release. The viability of this approach was demonstrated by Gibson et al. who showed that PtIVprodrugs containing two cytotoxic heavy metals displayed low systemic toxicity (Babu et al., 2023, Angew. Chem. Int. Ed., 62, e202217233). Furthermore, a conjugate linking doxorubicin to Oxa1', a PtIVanalogue of Oxa, exhibited superior tumor inhibition and enhanced immunogenicity in vivo compared to the coadministration of the constituent species (Sarkar et al., 2023, Angew. Chem. Int. Ed., 62, e202310774). Rationally combining Type I and Type II ICD stimuli within such construct presents an opportunity to intensify and diversify the immunogenic response shown for stand-alone ICD agents while addressing key issues associated with coadministration of multiple drugs. The present example reports the synthesis, characterization, and biological evaluation of a series of bi-, and tri-metallic complexes 3-5 (Figure 11) that contain Ru11- and Au^based ICD inducers linked to OxaIv. These conjugates were designed to codeliver Type I and Type II ICD stimuli, respectively, upon reduction of OxaIVto Oxa. The tri-metallic conjugate 5, in particular, demonstrated in vitro cytotoxicity, potent DAMP release, in vivo tumor inhibition, and vaccination model efficacy, outperforming both the individual agents and their physical mixtures. This is the first report on combining distinct metal complexes, where each is an ICD inducer.

[0459] Results and Discussion

[0460] Synthesis and Design of Mono-, Bi-, and Tri-Metallic Complexes 3 5

[0461] Complexes 3, 4, and 5 were designed and synthesized by derivatizing Ru11and

[0462] Au1scaffolds previously shown to modulate plectin and inhibit TrxR enzymes, as well as displaying features consistent with an ICD response in cancer cells (Figure

[0463] 11). Complex 1 contains a carboxylic acid functional group suitable for conjugation to the axialAttorney Docket No: 206161-0078-00WO position of an OxaIVscaffold, while complex 2 bears a primary amine, enabling linkage through a recently reported carbamate formation strategy (Babu et al., 2020, Inorg. Chem., 59, 5182).

[0464] Using this modular approach, bi-metallic complexes 3 and 4 were generated by coupling either complex 1 (Ru11) or complex 2 (Au1) to OxaIV, while tri-metallic complex 5 incorporated both metals in a single complex; it was prepared in accord with the synthetic strategy depicted in Figure 12. The approach used to access complex 5 differs from the coupling strategies typically used to prepared hetero-metallic complexes. Generally, separate metal complexes are prepared and then linked to one another as the final step. In case of the Ru11precursor, complex 1, was unable to be linked directly to the axial position of OxaIv. Thus, as an alternative, the pyridinecarbothioamide ligand was first coupled via anhydride preparation with subsequent addition of [Ru(η6-p-cymene)Cl2]2 to generate either complex 3 or 5. All newly synthesized mono-, bi-, and tri-metallic complexes were obtained in good yield and high purity. They were fully characterized by HPLC, NMR spectroscopy, HRMS, and elemental analysis.

[0465] Physiochemical Properties

[0466] The physicochemical properties of complexes 3-5 were assessed with the goal of evaluating their propensity to undergo reduction, lipophilicity, and extracellular stability under physiological conditions. All three complexes were subjected to stability assessment in RPMI1640 medium at 37 °C, monitored by HPLC. This analysis revealed distinct degradation profiles (Figure 13), with complex 5 displaying the highest stability (Z1 / 2 = 115.5 h), followed by complexes 4 ( / 1 / 2 = 89 h) and 3 ( / 1 / 2 = 5.8 h). The ability of complexes 3-5 to undergo reduction in the presence of a 10-fold excess of ascorbate at pH 7.0, 37 °C was also assessed by HPLC. All three complexes were found to be readily reduced under these conditions with half-lives of less than an hour (Table 3).

[0467] Table 3. Half-lives of complexes 3-5 in RPMI1640 medium determined in the presence of

[0468]

[0469] To complement these data, the lipophilicity of complexes 3-5 was examined, a key factor influencing membrane permeability and cellular uptake (Fernandez -Delgado et al., 2022, J. Inorg. Biochem., 227, 111688). The logP values of the new heterometallic complexes wereAttorney Docket No: 206161-0078-00WO evaluated using the octanol / water shake-flask method. Complex 3, bearing a Ru11complex conjugated to OxaIV, displayed a logP of —0.81 ± 0.02, indicating high hydrophilicity. The presence of the lipophilic Au1complex increased the logP value of complex 4 to 1.73 ± 0.36 and that of the tri -metallic complex 5 to 1.05 ± 0.01. The higher logP of complex 4 relative to 3 and 5 may result in increased membrane affinity (Liu et al., 2011, Pharm. Res., 28, 962).

[0470] Monitoring Reduction Products

[0471] As noted above, PtIVcomplexes are subject to reduction in cancer cells and in the TME. This leads to cleavage of the axial ligands and release of the active Pt11core (Wexselblatt, 2012, J. Inorg. Biochem., 117, 220). The reduction products of Au’-Oxa^-Ru11(complex 5) under reducing conditions (10 equiv. ascorbate, 37 °C, pH 7.0) were monitored using HPLC and electron- spray ionization mass spectrometry (Figure 14). As anticipated, the axial ligands (complex 1 (Ru11) and complex 2 (Au1)) were released alongside the Pt11drug, Oxa. Additionally, a hydroxyl-Au(I) species was observed (Figure 12, complex III) (—25%), previously reported as an ICD inducer; this product was presumed to arise from the partial degradation of the carbamate complex 2. A small quantity of a Ru11dimer (formed in < 5% yield) was also detected by HRMS. This latter finding is consistent with earlier reports describing RuII-F (Figure 10B) and other pyridinecarbothioamide Ru11complexes forming dimers in aqueous environments (Figure 15) (Meier et al., 2013, Chem. Sci., 4, 1837).

[0472] Antiproliferative Activity

[0473] The antiproliferative activity of the heterometallic complexes 3-5 was examined and compared against their monometallic constituent components, including a physical 1:1:1 mixture of 1 + Oxa + 2 after 72 h incubation across a panel of five cancer cell lines: A2780 (ovarian carcinoma), A2780cis (ovarian carcinoma resistant to cisplatin, also referred to as A2780CP), CT26 WT (murine colorectal carcinoma), A375 (melanoma), and PC9 (non-small cell lung cancer). The results are summarized in Table 4.

[0474] Table 4. ICso values [pM] for various cell lines after a 72 h incubation period (tested in

[0475] triplicate).

[0476]

[0477] Attorney Docket No: 206161-0078-00WO | PC9 | 8,2 ± 1,0 | >40 | 0,49 ± 0,13 | 24,2 ± 0,8 | 0,78 ± 0,23 | 0,53 ± 0,09 | 0.80 ± 0,04 | The monometallic agents (Oxa, and complexes 1 & 2) were assessed to establish a baseline for activity and to evaluate the individual contributions of each component. Oxa displayed low micromolar activity in the human cancer cell lines A2780, A2780cis, PC9, and A375, while showing reduced activity in CT26, with an ICso of 20 pM. Complex 1 was less active in all models, a finding ascribed to its poor cellular permeability resulting from its negatively charged carboxylate group. Complex 2, demonstrated low micromolar activity across most cell lines, similar to Oxa. Next, the heterometallic series of complexes 3-5 were examined in an effort to understand whether combining complexes into a single conjugate modulated the antiproliferative effects of the constituents. General trends emerged-complex 3 (PtIV-Run) showed increased activity compared to complex 1 but was not as active as Oxa, with its

[0478] ICso values exceeding 20 pM in most lines. Complex 4 (PtIV-Au!) retained the potency of complex 2 but did not significantly exceed it. Complex 5 which comprises all three metal complexes, demonstrated activity comparable to the mono-metal species, namely Oxa, complex 2, and complex 4, as well as a mixture consisting of a 1:1:1 molar ratio of 1 + Oxa + 2.

[0479] This leads to the suggestion that while combining multiple bioactive moieties may not necessarily lead to enhanced potency, possibly due to differences in individual potency, the activity of its dominant constituents is preserved. These results also led to the conclusion that the cytotoxic activity of the heterometallic series 3-5 is primarily driven by the platinum and gold constituents, with the ruthenium moiety contributing to a lesser extent.

[0480] Mechanism of A ction Studies

[0481] Apart from serving as putative ICD inducers, the multi-component complexes 3-5 were expected to interact with different cellular targets. Several targets were explored in addition to cellular and organelle uptake after 24 h incubation. A lipoate-to-dihydrolipoate reduction assay in HCT-116 cells was used to evaluate the ability of the complexes to inhibit reducing enzymes, such as lipoamide dehydrogenase, glutathione reductase, and TrxR (Arner et al., 1996, Biochem. Biophys. Res. Commun., 225, 268). Auranofin, which is a strong inhibitor of several reducing enzymes (Radenkovic et al., 2017, Biochem. Pharmacol., 146, 42), resulted in the lowest dihydrolipoate production (55% relative to control), indicating the highest degree of enzymes inhibition. The triple metal complex 5, a 1: 1: 1 mixture of 1 + Oxa + 2, and complex 2 followed with 60%, 65%, and 72% dihydrolipoate formation, respectively. The bimetallicAttorney Docket No: 206161-0078-00WO complexes 3 and 4, as well as Oxa and complex 1 showed activity similar to untreated cells (control) (Figure 16).

[0482] A number of gold and ruthenium complexes are known to inhibit members of the TrxR enzyme family (Salmain et al., 2023, Cancers, 15, 4448). TrxR is upregulated in several tumors (Ghareeb, 2020, Chemistry- A European Journal, 26, 10175; Bu et al., 2017, Life Sci., 178, 35). The activity of the gold- and ruthenium-containing complexes was assessed against TrxRl (found in the cytoplasm) and TrxR2 (found in the mitochondria). Specifically, the ability of the monometallic complexes and the triple 1 + Oxa + 2 mixture (simulating the products produced from complex 5 with its rapid half-life for reduction) to inhibit the isolated human TrxRl & TrxR2 enzymes was evaluated (Table 5). Oxa (25.6 and 28.2 pM) and auranofin (0.06 and 0.22 pM) were used as negative and positive controls, respectively. The Ru11complex 1 (3.44 and 4.36 pM) outperformed Oxa and was able to inhibit both enzymes at pM levels, whereas the Au1complex 2 (1.62 and 1.27 pM) showed higher inhibitory activity toward TrxR2. Equal molar ratios of 1 + Oxa + 2 (at 0.97 and 0.81 pM concentrations) gave rise to a synergistic effect as inferred from a combination index calculation involving both TrxRl and TrxR2. This latter finding was taken as a rationale for the further study of the tri-metal complex 5.

[0483] Table 5. ICso values [pM] for the inhibition of human TrxRl & TrxR2 after 75 min incubation at 37 °C (tested in triplicate).

[0484]

[0485] It is important to note the TrxR assay was performed using isolated enzymes. It thus does not take into consideration cellular uptake of the complexes nor organelle distribution.

[0486] Recognizing this, HCT-116 cells were incubated with 1 pM of complexes 1-5 for 24 h and quantified the total metal content via ICP-MS (Figure 17A). Complex 1 (containing only Ru11) showed low accumulation of ruthenium consistent with its minimal antiproliferative activity. The same proved true for complex 3 (PtIV-Run), which engendered only low levels of platinum and ruthenium accumulation; again, this finding provides a rationale for why complex 3 displays reduced cytotoxicity compared to Oxa. Complex 4 (Aur-PtIV) showed similar metal uptake as its monometallic counterparts, while complex 5 (AuIPtIV-RuII) was found to provide for increased accumulation of all three constituent metals, but particularly ruthenium, compared to complexes 3 and 4 or the 1:1:1 1 + Oxa + 2 mixture.

[0487] To understand further the metal distribution within the cell, samples were isolated fromAttorney Docket No: 206161-0078-00WO the nucleus, cytoplasm, and mitochondria from HCT-116 cells after 24 h incubation with 1 pM of complex 5 or the 1:1:1 1 + Oxa + 2 mixture. Quantification was achieved via ICP-MS. This study was carried out to test the expectation that TrxR2 enzyme inhibition would only be seen if both gold and ruthenium were taken up into the mitochondria concurrently. The results are presented in Figure 17B. They are shown in percentages due to the starting difference in total cellular uptake. The multi-metal complex 5 showed a statistically significant higher accumulation of gold and ruthenium in the mitochondria compared to the 1:1:1 mixture of 1 + Oxa + 2. This finding led to the suggestion that an ability to inhibit TrxR2 plays a role in the mechanism of action (MOA) of complex 5. Support for this conclusion came from the finding that complex 5 also increased ROS production in the mitochondria as inferred from confocal microscopy studies (Figure 18).

[0488] In Vitro Assessment of DAMP Production

[0489] To investigate the immunogenic potential of the new complexes, the DAMPs associated with ICD (ATP, HMGB1, and CRT) were monitored. This was done by incubating CT26 cells with IC50 concentrations of complexes 1-5 for 24 h. ATP release was markedly elevated in cells treated with complex 5 (>300% of control). A similar increase was seen for the mixture

[0490] (1 + Oxa + 2); however, significantly lower enhancements were seen for all other treatments (Figure 19). Notably, the bimetallic complexes 3 and 4 did not induce significant ATP release relative to their monometallic counterparts or control. This lack of ATP release may reflect poor cellular uptake (complex 3) or excessive lipophilicity that impedes intracellular distribution (complex 4).

[0491] Extracellular HMGB 1 was induced effectively by complex 5 (Figure 19B). Oxa alone produced a modest effect, consistent with its known ICD profile. The 1:1:1 mixture

[0492] of 1 + Oxa + 2 yielded HMGB1 levels comparable to those of complex 5, while the bimetallic derivatives (complexes 3 and 4) did not induce significant release after 24 h incubation.

[0493] Surface calreticulin display (Figure 19C) revealed CRT translocation in all tested complexes with complex 5 (~15%) and the physical mixture (1 + Oxa + 2), outperforming the mono and bi-metallic derivatives. During the early stages of apoptosis, immunogenic dying cells relocate calreticulin (CRT) and ERp57 from the perinuclear endoplasmic reticulum (ER) to the cell surface. The extemalization of the CRT / ERp57 complex acts as a pro-phagocytic “eat me” signal, facilitating recognition and engulfment by dendritic cells (Obeid et al., 2007, Cancer Res.,Attorney Docket No: 206161-0078-00WO 67, 7941). Thus, higher populations of pre-apoptotic cells may increase the immunogenic response in vitro. An annexin-V assay was used to determine the percentage of early apoptotic cells. As shown in Figure 19D, an increase in the percentage of early apoptotic cells was seen in the case of complex 5 (>35%) compared to the 1:1:1: mixture of 1 + Oxa + 2 (~ 10%) (Figure 20).

[0494] Altogether, the above results provide support for the suggestion that the integrated trimetallic scaffold embodied in complex 5 can induce production of all three ICD markers (DAMPs), outperforming both the individual monometallic constituents and the congeneric bimetallic constructs.

[0495] In Vivo Efficacy and Toxicity

[0496] Encouraged by the in vitro results obtained with complex 5, its in vivo antitumor activity was compared in a CT26 murine model against a 1:1:1 ratio of 1 + Oxa + 2, as well as doxorubicin, an FDA approved, nonmetal drug that displays ICD effects (Casares et al., 2005, J. Exp. Med., 2020, 1691) and was chosen as a mechanistically distinct control. The experimental protocol consisted of inoculating mice with 1.5 * 106CT26 cells on day 0. When the tumors became palpable, a series of four intraperitoneal (i.p.) injections were carried out on days 8, 10, 12, & 14. On day 16 mice (n = 5) were euthanized and organs including tumors (Figure 21) were collected and analyzed for their metal content via ICP-MS (Figure 22). The doxorubicin dosage was based on a previous report (Aston et al., 2017, BMC Cancer, 17, 684). The molar equivalence dosages for complex 5 and the 1 + Oxa + 2 mixture were calculated based on an Oxa dose of 4 mg kg '. Tumor growth reduction percentages are summarized in Figure 22B and tumor volume changes over time are shown in Figure 22C. Complex 5 displayed the highest tumor growth inhibition (~88%) followed by 1 + Oxa + 2 (~80%), both outperforming doxorubicin (~40%). However, as shown in Figure 22D, 1 + Oxa + 2 was associated with acute toxicity, as inferred from the observed reduction in body weight. This was not observed in case of 5. Thus, a clear benefit can be inferred for the combined three-metal approach embodied in complex 5.

[0497] To obtain a better understanding of the differences in toxicity, ICP-MS analyses were performed of tumor, spleen, heart, lung, kidney, and liver samples of the treated animals to quantify platinum, gold, and ruthenium content (Figure 23). Tumor and organs were mineralized using aqua regia and re-constituted in 2% nitric acid for analysis. In the case of complex 5,Attorney Docket No: 206161-0078-00WO similar accumulation levels across all tested organs, as well as tumor, were seen for all three metals and led to the suggestion that its stability is sufficient for in vivo use. Notably, the hepatic Au, renal Pt, and splenic Ru levels were increased for 1 + Oxa + 2 compared to 5. This was taken as an indication that the covalent conjugation of three metals into a single scaffold in the form of complex 5 can alter their biodistribution.

[0498] In Vivo Challenge and White Blood Cell Monitoring

[0499] Induction of an immunogenic response in vivo was determined using the established preclinical CT26 challenge model depicted in Figure 24A (Kepp et al., 2014, Oncoimmunology, 3, e955691). Briefly, 1.5 x 106CT26 cells pretreated for 24 h with the species of interest at a concentration corresponding to the ICso or control freeze-thaw cells were injected to the right flank (vaccination flank) of BALB / c mice (n = 5). After 7 days, the mice were challenged with 5 x 103naive CT26 cells injected into the left flank (challenge flank). Mice were monitored thereafter to assess the level, if any, of tumor development on the challenge (left) side. The results are summarized in Figure 24B. Monitoring was continued for 28 days. This revealed tumor free survival up to day 10 for the freeze-thaw group. These are animals in which ICD induction was not expected. Tumor free survival was seen up to day 14 and up to day 21 in the doxorubicin and 1 + Oxa + 2 groups, respectively. In contrast, the group treated with complex 5 displayed enhanced tumor-free survival with 40% of the animals surviving through the end of the study period (day 28).

[0500] Chemotherapeutics that elicit ICD immunotherapy properties are expected to activate both the innate and adaptive immune systems, particularly through maturing dendritic cells that stimulate CD8 + T-cell activation (Arimoto et al., 2024, Front. Immunol., 15,

[0501] 1390263). Unfortunately, validating such responses in vivo typically requires complex, time- and resource-intensive assays. Thus, an aim was to establish a potentially more facile method to monitor systemic immune engagement. Reports of changes in peripheral blood biomarkers in cancer patients receiving immunotherapies, such as PD-L1 inhibitors, provide support for the notion that changes in peripheral leukocyte dynamics could provide a marker for drug-induced immune activation (Sibille et al., 2021, Lung, 199, 549; Soyano et al., 2018, J. Immunother. Cancer, 6, 129). More specifically, it was hypothesized that blood-based white blood cells (WBC) profiling — total and differential — could provide an indicator of ICD induction in vivo.

[0502] To test this proposition, whole blood samples were collected from mice beforeAttorney Docket No: 206161-0078-00WO vaccination (day -7), before challenge (day 0), and 7 days after challenge (day 7) as outlined in Figure 24A. The samples were subjected to a manual count of total white blood cell (WBC) using Tuerk staining and differential leukocytes (monocytes, lymphocytes, neutrophils, eosinophils, and basophils) using Wright staining. The results are summarized in Figure 24C as total WBC per pL (Figure 24C), differential percentages of monocytes (Figure 24D), and lymphocytes (Figure 24E) corresponding to an innate and adaptive immune response, respectively. The neutrophil, eosinophil, and basophil levels remained unchanged. Note that mice were injected only with pretreated, dying tumor cells, not the compounds themselves; however, the cells in question could have retained the test species as the result of, e.g., intracellular accumulation. To the extent this occurred, it could influence the immune response.

[0503] As shown in Figure 24, at day -7, no significant differences in the total WBC counts or differential profiles were observed among the treatment groups in agreement with previous mice WBC counts (Abatan et al., 2008, J. Am. Assoc. Lab Anim. Sci., 47, 8). At day 0, a significant reduction in total WBC count was observed in the doxorubicin group. This can be ascribed to the myelosuppressive effect of doxorubicin (Bally et al., 1990, Cancer Chemother. Pharmacol., 27, 13). A similar decrease was noted in the 1 + Oxa + 2 mixture group, which is thought to reflect the leukopenia side effects associated with Oxa treatment (Yu et al., 2021, Front. Oncol., 11, 757196). In contrast, the freeze-thaw and complex 5 groups showed no statistically significant changes. These differing trends were retained through day 7. This is taken as evidence that neither the freeze-thaw control nor complex 5 induced systemic leukopenia. Differential analysis showed no change in monocyte or lymphocyte percentages in the freeze-thaw group across all time points, consistent with a lack of immunogenic DAMP release. Doxorubicin treatment led to a transient increase in lymphocyte percentages by day 0. Both the 1 + Oxa + 2 mixture and complex 5 groups exhibited elevated monocyte and lymphocyte percentages, with

[0504] complex 5 inducing a more pronounced and sustained response. These results align well with tumor free survival and led to the proposal that WBC count monitoring could emerge as a useful tool for monitoring ICD induction.

[0505] Conclusion

[0506] In summary, a tri-metallic PtIVprodrug (complex 5) that integrates Type I and Type II ICD inducers into a single molecular scaffold has been prepared. Designed to co-release Pt11, Ru11, and Au1species upon reduction, this complex offers a modular approach to multi-prongedAttorney Docket No: 206161-0078-00WO chemotherapy. The three different active metal species embodied in 5 were, in turn, found to inhibit TrxRl / TrxR2 and generate a robust ICD response in vitro as reflected in the production of key DAMPs. Although the in vitro ICso values of complex 5 are comparable to a 1:1:1 mixture of the single agents (1 + Oxa + 2), in vivo, complex 5 was found to reduce tumor growth, provide for favorable biodistribution and reduced acute toxicity effects (e.g., weight loss) compared to a mixture of its constituents. Complex 5 also prolonged tumor-free survival in a mouse challenge study, and elicited sustained leukocyte activation — highlighting its dual chemo-immunotherapeutic mode of action. This work underscores the potential of chemically integrated, multimodal ICD inducers to drive coordinated immunogenic responses. As such, it is expected to set the stage for future efforts to develop metal-based cancer immunotherapies.

[0507] The methods and materials are described herein.

[0508] Materials and G neral Methods

[0509] All chemicals and solvents used in this study were procured from commercial sources and used without further purification.

[0510] The newly synthesized Au, Ru and conjugate complexes were characterized by 'H NMR spectral, HRMS, and elemental analyses. Complexes that contain PtIVwere also characterized by195Pt NMR spectroscopy. Progress of reactions was monitored by analytical HPLC (Thermo Scientific UltiMate 3000) with a reverse-phase Cl 8 column Phenom enex Kinetex, length 100 mm, internal diameter 4.60 mm, particle size 2.6 pm, pore size 100 A. The purity and retention time (RT) of the newly synthesized compounds reported here were measured with the same analytical HPLC system water / acetonitrile gradient at a flow rate of 1 mL / min. Reaction mixtures were purified on a preparative HPLC system (Thermo Scientific UltimaMate 3000 station) equipped with a reverse-phase C18 column (Phenomenex Luna 250 x 21.2 mm, 10 pm, 100 A) using a similar mobile phase at a flow rate of 15 mL / min. UV spectroscopic detection was measured at 220 nm in the case of both the HPLC systems. Appropriate fractions were combined and lyophilized to yield the desired pure compounds.

[0511] All NMR spectroscopic data were collected on a Bruker AVANCE III™ HD 500 MHz spectrometer. The data were processed using either MestreNova or Bruker TopSpin 3.6.0 software.1H NMR chemical shifts were referenced with the individual solvent residual peaks of the respective NMR solvents.195Pt NMR chemical shifts were reported with respect to theAttorney Docket No: 206161-0078-00WO chemical shift of a standard (K2PtC14 in water) at -1624 ppm. High resolution mass spectra (HRMS) were recorded using a X500R QTOF by direct injection+ve mode electrospray ionization. Elemental analyses were performed using a Thermo Scientific FLASH 2000 element analyzer.

[0512] Synthesis

[0513] RuII-F (Plecstatin-1)

[0514] Plecstatin-1 was prepared using a reported procedure (Meier et al., 2013, Chem. Sci., 4, 1837).

[0515] ‘HNMR (500 MHz, DMSO-d6) 59.56 (d, J = 5.6 Hz, 1H), 8.18 (s, 1H), 7.73 (s, 1H), 7.47 - 7.13 (m, 5H), 6.00 (d, J = 6.0 Hz, 1H), 5.92 (d, J = 6.0 Hz, 1H), 5.84 (d, J = 6.8 Hz, 1H), 5.56 (d, J = 5.7 Hz, 1H), 2.64 (p, J = 6.9 Hz, 1H), 2.10 (s, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.03 (d, J = 6.9 Hz, 3H).

[0516] N-(4-Benzoic acid)-2-pyridinecarbothioamide (I)

[0517] 4-Aminobenzoic acid (3.42 g, 25 mmol), sulfur (2.41 g, 75 mmol), and sodium sulfite (0.13 g, 0.5 mol%) were heated at reflux in 2-picoline (15 mL), 135°C overnight. Afterwards, the volatiles were removed under reduced pressure and MeOH was added to form a yellow mass that was collected by filtration and washed with diethyl ether. The resulting product was recrystallized from hot methanol. Yield - 46%, 3 g.

[0518] 1HNMR(400 MHz, DMSO-d6) 5 12.44 (s, 1H), 8.68 (ddt, J = 4.8, 1.7, 0.8 Hz, 1H), 8.50 (dq, J = 8.0, 0.9 Hz, 1H), 8.30 - 8.09 (m, 2H), 8.08 - 7.95 (m, 3H), 7.66 (ddt, J = 7.5, 4.8, 0.9 Hz, 1H). HPLC - 5.4 min (0-100% acetonitrile (ACN) in 5.84 min + 2 min constant 100% ACN).

[0519] N-(4-Benzoic acid)-2-pyridinecarbothioamide anhydride (II)

[0520] N-(4-Benzoic acid)-2-pyridinecarbothioamide (150 mg, 0.581 mmol) was reacted with 0.48 equiv. of l-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) for 20 min in 35 mL of tetrahydrofuran (THF): dichloromethane (DCM) 1: 1 at room temperature. After confirmation of reaction completion by TLC, the reaction was concentrated under reduced pressure to 1 mL and the product was isolated by silica gel column chromatography using DCM as the mobile phase. Yield 85%, 123 mg. HPLC - 7.4 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN).Attorney Docket No: 206161-0078-00WO [Chlorido(η6-p-cymene)(N-(4-benzoic acid)-2-pyridinecarbothioamide) ruthenium(II)] chloride (Complex 1)

[0521] N-(4-Benzoic acid)-2-pyridinecarbothioamide (28.7 mg, 0.11 mmol) were dissolved in MeOH and the pH was adjusted to 6.6 with HC1. [Ru(η6-p-cymene)Cl2]2 (22 mg; 0.5 equiv.) were dissolved in MeOH and added at once and stirred for 15 min at room temperature. The reaction turned dark red and completion was monitored via HPLC. After the reaction was deemed complete, the reaction mixture was concentrated to 0.5 mL under reduced pressure and the product was isolated through precipitation using excess diethyl ether and after collection by filtration, washed extensively with ether. Yield - 96%, 60 mg.

[0522] 'H NMR (500 MHz, DMSO-d6) δ9.49 (dd, J = 5.7, 1.5 Hz, 1H), 8.24 (dd, J = 16.0, 6.2 Hz, 1H), 8.10 (td, J = 7.7, 1.5 Hz, 1H), 8.03 - 7.95 (m, 2H), 7.66 (ddd, J = 7.3, 5.7, 1.6 Hz, 1H), 7.20 (d, J = 8.1 Hz, 2H), 5.90 (d, J = 6.0 Hz, 1H), 5.88 - 5.77 (m, 1H), 5.75 (d, J = 6.0 Hz, 1H), 5.47 (d, J = 5.9 Hz, 1H), 2.64 (hept, J = 6.9 Hz, 1H), 2.09 (s, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.02 (d, J = 6.9 Hz, 3H). HPLC - 4.34 min (0-100% acetonitrile (ACN) in 5.84 min + 2 min constant 100% ACN) ESI-HRMS (m / z) calculated for [C23H24ClN2O2RuS-Cl-H]+: 493.04, found 493.05; Elemental analysis; calculated for C23H24Cl2N2O2RuS: C 48.94, H 4.29, N 4.96% Found: C, 48.62, H 4.30, N 4.91%.

[0523] (L3-bis(2,6-Diisopropylphenyl)-4,9-dioxo-L3,4,9-tetrahydro-2H-2λ3-naphtho[2,3-d]imidazol-2-yl)(l-(2-hydroxyethyl)-3-mesityl-l,3-dihydro-2H-2X3-imidazol-2-yl) gold(I)

[0524]

[0525] This Au(I) complex was prepared using a reported procedure (Sen et al., 2020, J. Am. Chem. Soc., 142, 20536).

[0526] ‘HNMR (500 MHz, DMSO-d6) δ8.03 (dd, J = 5.7, 3.4 Hz, 2H), 7.91 (dd, J = 5.9, 3.3 Hz, 2H), 7.63 (t, J = 7.8 Hz, 2H), 7.51 (d, J = 1.8 Hz, 1H), 7.34 (d, J = 7.8 Hz, 4H), 7.28 (d, J = 1.8 Hz, 1H), 6.82 (s, 2H), 4.93 (t, J = 4.9 Hz, 1H), 3.58 (t, J = 5.0 Hz, 2H), 3.23 (q, J = 5.0 Hz, 2H), 2.58 -2.51 (m, 8H), 2.40 (s, 3H), 1.56 (s, 6H), 1.05 (dd, J = 6.8, 2.8 Hz, 20H). HPLC - 6.7 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN)

[0527] (L3-bis(2,6-Diisopropylphenyl)-4,9-dioxo-L3,4,9-tetrahvdro-2H-2k3-naphthor2,3- izol-2-yl)(l-(2-((((2,5-dioxopyrrolidin-l-yl)oxy)carbonyl)oxy)ethyl)-3-mesityl-l,3- dihy dro-2H-2L3 -imi dazol -2-yl) e ol d (I)

[0528]

[0529] Attorney Docket No: 206161-0078-00WO 30 mg (0.03 mmol) of (l,3-bis(2,6-diisopropylphenyl)-4,9-dioxo-l,3,4,9-tetrahydro-2 7-2X3-naphtho[2,3- ]imidazol-2-yl)(l-(2-hydroxyethyl)-3-mesityl-l,3-dihydro-2 / / -2k3-imidazol-2-yl) gold(I) were reacted with 1 equiv. DMAP (3.3 mg) and 10 equiv. N, N'-disuccinimidyl carbonate (DSC) (70 mg) for 60 min in ACN. Afterwards, the product, referred to as the activated form, was purified using prep-HPLC (50-100% ACN in 0.1% TF A in 7.5 min + 5 min constant 100% ACN) and lyophilized to give a pale-yellow solid as the TFA salt. Yield - 79%, 26.8 mg. HPLC - 6.7 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN)

[0530] (l-(2-(((2-Aminoethyl)carbamoyl)oxy)ethyl)-3-mesityl-l,3-dihvdro-2H- imidazol-2-

[0531]

[0532] vl)(l,3-bis(2,6-dii i-4,9-dioxo-l,3,4,9-tetrahvdro-2H-2X3-i.,3-i

[0533] 2-- TFA salt

[0534]

[0535] 20 mg (0.02 mmol) of (l,3-bis(2,6-diisopropylphenyl)-4,9-dioxo-l,3,4,9-tetrahydro-2H-2X3-naphtho[2,3-d]imidazol-2-yl)(l-(2-((((2,5-dioxopyrrolidin-l-yl)oxy)carbonyl)oxy)ethyl)-3-mesityl-l,3-dihydro-2H-2X3-imidazol-2-yl) gold(I) were dissolved in 5 mL ACN and 8 equiv. of ethylenediamine were dissolved in 2 mL ACN and added dropwise while vigorously stirring for 10 min at room temperature. Afterwards, the reaction volume was reduced to 0.5 mL under reduced pressure and the product precipitated using excess diethyl ether. After collection by filtration, it was washed 3 times with ether. Yield- 90%, 17 mg.

[0536] For biological work, this compound was isolated as its TFA salt using prep-HPLC (0-100% ACN in 0.1% TFA in 15 min + 5 min constant 100% ACN).

[0537] ‘HNMR (500 MHz, DMSO-d6) δ8.03 (dd, J = 5.7, 3.3 Hz, 2H), 7.92 (dd, J = 5.8, 3.3 Hz, 2H), 7.63 (s, 2H), 7.52 (s, 2H), 7.34 (d, J = 7.8 Hz, 4H), 6.83 (s, 1H), 6.53 (s, 2H), 3.79 -3.75 (m, 4H), 3.16 (q, J = 6.5 Hz, 2H), 2.81 (t, 2H), 2.55 (q, J = 6.8 Hz, 8H), 2.41 (s, 3H), 1.92 (s, 2H), 1.56 (s, 6H), 1.05 (dd, J = 6.8, 3.2 Hz, 20H). HPLC - 5.64 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN) ESI-HRMS (m / z) calculated for [C52H62AuN6O4]+: 1032.07, found 1031.44; Elemental analysis calculated for C54H62AuF3N6O5: C 57.44, H 5.54, N 7.44% Found: C, 57.26, H 5.34, N 7.11 %.

[0538] Oxali(MSC)(OH) (Complex V)

[0539] This mono-activated oxaliplatin(IV) was prepared using a reported procedure (Babu et al., 2020, Inorg. Chem., 59, 5182).Attorney Docket No: 206161-0078-00WO Oxali(N-(4-Benzoic acid)-2-pyridinecarbothioamide)(OH) and Oxali(N-(4-Benzoic acid)-2- x VI)

[0540] 40 mg (0.09 mmol) of Pt(IV) oxali(OH)2 were suspended in 4 mL of DMSO to which 51 mg (1.1 equiv.) N-(4-benzoic acid)-2-pyridinecarbothioamide anhydride were added. The reaction was allowed to proceed overnight at 40°C. The following day, the formation of the product was confirmed using195Pt NMR spectroscopy and analytical HPLC. It was extracted using diethyl ether to give a bright yellow solid. Yield - 78%, 48.5 mg.

[0541] For the preparation of oxali(IV)-Ru(II) (H), oxali(N-(4-benzoic acid)-2-pyridinecarbothioamide)(OH) was dissolved in MeOH and further purified via prep-HPLC (0-100% ACN in water over 15 min). HPLC - 4.5 min (0-100% acetonitrile (ACN) in 5.84 min + 2 min constant 100% ACN)

[0542] For activation of the second axial position, 5 equiv. of N, N'-disuccinimidyl carbonate (DSC) were added in situ after an overnight reaction over the course of 1 hr at room temperature. The product was then purified using prep-HPLC (0-100% ACN in water over 15 min) and lyophilized. Yield - 97%, 50 mg (based on 25.7 mg of oxali(OH)2 starting material). HPLC - 4.9 min (0-100% acetonitrile (ACN) in 5.84 min + 2 min constant 100% ACN)

[0543] [Oxali(IV)-Ru(II)] chloride (Complex 3)

[0544] Lyophilized oxali(N-(4-benzoic acid)-2-pyridinecarbothioamide)(OH) (G) (29.9 mg, 0.04 mmol) were dissolved in 1.5 mL of MeOH and in a different vial, 14.3 mg [Ru(η6-p-cymene)Cl2]2 (0.5 equiv.) were dissolved in 1 mL MeOH. Both solutions were combined in a dropwise manner with stirring over the course of 10 min at room temperature. Once the reaction was deemed complete, the solution was concentrated under reduced pressure to a volume of 0.5 mL. The product was precipitated with excess diethyl ether and after being collected by filtration the product was washed several times with ether. Yield - 87%, 37.8 mg.

[0545] 1H NMR (500 MHz, DMSO-d6) δ9.47 (d,.7 = 6.1 Hz, 1H), 8.33 (s, 1H), 8.08 (t, J= 7.8 Hz, 1H), 7.93 - 7.86 (m, 2H), 7.65 (t, J= 6.3 Hz, 1H), 7.41 (s, 1H), 7.14 (s, 2H), 5.88 - 5.72 (m, 3H), 5.45 (d, J= 6.0 Hz, 1H), 2.77 - 2.55 (m, 4H), 2.36 - 2.25 (m, 1H), 2.10 - 2.08 (m, 3H), 1.58 - 1.50 (m, 4H), 1.21 - 1.03 (m, 8H).195PtNMR (108 MHz, DMSO) 5 1406.46. HPLC -3.91 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN) ESI-MS (m / z) calculated for [C31H35ClN4O7PtRuS-Cl-H]+: 905.87, found 906.10; Elemental analysis calculated for C31H35Cl2N4O7PtRuS: C 38.08, H 3.92, N 5.73% Found: C, 37.92, H 3.81, N 5.81%.Attorney Docket No: 206161-0078-00WO

[0546] [Oxali-Au(I)] TFA (Complex 4)

[0547] 30 mg (0.026 mmol) of (l-(2-(((2-aminoethyl)carbamoyl)oxy)ethyl)-3-mesityl-l,3-dihydro-2H-2L3-imidazol-2-yl)(l,3-bis(2,6-diisopropylphenyl)-4,9-dioxo-l,3,4,9-tetrahydro-2H-2X3-naphtho[2,3-d]imidazol-2-yl)gold(I) were dissolved in 3 mL of ACN and 2 equiv. of triethylamine (TEA) were added at once. Separately, 18.2 mg of oxali(MSC)(OH) were dissolved in 1 mL DMF and added dropwise to the gold solution (complex 2) under stirring for 3 h in room temperature. After confirmation of product formation and reaction completion by analytical HPLC, the product was purified using prep-HPLC (50-100% ACN in 0.1% TFA over 12.5 min + 5 min constant 100% ACN) and lyophilized as TFA salt. Yield - 15.2 mg, 38.5%.

[0548] 'H NVIR (500 MHz, DMSO-d6) δ8.03 (dd, J = 5.7, 3.3 Hz, 2H), 7.91 (dd, J = 5.8, 3.3 Hz, 2H), 7.63 (t, J = 7.8 Hz, 2H), 7.51 (s, 1H), 7.35 (d, J = 7.8 Hz, 4H), 7.06 (s, 2H), 6.82 (s, 2H), 3.83 - 3.71 (m, 7H), 2.97 - 2.92 (m, 5H), 2.91 - 2.83 (m, 2H), 2.54 (q, J = 6.0 Hz, 6H), 2.41 (s, 3H), 2.16 - 1.99 (m, 2H), 1.56 (s, 6H), 1.49 (t, J = 15.4 Hz, 4H), 1.32 (s, 1H), 1.05 (dd, J = 6.8, 4.3 Hz, 25H).195Pt NMR (108 MHz, DMSO-d6) δ 1417.35. HPLC - 6.03 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN) ESI-HRMS (m / z) calculated for [C61H76AuN8O11Pt]: 1489.37, found 1489.49; Elemental analysis calculated for C61H76AuF3N8O11PPt: C 44.83, H 4.69, N 6.86% Found: C, 44.74, H 4.39, N 6.91%.

[0549] Oxali(N-(4-benzoic acid)-2-pyridinecarbothioamide)((l-(2-(((2-aminoethvl)carbamovl)oxv)ethvl)-3-mesitvl-l,3-dihvdro-2H-213-imidazol-2-vl)(l,3-bis(2,6-diisopropvlphenvl)-4,9-dioxo-l,3,4,9-tetrahvdro-2H-2 3-naphtho[2,3-d]imidazol-2-vl)gold(I)) (Complex VII)

[0550] Oxali(N-(4-benzoic acid)-2-pyridinecarbothioamide)(MSC) (21 mg, 0.026 mmol, 1.3 equiv.) were dissolved in 2 mL DMF and in a different vial, 21 mg of (l-(2-(((2-aminoethyl)carbamoyl)oxy)ethyl)-3-mesityl-l,3-dihydro-2H-2X3-imidazol-2-yl)(l,3-bis(2,6-diisopropylphenyl)-4,9-dioxo-l,3,4,9-tetrahydro-2H-2X3-naphtho[2,3-d]imidazol-2-yl)gold(I) (1 equiv.) and 2 equiv. of TEA were dissolved in 2 mL of DMF and added dropwise to the oxaliplatin solution over the course of 1 h at room temperature. Once the reaction was deemed complete via analytical HPLC, the product was purified using prep-HPLC (0-100% ACN in 0.1% TFA in 15 min + 5 min constant 100% ACN) and lyophilized as the TFA salt. Yield -73.5%, 25 mg. HPLC - 6.7 min (0-100% ACN 5.84 min + 2 min constant 100% ACN).Attorney Docket No: 206161-0078-00WO

[0551] [Au(I)-oxali(IV)-Ru(II)] chloride (Complex 5)

[0552] The triple metal complex 5 was prepared by dissolving in two separate vials, 20 mg (0.011 mmol) of lyophilized oxali(N-(4-benzoic acid)-2-pyridinecarbothioamide)((l-(2-(((2-aminoethyl)carbamoyl)oxy)ethyl)-3-mesityl-l,3-dihydro-2H-2X3-imidazol-2-yl)(l,3-bis(2,6-diisopropylphenyl)-4,9-dioxo-l,3,4,9-tetrahydro-2H-2X3-naphtho[2,3-d]imidazol-2-yl)gold(I)) in 1 mL MeOH and 10 mg [Ru(η6-p-cymene)Cl2]2 (1.4 equiv.) in 1 mL MeOH. The reagents were then combined at once and the mixture allowed to stir for 10 min in room temperature. After the reaction was deemed complete via analytical HPLC, the reaction volume was concentrated to 0.5 mL. The product was then precipitated with excess diethyl ether and after collecting by filtration washed several times with ether. Yield - 85%, 19.3 mg.

[0553] ‘HNMR (500 MHz, DMSO-d6) δ9.43 (d, J = 5.8 Hz, 1H), 7.97 (ddd, J = 58.9, 5.9, 3.4 Hz, 5H), 7.62 (dt, J = 19.3, 7.5 Hz, 4H), 7.35 (d, J = 7.7 Hz, 4H), 7.10 - 6.99 (m, 3H), 6.83 (s, 2H), 5.84 - 5.76 (m, 3H), 5.67 (d, J = 5.9 Hz, 1H), 5.39 (d, J = 6.1 Hz, 1H), 4.86 (d, J = 5.2 Hz, 1H), 4.62 (t, J = 5.7 Hz, 1H), 4.05 - 3.88 (m, 4H), 3.75 (s, 6H), 3.39 (q, J = 7.0 Hz, 4H), 3.05 -2.56 (m, 14H), 2.41 (s, 3H), 2.31 - 2.25 (m, 2H), 2.08 (d, J = 10.6 Hz, 2H), 1.57 (s, 6H), 1.27 -1.00 (m, 30H).195PtNMR (108 MHz, DMSO-d6) δ 1601.30. HPLC - 5.99 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN) ESI-HRMS (m / z) calculated for [C84H98AuClN10O12PtRuS-Cl-H]2+: 981.97, found 981.76; Elemental analysis calculated for C84H98AuCl3N10O12PtRuS: C 48.71, H 4.77, N 6.76% Found: C, 48.97, H 4.70, N 6.91%.

[0554] Reduction and Stability

[0555] The dual and triple metal complexes 3-5 were dissolved, respectively, in MeOH. A concentrated solution of ascorbic acid was prepared in 1:1 MeOH: H2O, and the pH was adjusted to 7.0 with NaOH. A 10-fold molar excess of the ascorbic acid solution was added to the complexes and the expected reduction monitored by analytical HPLC. The half-lives (t1 / 2) for the reduction of all three complexes were determined via the linear fitting of ln(At / Ao) vs time (t) in accord with the pseudo first order rate equation At = Aoe-kt, where Ao and At are the integrated areas of the HPLC peaks of the respective complexes at t = 0 and at time t, respectively, and k (slope) is the rate constant. The value of ti / 2 was calculated using the equation t1 / 2= -ln(2) / k.

[0556] Stability studies were conducted by dissolving the complexes in 1% DMSO and RPMI medium at pH 7.4, and maintaining them at 37°C. HPLC chromatograms were recorded until theAttorney Docket No: 206161-0078-00WO peak areas were less than half the starting peak area. The ti / 2 value was calculated by linear fitting of ln(At / Ao) vs time (t) where At and Ao are the integrated peak areas determined by HPLC at t = 0 and at time t.

[0557] Shake-Flask LogP Measurements

[0558] The octanol-water partition coefficients for the metal complexes 3-5 were determined using a modification of a reported shake-flask method (Cirri et al., 2017, Dalton Trans., 46, 3311). Water (50 mL) and n-octanol (50 mL) were shaken together for 72 hours to allow saturation of both phases. A solution of each complex was prepared in the aqueous phase with the addition of 100 pL of DMSO. An equal volume of octanol was then added. Due to the stability of the complexes in octanol and water, the biphasic solutions were mixed for ten minutes and then allowed to sit for 15 minutes. Samples were then centrifuged for 15 minutes at 3000 g to allow separation. Aliquots of each phase were taken and further spun in a microcentrifuge carefully withdrawing samples for analysis. The concentrations of the complexes in both phases were determined by UV-Vis spectroscopy. The reported logP values are defined as log{[complex]octanol / [complex]water}. Final values are reported as the mean of three independent determinations.

[0559] Cell Culture Maintenance

[0560] A375 human malignant melanoma cells, PC9 human non-small cell lung carcinoma cells, and CT26 WT murine colon carcinoma cells were maintained in DMEM (Dulbecco's Modified Eagle Medium) (high glucose, no glutamine) supplemented with L-glutamine solution (2% v / v; final concentration 4 mM), 10% (v / v) heat-inactivated fetal bovine serum, and 1% (v / v) Pen-Strep solution (containing penicillin: 10,000 units / mL and streptomycin: 10 mg / mL) and were passaged twice a week. A2780 human ovarian carcinoma cells, and A2780cis (cisplatinresistant) ovarian carcinoma cells were cultured in RPMI 1640 (no glutamine) supplemented with heat-inactivated fetal bovine serum (10% v / v), gentamycin sulfate solution (50 pg / mL) and L-glutamine solution (1% v / v; final concentration 2 mM). Once a week, a solution of cisplatin in RPMI medium (final concentration: 1 pM) was added to the A2780cis cells to maintain their resistance. RPMI1640, DMEM high glucose, L-glutamine solution, and then Pen-Strep solution were purchased from Sartorius; heat-inactivated fetal bovine serum (non-USA origin, sterile-filtered) was purchased from Sigma. A375, PC9, A2780, and A2780cis cells were obtained fromAttorney Docket No: 206161-0078-00WO the American Type Culture Collection (ATCC, Rockville, MD), the CT26 WT cells were a gift given from Prof. Galia Blum’s lab.

[0561] Antiproliferative assay in tumorigenic cells

[0562] A375 melanoma cells (5000 cells / well), PC9 small lung cell carcinoma cells (5000 cells / well), CT26 WT murine colon carcinoma cells (5000 cells / well), A2780 ovarian carcinoma cells (5000 cells / well), and A2780cis cisplatin-resistant ovarian carcinoma cells (7000 cells / well), were seeded in flat-bottom 96-well plates in their respective cell culture media (100 pL) and incubated at 37°C in a 5% CO2 environment for 24 h. After that, the media were replaced with the fresh media. Stock solutions of the compounds in DMSO or in cell culture medium (for Oxa) were freshly prepared and diluted with the respective cell culture medium to graded concentrations (final concentration of DMSOmax: 0.5% v / v). After 72 h of exposure, the media were removed and 100 pL of 0.5 mg / mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) in DMEM or RPMI were added and the plate in question further incubated for an additional 1 h. The media containing the MTT solution was removed and the resulting formazan crystals were dissolved in 100 pL DMSO. The absorbance of the solution in each well was read at 570 nm using a BioTek Cytation3 plate reader. The IC50 value, which is the drug concentration needed for 50% reduction in survival, based on the survival curve, was calculated by fitting nonlinear curves in GraphPad Prism 5 Ver 5.03, using a normalized response variable slope model constructed by plotting cell viability (%) vs log of the concentration of the complex in question in nM. The results are presented as the mean values of three independent experiments.

[0563] Lipoate Reduction Assay

[0564] Lipoate reduction was evaluated using a previously reported protocol (Sen et al., 2019, Chem. Commun., 55, 10627).

[0565] In short, HCT-116 cells were harvested and seeded at a density of 10,000 cells / well in 96-well culture plates. Following an overnight incubation at 37°C under a 5% CO2 atmosphere, the medium was replaced, and the cells incubated with 1 pM of each complex for additional 24 hr. Thereafter, the media were removed from each well, which were then washed with 200 pL of HBSS solution. Finally, 100 pL of 5 mM lipoate and 1 mM of DTNB solutions were added to each well. The absorbance of each well at 405 nm was recorded immediately and once every 20Attorney Docket No: 206161-0078-00WO min for one hour using a microplate reader. Plates were covered with aluminum foil between readings.

[0566] Human TrxRl vs TrxR2 inhibition

[0567] Human TrxRl and TrxR2 were purchased from SeLENOZYME and inhibition studies were carried out by means of a DTNB assay in 96-well culture plates. Enzymes were diluted to achieve a concentration of 3.58 U mL1. The compounds subject to testing were freshly dissolved in DMF. 10 pL aliquots of the enzyme solution and 10 pL of solutions of the compounds at graded concentrations or 10 pL of 1% DMF in PBS (positive control) were added and incubated for 75 min at 37 °C. A second control consisted of 10 pL of the highest concentration of each compound with 10 pL of PBS. After the chosen incubation time, 10 pL of NADPH (10 mM), 160 pL TE buffer (50 mM Tris-HCl, 2 mM EDTA, pH 7.5) and 10 pL ethanolic DTNB (50 mM) were added producing a total reaction volume of 200 pL. After proper mixing, the formation of 5-TNB was monitored with a microplate reader at 405 nm. This was done 10 times at 30 second intervals over the course of about 5 min. A TNB standard curve (0-2 mM in 200 pL TE buffer) was used to calculate the exact DTNB consumed in the reaction with linear region slopes being calculated by plotting A405 vs time (min). The IC50 values representing the concentration of compound serving to decrease the enzymatic activity of the untreated control by 50% were calculated and are given as the mean and standard error of three repeated experiments. The combination index (CI) was calculated using the Chou-Talalay method

[0568]

[0569] where (D)1, (D)2 and (D)3 are the respective combination doses of compound 1 and compound 2 that yield an effect of 50% growth inhibition, with (Dx)1, (Dx)2 and (Dx)3 being the corresponding single doses for compounds 1, 2 & 3 that result in the same effect. A CI value of less than, equiv. to, and greater than 1 indicates synergy, additivity, and antagonism, respectively. The 1:1:1 mixture of l+Oxa+2 yielded a CI score of 0.92 & 0.85 against TrxRl and TrxR2 respectively.

[0570] Total Cellular Metal Accumulation

[0571] 1 x 106HCT-116 cells were seeded in a 6-well plate (2 mL RPMI-1640). AfterAttorney Docket No: 206161-0078-00WO incubating overnight, the medium was replaced, and the cells were treated with the test compounds (1 pM) for 24 h. The resulting cell monolayers were washed twice with cold PBS, harvested and counted in PBS for a total volume of 400 pL. Samples were divided, and each was mineralized with 1 mL aqua regia and evaporated to dryness on a 110 °C hot plate overnight. Later, 1 mL of 2% HC1 + 1% thiourea was added to each vial. Samples were quantified via ICP-MS. Metal accumulation levels were determined using the relative isotopic prevalence of195Pt,101Ru, and197Au.

[0572] Metal Accumulation in Organelles

[0573] 10 x 106HCT-116 cells were seeded in T-150 flasks (50 mL RPMI-1640). After incubating overnight, the medium was replaced and the cells were treated with either a 1:1:1 mixture of l+Oxa+2 or complex 5 at 1 pM concentration for 24 h. The resulting cell monolayers were washed twice with cold PBS, harvested with trypsin, counted and resuspended in PBS for a total volume of 1000 pL. Isolation of nuclei, cytoplasm, and mitochondria was carried out using a reported procedure (dos Santos et al., 2024, Analytical Biochemistry, 687, 115445). Samples were quantified via ICP-MS. Metal accumulations were determined using the relative isotopic prevalence of195Pt,101Ru, and197Au.

[0574] Annexin- V Apoptosis Assay

[0575] 1 * 106CT-26 cells were seeded in a 6-well plate (2 mL RPMI-1640). After incubating overnight, the medium was replaced, and the cells were treated with the test complexes at their respective IC50 concentrations for 24 h. The cells were harvested using 0.5 mL Trypsin-EDTA (0.25%) and plated cells were obtained by centrifugation. Afterwards, the cells were stained using the Invitrogen Dead Cell Apoptosis Kit (Catalog V13241) with Annexin V Alexa Fluor 488 & propidium iodide and analyzed using a Cytek Northern Lights flow cytometer.

[0576] CRT Translocation Quantification

[0577] 1 x 106CT-26 cells were seeded in a 6-well plate (2 mL RPMI-1640). After incubating overnight, the medium was replaced, and the cells were treated with the test complexes at their respective IC50 concentrations for 24 h. The cells were harvested using 0.5 mL Trypsin-EDTA (0.25%) and plated cells were obtained by centrifugation. CRT translocation was determined by reported procedure (Liu et al., 2020, Methods in Enzymology, 1-13) and analyzed using a CytekAttorney Docket No: 206161-0078-00WO Northern Lights flow cytometer.

[0578] Quantification of ATP Release

[0579] 1 x 106CT-26 cells were seeded in a 6-well plate (2 mL RPMI-1640). After incubating overnight, the medium was replaced, and the cells were treated with the test complexes at their respective IC50concentration for 24 h. The ATP release of the medium was quantified using Invitrogen ATP Determination Kit (Catalog A22066) according to the manufacturer’s instructions.

[0580] HMGB1 ELISA Assay

[0581] 1 * 106CT-26 cells were seeded in a 6-well plate (2 mL RPMI-1640). After overnight incubation, the medium was replaced and the cells were treated with the test complexes at their respective IC50concentration for 24 h. The HMGB1 release of the supernatant was quantified using HMGB1 Detection Kit ELISA (Chondrex, Catalog 6010) according to the manufacturer’s instructions.

[0582] Living Cells ROS Detection Confocal Microscopy

[0583] HCT-116 Tumor cells were seeded at a density of 1 x 105cells overnight in 35 mm glass dishes of 10 mm diameter. Afterwards, cells in the control group (no treatment) were subject to a medium change while others were incubated with a 1: 1: 1 mixture of 1 + oxaliplatin + 2 or complex 5 for 24 h at the respective IC50 concentrations. Post-incubation, the media were removed and the cells were washed (2x) with PBS. Cells were then incubated with 1 pM CM-H2DCFDA in the medium at 37 °C for 15 min. The dye-medium solution was removed, and the cells were washed with PBS (2x) before 50 nM Mitotracker® Red in the medium were added and allowed to incubate for 30 min at 37 °C. Later, the dye was washed off with PBS and 5 ug / mL Hoechst 33342 were added and the cells were allowed to stand for 30 min. Lastly, the cells were washed twice with PBS and RPMI1640 (free of phenol red) was added. The cells were then imaged fluorescently on a Nikon AXR-N SPARC laser confocal microscope while incubating at 37 °C.

[0584] In Vivo Tumor Inhibition Efficacy

[0585] Procedures were conducted in accordance with the Guide for the Care and Use ofAttorney Docket No: 206161-0078-00WO Laboratory Animals (U. S. Public Health Service, National Institute of Health) and the protocol for this experiment was approved by the Institutional Animal Care and Use Committee (IACUC, protocol numbers AUP -2022-00101 & AUP-2024-00337) at The University of Texas at Austin. Briefly, 6-8 weeks female BALB / c mice were acclimatized for 7 days thereafter, murine colon carcinoma cells, CT26 (1.5 x 106cells in 100 pL of sterile PBS) were subcutaneously injected to the right flank. The experiments were initiated once tumors became palpable on Day 8. At this point, the animals were separated to 4 groups (n = 5). The animals were monitored for the development of pain or distress symptoms with the body weight and tumor size also being closely monitored. Control mice, treated with 100 pL of sterile saline, as well as those treated with doxorubicin 2 mg / kg, a physical mixture consisting of complex 1 (5.7 mg / kg) + Oxa (4 mg / kg) + complex 2 (12 mg / kg), and complex 5 (21 mg / kg) were administrated i.p. on days 8, 10, 12 & 14. On day 16, mice were euthanized, and tumor and organs (liver, kidney, spleen, heart and lungs) were collected for ICP-MS metal quantification.

[0586] Metal Accumulation In Vivo

[0587] Organs were weighed and mineralized with aqua regia for 3 h. Afterwards, solutions were completely dried at 110 °C and 1000 pL of 2% HNO3 was added. The gold, platinum and ruthenium content of each sample was determined by ICP-MS.

[0588] In Vivo Tumor Rechallenge

[0589] All animals were group-housed in a semi-barrier animal facility and kept in clear cages with water and laboratory food pellets available. Procedures were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (U. S. Public Health Service, National Institute of Health) and the protocol for this experiment was approved by the Institutional Animal Care and Use Committee (IACUC, protocol number AUP-2024-00337) at The University of Texas at Austin. Immunocompetent female BALB / c mice (Jackson Laboratory, Stock No: 000651; 6-8 weeks at the beginning of the experiment) were used for these studies.

[0590] CT26 cells were pretreated with IC50 concentrations of the test compounds for 24 h prior to inoculation or only subjected to medium change (control group). Animals were separated to 4 groups (n = 5) and were injected with 1.5* 106cells to the right flank treated with 3X freeze-thaw cells, doxorubicin, a mixture of 1 + 2 + oxaliplatin or complex 5. After 7 days, mice were inoculated s.c. with 5 x HP naive CT26 cancer cells into the contralateral flank. Prior to allAttorney Docket No: 206161-0078-00WO injections, the supernatant of one flask per harvest day was tested for mycoplasma contamination (MycoAlert™, Lonza, Rockland, ME), which yielded negative results on all days. Body weights and tumor measurements were checked daily, and tumor development was compared among groups.

[0591] Total WBC and Differential Manual Count

[0592] Blood samples were collected from all mice groups by tail vein and were analyzed for total WBC count and differential count (Biorner, 2019, Pathobiol. Aging Age Relat. Dis., 9, 1647400). Blood was draw on Day -7 (before vaccination), Day 0 (before rechallenge) and Day 7. Total WBC was analyzed by adding 2 pL of blood to 38 pL Tuerk solution (Sigma- Aldrich product - 93770) and was counted using a hemocytometer after 45 min under a lOx light microscope. Differential counting was done by preparing blood smears of blood samples, letting them air dry, fixing with methanol, and staining with Wright Stain solution (Sigma- Aldrich product - 45253). 200 WBC cells were counted and classified under lOOOx magnification using a Leica DMI6000b microscope.

[0593] ion multimetal

[0594]

[0595] ex induces immunogenic cell death with distinct

[0596]

[0597] The present example describes a Pt(IV)-Au(I)-gemcitabine prodrug that co-releases oxaliplatin, a redox active gold N-heterocyclic carbene (NHC) and gemcitabine upon intracellular reduction. Relative to its constituents, this prodrug displays improved cytotoxicity, metal uptake and an in-vitro immunogenic cell death response.

[0598] Multimetallic complexes continue to attract interest as platforms capable of integrating distinct modes of biological reactivity within a single metalloconstruct (Curado, 2019, Metalbased Anticancer Agents, 143). By combining multiple metal centers within a well-defined molecular scaffold, it becomes possible to achieve complementary reactivity benefits while avoiding bioavailability and side effect limitations associated with physical drug mixtures (Babu et al., 2023, Angew. Chem. Int. Ed., 62, e202217233). The present example demonstrates the promise of this approach via a gold N-heterocyclic carbene (NHC) gemcitabine prodrug linked through a platinum center.

[0599] Platinum(II)-based agents, including cisplatin, carboplatin, and oxaliplatin, remain central to chemotherapy yet, severe, long lasting side effects, such as neurotoxicity, ototoxicity andAttorney Docket No: 206161-0078-00WO nephrotoxicity provide limitations to their clinical use (Oun et al., 2018, Dalton Trans., 47, 6645). Most side effects of platinum(II) agents reflect platinum accumulation in organs that are not associated with the tumor or the tumor microenvironment (TME) (Zhang et al., 2025, PeerJ, 13, el9375). Decreasing the concentration of available platinum at these remote sites could therefore translate into improved clinical outcomes. One possible means of achieving this goal is to use Pt(IV) complexes as prodrugs for the corresponding Pt(II) species. Pt(IV) complexes are typically hexacoordinate, whereas the FDA-approved Pt(II) drugs are tetracoordinate. The two additional coordinated moieties, typically referred to as the axial ligands, militate against interactions with various biomolecules, such as histidine- and cysteine-rich proteins (Johnstone et al., 2016, Chem. Rev., 116, 3436). The additional coordination sites also allow for structural modifications via conjugation of ligands that can improve the pharmacological properties of the complex as a whole (Gibson, 2021, ChemMedChem, 16, 2188). Gibson, et al. recently reported that Pt(IV) prodrugs have lower metal accumulation in off-target organs, as well as a lower incidence of chemotherapy-induced peripheral neuropathy (CIPN) in-vivo. CIPN is a long lasting side effect that affects more than 70% of patients receiving Pt(II) drugs (Babu et al., 2025, J. Med. Chem., 68, 1608).

[0600] Gold(I) complexes have also attracted interest as anticancer agents, in part due to their ability to inhibit members of the thioredoxin reductase (TrxR) family that are often upregulated in malignant cells (Salmain et al., 2023, Cancers, 15, 4448). TrxR enzymes are key regulators of cellular redox homeostasis and are found in cytoplasm (TrxRl) and mitochondria (TrxR2) (Mustacich, 2000, Biochem. J., 346, 1). Importantly, several gold-based anticancer agents, as well as a number of other metal complexes, have been shown to induce ICD (Zhang et al., 2023, Angew. Chem. Int. Ed., 62, e202300662). ICD is a regulated form of cell death in which tumor cell stress leads to the release of damage-associated molecular patterns (DAMPs), thereby facilitating antigen presentation and activation of an antitumor immune response (Sen et al., 2022, Chem. Soc. Rev., 51, 1212). Combining a gold-based TrxR inhibitor (Babu et al., 2025, Angew. Chem. Int. Ed., 64, e202514351) with a Pt(IV) core is attractive as a means to improve the efficacy of both classes of anticancer agents.

[0601] Recent reports provide a first-generation bimetallic complex (Gen 1) that served as a proof-of-concept demonstration of this strategy. Briefly, Gen 1 served to show that co-delivery of both metals can increase an early apoptotic phase which is important in ICD. However, Gen 1 exhibited modest cytotoxicity and cellular uptake. A rational redesign was thereforeAttorney Docket No: 206161-0078-00WO implemented to generate a scaffold with improved cytotoxicity that would also induce a robust ICD-associated cellular response.

[0602] Herein, the chemical synthesis, characterization, and biological evaluation of a next generation multi-action multimetal complex (Gen 2) is reported (Figure 25). This new construct incorporates on opposing axial ligand positions both an Au(I) bis-NHC ICD inducer and the FDA approved anticancer drug, gemcitabine. Gemcitabine was chosen for its antiproliferative activity, relative high water solubility, ability to potentiate an immune response (Liu et al., 2010, Br. J. Cancer, 102, 115), as well as the fact that it is co-administered with oxaliplatin in the clinic (Gutierrez et al., 2014, OncoTargets Ther., 7, 2093). As detailed below, Gen 2 demonstrates improved cytotoxicity compared to Gen 1 and various monometallic controls. Additionally, Gen 2 displayed good nuclear and mitochondrial co-accumulation. It also induced recognized ICD-related DAMPs, including i) calreticulin (CRT) translocation to the cell membrane, ii) transcriptional activation of high mobility group box 1 protein (HMGB1), iii) tumor necrosis factor 2 (TNFR2), iv) p53, v) dendritic cell and natural killer cell (DC-NK) signaling, and vi) G2 / M checkpoint pathways. The transcriptional effects observed for Gen 2 are distinct from those triggered by oxaliplatin and gemcitabine, highlighting the unique multi-action behavior arising from covalent incorporation of multiple agents within a single prodrug.

[0603] The synthetic route to Pt(IV)-Au(I) Gen 2 is shown in Figure 26. Briefly, an asymmetric Au(I) bis NHC was prepared by reacting chloro(dimethylsulfide)gold(I) with a redox active 1,4-naphthoquinone NHC to give the corresponding NHC-Au-Cl complex in high yield. The chlorido ligand was first replaced by hydroxide and subsequently by an acetonyl ligand. The resulting acetonyl derivative enabled the preparation of the bis-Au(I)-NHC complex in high yield (Sen et al., 2020, J. Am. Chem. Soc., 142, 20536). In order to facilitate the conjugation to Pt(IV), this hydroxyl was reacted with l,l'-carbonyldiimidazole and subsequently with ethylenediamine yielding a primary amine end group. Separately, oxaliplatin(IV) bearing two hydroxyls was conjugated first to gemcitabine bearing Boc protecting groups on the amine and 3’OH sites. Next, the protecting groups were removed by treating with a nitric acid: CH2C12 mixture for 10 min. TFA was avoided in this step as it can coordinate to the trans axial position (Wexselblatt et al., 2013, Angew. Chem. Int. Ed., 52, 6059). This gemcitabine-containing intermediate was then reacted with disuccinimidyl carbonate and subsequently with the primary amine of the bis NHC Au(I) using a carbamate strategy (Babu et al., 2020, Inorg. Chem., 59, 5182) to yield the multimetal complex in 33% yield following purification using preparativeAttorney Docket No: 206161-0078-00WO HPLC.

[0604] The Gen 2 prodrug was characterized by1H,13C, and195Pt spectroscopies, as well as by HRMS. Its physicochemical properties, including stability (ti / 2) under physiological conditions and propensity to undergo reduction, were then assessed (Figure 27, Figure 28). A key criteria for a prodrug is that it remains largely intact until it reaches its target (Markovic et al., 2020, Pharmaceutics, 12, 1031). Stability was assessed by dissolving the complex in 1% DMSO in RPMI1640 cell culture medium at 37 °C and monitoring changes (if any) by HPLC. The ability of Gen 2 to undergo reduction in the presence of a 10-fold excess of ascorbate (two electron donor), GSH (one electron donor) or a mixture of both to simulate biologically redox conditions at pH 7.0, 37 °C was also assessed by HPLC. It was found to be reduced rapidly under these conditions, leading to the concurrent release of the Au(I) complex, the gemcitabine axial ligand, and free oxaliplatin as confirmed by LC-MS (Figure 27). On the other hand, in the absence of a reductant, Gen 2 proved stable under physiological conditions with a ti / 2 for decomposition of 51 h (Figure 28).

[0605] Cytotoxicity was then assessed in CT26 colorectal carcinoma cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Both Gen 2 and gemcitabine displayed steep dose-response curves and sub-nanomolar IC50 values that were lower than those observed for Gen 1 and its monometallic precursors (Figure 29). A similar trend was also found in A549 human lung carcinoma cells where Gen 2 produced low nanomolar ICso values, comparable to gemcitabine and approximately two orders of magnitude lower than oxaliplatin or Gen 1 (Table 6). On this basis, it is suggested that cancer cell death is mediated primarily through the gemcitabine, which is released from the multifunctional prodrug inside the cancer cells.

[0606] Table 6. IC50 values [pM] in A549 cells after a 72 h incubation period (tested in triplicate).

[0607]

[0608] To determine whether the enhanced antiproliferative activity of Gen 2 is further driven by altered intracellular uptake, total cellular uptake of platinum and gold was quantified by inductively coupled plasma mass spectrometry (ICP-MS). CT26 cells were treated for 24 h with equimolar concentrations of oxaliplatin, Au(I)-amine, Pt-Au (Gen 1), and Pt-Au (Gen 2) (FigureAttorney Docket No: 206161-0078-00WO 30, top). Gen 2 exhibited a statistically significant increase in total platinum uptake relative to both oxaliplatin and Gen 1. In contrast, gold uptake was reduced compared to what was seen for Au(I)-amine; however, it proved significantly higher than that observed for Gen 1. These findings were taken as evidence of improved co-delivery of both metals (platinum and gold) by the second-generation Gen 2 scaffold.

[0609] To probe further subcellular metal distribution following intracellular reduction, nuclei, cytoplasm, and mitochondria were isolated from CT26 cells incubated for 24 h with equimolar concentrations of either 1) a 1:1:1 physical mixture of oxaliplatin, Au(I)-amine, and gemcitabine, or 2) Gen 2 (Figure 30, bottom). In both cases, platinum predominantly localized to the nucleus. No statistically significant difference in nuclear platinum levels was observed between the two treatments. In contrast, Gen 2 displayed higher gold content within the mitochondrial fraction relative to the physical mixture.

[0610] Based on the above findings, it is suggested that incorporation of platinum, gold and a nucleoside drug, gemcitabine, within a single prodrug increases the total cellular accumulation of both metals relative to Gen 1. It also modifies the intracellular distribution relative to a physical mixture of the constituents. The enhanced cytotoxic potency of Gen 2 is therefore not solely attributable to axial gemcitabine release but is accompanied by increased platinum uptake and altered subcellular distribution of the metal components following reduction. Such changes in metal uptake and localization may lead to a diverse cellular response. This appreciation prompted the investigation of the ICD potential of Gen 2 in-vitro.

[0611] Transcriptional analysis of ICD has largely focused on immune cell populations or TME remodeling (Zhang et al., 2023, Aging, 15, 10305). In contrast, pathway-level transcriptional responses within tumor cells after chemotherapeutic treatment, and their relevance to ICD-associated signaling is underexplored (Sha et al., 2025, Sci. Rep., 15, 23501). Next determined was whether Gen 2 elicits canonical gene expression pathways that are linked to ICD. RNA profiling was performed on RNA isolated from CT26 cells treated with either Gen 2, oxaliplatin, or gemcitabine. Oxaliplatin and gemcitabine are FDA approved drugs with well-established mechanisms of action (MOAs). They were therefore used as controls. The differential expression for the three groups was analyzed by ingenuity pathway analysis (IP A) and compared to untreated cells. This approach evaluates changes across groups of functionally related genes rather than isolated transcriptional events, allowing in principle a broader understanding of downstream cellular response impact (Cirillo et al., 2017, Front. Genet., 8).Attorney Docket No: 206161-0078-00WO The pathways affected by oxaliplatin were related to upregulation of oxidative phosphorylation, Eukaryotic Translation Initiation Factor 2 (EIF2) signaling and inhibition of mitochondrial dysfunction (Figure 31). This correlates with the findings of Sastre-Serra et al. that led to oxidative phosphorylation being suggested as a predictive biomarker for oxaliplatin response in colorectal cancer (Martinez-Bernabe et al., 2024, Biomolecules, 14, 1359). In the case of gemcitabine, the pathways affected were associated with pro-inflammatory responses, a finding consistent with the immunomodulatory functions of gemcitabine in cancer (Larson et al., 2024, Cancer Med., 13, e2787). In contrast, Gen 2 was found to upregulate signaling pathways associated with an immunogenic response (Figure 32). Activation of G2 / M DNA damage checkpoint signaling was observed. This led to the suggestion that Gen 2 causes cell cycle arrest and death to occur at the G2 / M transition phase. Polo-like kinase (PLK) signaling pathway inhibition was seen and provides further evidence in support of the hypothesis that Gen 2 causes cell cycle arrest and death at the G2 / M transition phase as these kinases are essential for cell cycle regulation beginning at the G2 / M phase (Iliaki et al., 2021, Biochem. Pharmacol., 193, 114747).

[0612] The activation of p53 signaling is a cellular response to stress, such as oxidation and DNA damage, that is associated with oxaliplatin and Au(I) naphthoquinone NHC (Faivre et al., 2003, Biochem. Pharmacol., 66, 225; McCall et al., 2017, Chem. Sci., 8, 5918). The activation of HMGB1 signaling and TNFR2 signaling is consistent with Gen 2 causing inflammation due to activation of inflammatory cells through HMGB1 and other activating proteins correlated with induction of an immune response (Wen et al., 2023, Front. Biosci. -Landmark, 28, 260; Bai et al., 2022, Front. Immunol., 13). Gen 2-induced inflammatory signaling coincides with the upregulated crosstalk between DC-NK signaling that is required for the activation and subsequent immune cell amplification associated with the activation of both an innate and adaptive immune response (Zhao, 2022, Front. Immunol., 13). Inhibition of the interlukin-10 (IL- 10) signaling pathway was also seen. The IL- 10 signaling pathway is mostly associated with an anti-inflammatory response led to the proposal that inflammation effects caused by Gen 2 are enhanced. Additionally, the cytokine IL- 10 has been shown to downregulate T-cell function and thus help tumors evade detection by the immune system (Sato et al., 2011, Immunol. Res., 51, 170). It is reasonable to expect that inhibition of this pathway would result in low levels of IL- 10 within the TME and hence an active immune response (Showalter et al., 2017, Cytokine, 97, 123). Taken in concert, the concurrent activation / inhibition of these pathways is associated withAttorney Docket No: 206161-0078-00WO dying cancer cells that promote inflammatory signaling and activation of both innate and adaptive immunogenic responses. In order to validate ICD potential from RNA sequencing Gen 2 ATP and HMGB1 release from CT26 cells were compared. The total release of both DAMPs was significantly higher compared to oxaliplatin and gemcitabine (Figure 31, Figure 33).

[0613] During ICD, CRT translocate from the endoplasmic reticulum (ER) to the cell surface of tumor cells and acts as a pro-phagocytic “eat me” signal for antigen presenting cells (APCs) (Kielbik et al., 2021, Cells, 10, 130). As translocation is a post-translational process and cannot be inferred from RNA sequencing data, CRT translocation was examined to validate ICD induction at the cellular level. Confocal microscopy of CT26 cells treated with either oxaliplatin, gemcitabine, or Gen 2 exhibited increased co-localization of emission signals from a commercially available CRT antibody (green) with cell membrane immunostaining with wheatgerm agglutinin (WGA) antibody (red). Gen 2 exhibited the greatest amount of CRT translocation compared to oxaliplatin and gemcitabine (Figure 34). Taken together, RNA-sequence pathway analysis and DAMPs assessment provide evidence that the immunogenic response elicited by the multimetal complex, Gen 2, is substantially enhanced relative to its individual constituent agents.

[0614] In summary, the present example reports a next-generation Pt(IV)-Au(I) multimetal prodrug that integrates platinum-based DNA damage, gold-mediated redox stress, and nucleoside-driven antiproliferative activity within a single, reduction-activated scaffold. Relative to its first-generation analogue (Gen 1) and to physical mixtures of the constituent agents, Gen 2 displays; enhanced cellular uptake, improved subcellul ar metal distribution, and increased cytotoxic potency. Moreover, RNA pathway analysis revealed activation of multiple pathways associated with ICD, an inference further supported by DAMPs measurement in-vitro. These findings led to the proposal that integration of multiple anticancer agents within a single prodrug can yield cellular responses distinct from those of the constituent agents and that, as such, the approach described here may have a role to play in the development of next generation drugs.

[0615] The materials and methods utilized are described herein.

[0616] Materials and General Methods

[0617] All chemical reactions were conducted under a nitrogen atmosphere using Schlenk techniques unless otherwise noted. Glassware was oven dried at 120°C before use. All materialsAttorney Docket No: 206161-0078-00WO were obtained from commercial sources at the highest purity available and used without further purification. Chemicals were purchased from Sigma-Aldrich. Solvents were either dried using a solvent purification system (dichloromethane (DCM), acetonitrile, methanol) or dried over molecular sieves (toluene) (3 A) and degassed prior to use. Complexes were characterized by 'H &195Pt NMR spectroscopy, HRMS, and elemental analyses. Progress of reactions was monitored by analytical HPLC (Thermo Scientific UltiMate 3000) with a reverse-phase C18 column Phenomenex Kinetex, length 100 mm, internal diameter 4.60 mm, particle size 2.6 pm, pore size 100 A. The purity and retention time (RT) of the newly synthesized complex (Gen 2) was measured with the same analytical HPLC system water / acetonitrile gradient at a flow rate of 1 mL / min. Reaction mixtures were purified on a preparative HPLC system (Thermo Scientific UltimaMate 3000 station) equipped with a reverse-phase C18 column (Phenomenex Luna 250 x 21.2 mm, 10 pm, 100 A) using a similar mobile phase at a flow rate of 15 mL / min. UV spectroscopic detection was measured at 220 nm in the case of both the HPLC systems.

[0618] Appropriate fractions were combined and lyophilized to yield the desired pure compounds.

[0619] All NMR spectroscopic data were collected on a Bruker AVANCE III™ HD 500 MHz spectrometer or a Varian Inova 400 MHz. The data were processed using either MestreNova software.1H NMR chemical shifts were referenced with the individual solvent residual peaks of the respective NMR solvents.195Pt NMR chemical shifts were reported with respect to the chemical shift of a standard (K^PtCh in water) at -1624 ppm. High resolution mass spectra (HRMS) were recorded using a X500R QTOF by direct injection+ve mode electrospray ionization.

[0620] Synthesis

[0621] (L3-bis(2,6-Diisopropylphenyl)-4,9-dioxo-L3,4,9-tetrahvdro-2H-2X3-naphthor2,3-d]imidazol-2-yl)(l-(2-hydroxyethyl)-3-mesityl-L3-dihydro-2H-2k3-imidazol-2-yl) gold(I) (Complex 1)

[0622] This Au(I) complex was prepared using a reported procedure (Sen et al., 2020, J. Am. Chem. Soc., 142, 20536).

[0623] ‘HNMR (500 MHz, DMSO-d6) 58.03 (dd, J= 5.7, 3.4 Hz, 2H), 7.91 (dd, J= 5.9, 3.3 Hz, 2H), 7.63 (t, J= 7.8 Hz, 2H), 7.51 (d, J= 1.8 Hz, 1H), 7.34 (d, J= 7.8 Hz, 4H), 7.28 (d, J = 1.8 Hz, 1H), 6.82 (s, 2H), 4.93 (t, J= 4.9 Hz, 1H), 3.58 (t, J= 5.0 Hz, 2H), 3.23 (q, J= 5.0 Hz, 2H), 2.58 -2.51 (m, 8H), 2.40 (s, 3H), 1.56 (s, 6H), 1.05 (dd, J= 6.8, 2.8 Hz, 20H). HPLC - 6.7 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN), ESI-HRMS (m / z) calculated forAttorney Docket No: 206161-0078-00WO [C49H56AUN4O3]+: 945.98, found 945.39.

[0624] ( 1 -(2-((lH-Imidazole- 1 -carbonyl)oxy)ethyl)-3 -mesityl- 1,3-dihy dro-2H-2 3 -imidazol-2-yl)(L3-bis(2,6-diisopropylphenyl)-4,9-dioxo-l,3,4,9-tetrahvdro-2H- naphthor2,3-d]imidazol-

[0625]

[0626] 2-yl) gold(T)

[0627] To an oven-dried 25-mL three-neck round bottom flask was added 1,1’-carbonyldiimidazole (187 mg, 1.15 mmol, 6 equiv.). After purging with N2, 2 mL dry DCM and diisopropylamine (DIPEA) (50.3 pL, 0.289 mmol, 1.5 equiv.) were added to the flask. A solution of compound [1][PF6] (211 mg, 0.192 mmol, 1 equiv.) in 4 mL dry DCM was made up in an oven-dried 10-mL scintillation vial and added dropwise to the flask over the course of 10 min. The mixture was stirred at room temperature for 4 h to produce a clear yellow liquid. The mixture was concentrated under reduced pressure and purified on a silica gel column with 10% MeOH / DCM as the mobile phase. The fractions containing pure product were collected and dried in vacuo to afford 2 as a yellow solid. Yield: 184 mg (80.3%) ESI-HRMS (acetonitrile) (m / z): calculated for C55H55AuN6O: 1039.4180, observed: 1039.4171.rH NMR (600 MHz, DMSO-d6) δ8.08 (s, 1H), 8.01 (dd, J= 5.7, 3.3 Hz, 2H), 7.89 (dd, J= 5.8, 3.3 Hz, 2H), 7.81 (d, J= 2.0 Hz, 1H), 7.61 (t, J= 7.8 Hz, 2H), 7.42 (s, 1H), 7.32 (m, 5H), 7.05 (s, 1H), 6.80 (s, 2H), 4.26 (t, J = 4.9 Hz, 2H), 3.93 (t, J= 5.0 Hz, 2H), 2.52 (m, 4H), 2.38 (s, 3H), 1.51 (s, 6H), 1.02 (dd, J= 6.8, 4.8 Hz, 24H),13C NMR (151 MHz, DMSO) 8 192.72, 181.06, 174.97, 148.03, 145.25, 138.99, 137.52, 135.06, 134.13, 133.95, 133.43, 133.06, 132.48, 131.26, 130.94, 129.69, 126.72, 124.46, 124.44, 123.84, 117.79, 66.38, 65.36, 49.06, 40.39, 40.25, 40.11, 39.97, 39.83, 39.69, 39.56, 28.35, 24.55, 23.97, 21.24, 17.02, 15.62.

[0628] (l-(2-(((2-Aminoethyl)carbamoyl)oxy)ethyl)-3-mesityl-l,3-dihydro-2H-2X3-imidazol-2-yl)(l,3-bis(2,6-diisopropylphenyl)-4,9-di oxo-1, 3,4, 9-tetrahydro-2H- naphthor2,3-d1imidazol-

[0629]

[0630] 2-yl)gold(D acetate salt (3)

[0631] To an oven-dried 10-mL two-neck round bottom flask was added compound 2 (68.0 mg, 57.4 pmol, 1 equiv.). After purging with N2, 4 mL dry DCM was added to the flask.

[0632] Ethylenediamine (23.0 pL, 344 pmol, 6 equiv.) and TEA (12.0 pL, 86.1 pmol, 1.5 equiv.) were then added. The mixture was stirred at room temperature for 3.5 h to produce a yellow clear liquid. The mixture was subject to flash column chromatography (silica gel, DCM: MeOH (with 7% w / v NH4OAC) = 98:2 and then 80:20). The volatiles in the fractions were evaporated offAttorney Docket No: 206161-0078-00WO under reduced pressure, and the remaining aqueous suspension was lyophilized for 48 h to afford a light yellow solid. Yield: 62.4 mg (92%). ESI-HRMS (acetonitrile) (m / z): calculated for C52H62AuN6O4: 1031.4493, observed: 1031.4474. 'HNMR (500 MHz, DMSO-d6) δ8.02 (dd, J = 5.8, 3.3 Hz, 2H), 7.91 (dd, J = 5.8, 3.3 Hz, 2H), 7.62 (t, J= 7.8 Hz, 2H), 7.52 (s, 1H), 7.34 (d, J = 7.8 Hz, 4H), 7.26 (s, 1H), 6.82 (s, 2H), 3.81 - 3.70 (m, 4H), 3.14 (q, J= 6.3 Hz, 2H), 2.78 (t, J = 6.7 Hz, 2H), 2.58 -2.51 (m, 4H), 2.40 (s, 3H), 1.56 (s, 6H), 1.04 (dd, J= 6.9, 3.7 Hz, 24H),13C NMR (126 MHz, DMSO) 6 180.16, 174.39, 155.20, 144.61, 138.33, 134.47, 133.62, 133.47, 132.82, 132.46, 131.87, 130.65, 129.06, 126.13, 123.86, 123.33, 62.50, 49.28, 39.95, 39.85, 39.78, 39.69, 39.61, 39.52, 39.45, 39.35, 39.28, 39.19, 39.02, 38.85, 28.88, 27.76, 23.97, 23.40, 20.68, 16.56.

[0633] OxaliIV(Gem)(Au(D) (Gen 1)

[0634] This Pt(IV)-Au(I) complex was prepared using a reported procedure (Babu et al., Angew. Chem. Int. Ed., e202514351).

[0635] 'HNMR (500 MHz, DMSO-d6) δ8.03 (dd, J= 5.7, 3.3 Hz, 2H), 7.91 (dd, J= 5.8, 3.3 Hz, 2H), 7.63 (t, J= 7.8 Hz, 2H), 7.51 (s, 1H), 7.35 (d, J= 7.8 Hz, 4H), 7.06 (s, 2H), 6.82 (s, 2H), 3.83 -3.71 (m, 7H), 2.97 - 2.92 (m, 5H), 2.91 - 2.83 (m, 2H), 2.54 (q, J= 6.0 Hz, 6H), 2.41 (s, 3H), 2.16 - 1.99 (m, 2H), 1.56 (s, 6H), 1.49 (t, J= 15.4 Hz, 4H), 1.32 (s, 1H), 1.05 (dd, J= 6.8, 4.3 Hz, 25H).195PtNMR(108 MHz, DMSO-d6) δ 1417.35. HPLC - 6.03 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN) ESI-HRMS (mlz) calculated for [C61H76AuN8O11Pt]+: 1489.37, found 1489.49.

[0636] cct-rPt((lR,2R)-DACH)(ox)( Gem-Bis BOC protected)(OH)1 (5)

[0637] 98.5 mg of 4 were dissolved in 10 mL of DMSO and 165.7 mg (1.2 equiv.) of gem protected-DSC ( were added. The reaction mixture was stirred overnight at 30°C. Afterwards, the presumed product was collected through ether precipitation and washed several times with ether. Yield - 75%, 158 mg.195Pt NMR (108 MHz, DMSO) 5 1416.64. HPLC - 4.81 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN)

[0638] cct-rPt((lR,2R)-DACH)(ox)(gemcitabine)(OH)1 (Oxali(Gem)(OH) (6)

[0639] 220 mg of 5 were stirred in 6 mL of a 2: 1 DCM: HNO3 mixture for 10 min until a clear solution was formed. Afterwards, the volatiles were evaporated off under reduced pressure and the product was precipitated using methanol and diethyl ether to give 163.8 mg of a grey colorAttorney Docket No: 206161-0078-00WO product. Yield 95%. HPLC - 2.91 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN)

[0640] cct-lPt((l R.2R)-DACH)(ox)(gcmcitabinc)(succinimidyl carbonate )1 (7)

[0641] 115 mg of 6 were dissolved in 3mL of DMF and 204 mg (5 equiv.) of N, N’-Disuccinimidyl carbonate was added for 1 h. The reaction was monitored via HPLC. Once the reaction was deemed complete, the volatiles were removed under reduced pressure and the product was extracted using ACN and diethyl ether. Yield - 80%, 110 mg.195Pt NMR (108 MHz, DMSO) 8 1684.71. HPLC - 3.00 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN)

[0642] OxaliIV(Gem)(Au(I)l (Gen 2)

[0643] To an oven-dried 10-mL two-neck round bottom flask was added 3 (15.0 mg, 12.7 pmol, 1 equiv.) and 7 (14.3 mg, 16.6 pmol, 1.3 equiv ). After purging withN2, 1 mL dry DMF and TEA (4.6 pL, 33.1 pmol, 2.6 equiv.) were added to the flask. The mixture was stirred at room temperature for 4 h. Boc2O (5.9 pL, 25.5 pmol, 2 equiv.) and additional TEA (3.6 pL, 25.5 pmol, 2 equiv.) were then added to the flask and the mixture was further stirred at room temperature for 2 h. The volatiles were evaporated off under reduced pressure and the remaining mixture was re-dissolved in 400 pL MeOH. The mixture was purified using a semi-preparative RP-HPLC. Solvent was evaporated under reduced pressure and the resulting mixture subject to PF6 anion exchange chromatography. The aqueous suspension obtained in this way was lyophilized for 48 h to afford a light-yellow solid (8.8 mg, 33%). 'H NMR (600 MHz, DMSO-de) δ8.00 (dt, J = 7.4, 3.7 Hz, 2H), 7.89 (dd, J = 5.8, 3.3 Hz, 2H), 7.61 (t, J = 7.8 Hz, 2H), 7.50 (s, 1H), 7.48 (s, 1H), 7.40 (s, 1H), 7.35 (s, 1H), 7.32 (d, J = 8.0 Hz, 5H), 7.05 (s, 1H), 6.85 (d, J = 6.0 Hz, 1H), 6.79 (s, 2H), 6.14 (s, 1H), 5.77 (d, J = 7.5 Hz, 1H), 4.30 - 3.85 (m, 4H), 3.71 (s, 3H), 2.91 (s, 4H), 2.57 (s, 3H), 2.55 - 2.48 (m, 3H), 2.38 (s, 4H), 1.54 (s, 6H), 1.48 (s, 6H), 1.12 (d, J = 9.1 Hz, 0H), 1.02 (dd, J = 6.8, 4.8 Hz, 25H).13C NMR (151 MHz, DMSO-d6) δ 192.93, 180.75, 174.96, 166.09, 158.05, 155.82, 155.11, 154.98, 145.21, 138.91, 135.05, 134.22, 134.07, 133.41, 133.05, 132.46, 131.25, 129.64, 126.72, 124.45, 123.48, 118.75, 95.30, 94.99, 80.85, 77.88, 66.48, 62.59, 62.25, 60.09, 58.97, 49.32, 40.40, 40.26, 40.12, 39.98, 39.84, 39.70, 39.56, 33.28, 31.73, 31.38, 29.22, 29.14, 28.36, 24.54, 23.97, 23.30, 22.53, 21.25, 17.13.195Pt NMR (108 MHz, DMSO) 8 1601.46. HPLC - 5.70 min (0-100% ACN in 5.84 min + 2 min constant 100% ACN). ESI-HRMS (acetonitrile) (m / z): calculated for C71H85AuF2N11O16Pt: 1778.57,Attorney Docket No: 206161-0078-00WO observed: 1778.54.

[0644] Reduction and Stability

[0645] The second generation Pt(IV)-Au(I) complex was dissolved in MeOH. Concentrated solutions of ascorbic acid, GSH, or a mixture of both GSH and ascorbic acid were prepared in water, and the pH was adjusted to 7.0 with NaOH. A 10-fold molar excess of the corresponding solution was then added and reduction was monitored by analytical HPLC. The half-lives ( / 1 / 2) for reduction was determined via linear fitting of ln(At / Ao) vs time (t) in accord with the pseudo first order rate equation At = Aoe-kt, where Ao and At are the integrated areas of the HPLC peaks of the respective complexes at t = 0 and at time t, respectively, and k (slope) is the rate constant. The value of Z1 / 2 was calculated using the equation / 1 / 2 = -ln(2) / k.

[0646] Stability studies were conducted by dissolving the complex in 1% DMSO and RPMI medium at pH 7.4, and maintaining them at 37°C. HPLC chromatograms were recorded until the peak areas were less than half the starting peak area. The / 1 2 value was calculated by linear fitting of ln(At / Ao) vs time ( / ) where At and Ao are the integrated peak areas determined by HPLC at t = 0 and at time t.

[0647] Antiproliferative Assay in Tumorigenic Cells

[0648] Cell proliferation studies: A549 (ATCC®) cells and CT26 (ATCC®) cells were harvested and seeded into 96-well culture plates (Costar 07-200-90) in 100 pL of culture medium containing 10% fetal bovine serum (FBS) and 2% penicillin / streptomycin (P / S). The cells were allowed to incubate overnight at 37 °C in the presence of 5% CO2. A549 cells were seeded at a density of 1500 cells / well and CT26 at a density of 750 cells / well. The next day, appropriate serial dilutions of drug stocks in culture media were made. To each well of a 96 well plate was added 100 pL of the appropriate solution. After a total of three days, a 50 pL aliquot of 3 mg / mL tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (Alfa Aesar LI 1939), dissolved in culture medium without FBS was added to each well, followed by a 4 h incubation period at 37 °C. After removal of the medium, the resulting formazan crystals were dissolved in 50 pL DMSO and the absorbance was measured at 560-650 nm using a microplate reader (Molecular Devices, Sunnyvale, CA). Absorbance values were corrected for background and then normalized to wells containing untreated cells. The resulting dose response curves were subjected to linear regression analysis using Origin (OriginLab, Inc.) to determine the IC50Attorney Docket No: 206161-0078-00WO values. Data are shown as mean inhibition of proliferation or growth as a percentage of control cells and are from 3 replicate experiments. The maximum concentration of DMSO used was 0.1%. This concentration of DMSO was determined to be non-toxic in separate control experiments.

[0649] Total Cellular Metal Accumulation

[0650] 1 x 106CT26 cells were seeded in a 6-well plate (2 mL RPMI-1640) containing 10% FBS and 2% P / S. After incubating overnight, the cell media was replaced, with new media containing test compounds (1 pM) for 24 h. After 24 hours, cell monolayers were washed twice with cold PBS, harvested and counted in PBS for a total volume of 400 pL. Samples were divided, and each was mineralized with 1 mL aqua regia and evaporated to dryness on a 110 °C hot plate overnight. Later, 1 mL of 2% HC1 + 1% thiourea was added to each vial. Samples were quantified via ICP-MS. Metal accumulation levels were determined using the relative isotopic prevalence of195Pt and197Au. Experiments were performed in triplicate (n = 3), and data are reported as mean ± SD. Statistical analysis was performed using a two-way ANOVA followed by Tukey’s post hoc test.

[0651] Metal Accumulation in Organelles

[0652] 10 x 106CT26 cells were seeded in T-150 flasks (50 mL RPMI-1640) containing 10% FBS and 2% P / S. After incubating overnight, the medium was replaced, and the cells were treated with either a 1:1:1 mixture of Au(I)-amine + oxaliplatin + gemcitabine or Pt(IV)-Au(I) Gen 2 at 1 pM concentration for 24 h. The resulting cell monolayers were washed twice with cold PBS, harvested with trypsin, counted and resuspended in PBS for a total volume of 1000 pL. Isolation of nuclei, cytoplasm, and mitochondria was carried out using a reported procedure (Dos Santos et al., 2024, Anal. Biochem., 687, 115445). Samples were quantified via ICP-MS. Metal accumulation levels were determined using the relative isotopic prevalence of195Pt and197AU. Experiments were performed in triplicate (n = 3), and statistical analysis was carried out using a two-way ANOVA followed by Tukey’s post hoc test.

[0653] Extracellular A TP Release

[0654] Extracellular ATP was quantified following the RealTime-Glo Extracellular ATP protocol (Promega catalogue number GA5010) after 24 h exposure of CT26 cells to eitherAttorney Docket No: 206161-0078-00WO oxaliplatin (150 pM), gemcitabine (0.5 pM) or Pt(IV)-Au(I) Gen 2 (1.25 pM). Experiments were performed in triplicate (n = 3), and statistical analysis was carried out using a one-way ANOVA followed by Tukey’s post hoc test.

[0655] HMGB1 Release

[0656] HMGB1 release was quantified using a commercially available mouse HMGB-1 ELISA kit (Invitrogen catalogue number EEL 102) after 24 h exposure of CE26 cells to either oxaliplatin (150 pM), gemcitabine (0.5 pM) or Pt(IV)-Au(I) Gen 2 (1.25 pM). Experiments were performed in triplicate (n = 3), and statistical analysis was carried out using a one-way ANOVA followed by Tukey’s post hoc test.

[0657] CRT Translocation Confocal Microscopy

[0658] CT26 cells were seeded at a density of 3 × 105cells / dish overnight in 35 mm dishes with a 10 mm glass diameter containing a poly-D lysine coat (Mat Tek P35GC-1.5- 10-C). Cells were then incubated overnight at 37 C in the presence of 5% CO2. After overnight incubation, the media was removed and each dish was given new media with the respective treatments (oxaliplatin - 300 pM, gemcitabine - 1 pM, Pt(IV)-Au(I) Gen 2 - 2.5 pM). Untreated group received media only. Cells were incubated for another 4 hours at 37 °C. Post incubation, the media was removed, and the cells washed (3x) with HBSS. Cells were then fixed with 4% paraformaldehyde for 20 min at RT. After fixation, the cells were washed (3x) with HBSS. For staining, cells were incubated with CRT polyclonal antibody (Invitrogen PA3-900) in cell staining buffer (Biolegend 420201) at a 1:200 dilution for 1 h on ice. Cells were washed (3x) with HBSS and kept in the dark. Next, the cells were stained with goat anti-rabbit IgG Alexa Fluor 488 antibody (Invitrogen A-l 1008) in cell staining buffer at a 1:500 dilution for 30 min on ice. The cells were washed (3x) with HBSS stained with Hoechst 1 pg / mL and wheat germ agglutinin Alexa Fluor 633 5 pg / mL (Invitrogen W21404) in PBS for 5 min at RT and directly imaged fluorescently on a Leica SP5 white light laser confocal microscope. Images were taken with a 63X, NA 1.4 objective.

[0659] RNA Sequencing (RNA-Seq)

[0660] CT26 cells were seeded at a density of 1 x 106cells / 10 mL in a T75 tissue culture flask. All cells came from the same starting flask. Once seeded, the flasks were incubated for 24 hours.Attorney Docket No: 206161-0078-00WO After 24 hours old media was removed from each flask and 10 mL of fresh media containing each compound at the IC50concentration was added. For the control flask only 10 mL of fresh media was added (untreated). After 4 hour incubation at 37 °C in the presence of 5% CO2, the media was removed from each flask and the cells were washed with warm PBS and treated with trypsin. The trypsin was quenched with media and the cells were transferred to 15 mL centrifuge tubes where they were pelleted. The media was discarded, and the cell pellet was washed 3x with PBS. Cells were then re-suspended in PBS and treated with QIAzol Lysis Reagent and homogenized by vigorous vortexing and shaking. The QIAGEN RNeasy Plus Universal Mini Total RNA protocol was then picked up at Step 4. RNA was eluted in two volumes of 30 pL each for a final volume of 60 pL RNA. The RNA concentration was measured using a Thermo Scientific NanoDrop 2000c Spectrophotometer. The Agilent TapeStation system was used to ensure the integrity of the RNA through visualization of ribosomal subunits. Samples were submitted for microarray analysis, from 3 independent experiments to the Interdisciplinary Center for Biotechnology Research at the University of Florida. Common genes between different comparisons within three biological replicates were analyzed based on the cutoffs (abs(log2(FC)) > 1, and the FDR-corrected P-value < 0.05. Analysis settings for Ingenuity Canonical Pathways: Cutoff before duplicate resolution = True, Resolve duplicate on Expression log fold change, Color using Expression log fold change, Cutoff for Expression log fold change down regulated -1 and up regulated 1.0, Cutoff for Expression value 0.05, Reference set Ingenuity Knowledge Base (Genes Only).

[0661] All references throughout this application, for example patent documents, including issued or granted patents or equivalents and patent application publications, and non-patent literature documents or other source material are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference.

[0662] All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. References cited herein are incorporated by reference herein in their entirety to indicate the state of the art, in some cases as of their filing date, and it is intended that this information can be employed herein, if needed, to exclude (for example, to disclaim) specific embodiments that are in the prior art.

Claims

Attorney Docket No: 206161-0078-00WOCLAIMSWe claim:

1. A multifunctional prodrug comprising a first activatable anticancer agent, a second activatable anticancer agent, and platinum(IV), wherein the first activatable anticancer agent is linked to the second activatable anticancer agent via the platinum(IV).

2. The multifunctional prodrug of claim 1, wherein reduction of the platinum(IV) to platinum(II) releases a first active anticancer agent and a second active anticancer agent.

3. The multifunctional prodrug of claim 1, wherein the first activatable anticancer agent comprises a gold(I) complex.

4. The multifunctional prodrug of claim 1, wherein the first activatable anticancer agent comprises a structure of FormulFormula (I),wherein:each instance of R1, R2, and R3is independently selected from the group consisting of hydrogen, deuterium, halogen, Ci-Cio alkyl, Ci-Cio haloalkyl, C2-C10 alkenyl, C2-C10 haloalkenyl, C2-C10 alkynyl, C2-C10 haloalkynyl, C3-C10 cycloalkyl, and combinations thereof;n, m, and o are all integers from 0 to 5; andAttorney Docket No: 206161-0078-00WOrepresents a connection to the rest of the multifunctional prodrug.

5. The multifunctional prodrug of claim 1, wherein the first activatable anticancer agent comprises the structure Formula (III)Formula (III),wherein:A" represents a connection to the rest of the multifunctional prodrug.

6. The multifunctional prodrug of claim 1, wherein the first active anticancer agent comprises7. The multifunctional prodrug of claim 1, wherein the second activatable anticancer agent comprises:a) a carboxylic acid, conjugated to the platinum(IV); orAttorney Docket No: 206161-0078-00WOb) a primary or secondary alcohol, which may be functionalized into a carbonate, which is conjugated to the platinum(IV); orc) a primary or secondary amine, which may be functionalized into a carbonate, which is conjugated to the platinum(IV).

8. The multifunctional prodrug of claim 1, wherein the multifunctional prodrug comprises a structure of Formula (IV)Formula (IV),wherein:" represents a connection to the second activatable anticancer agent, and L1, L2, L3, and L4each represent monoanionic or monodentate ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentate ligand.

9. The multifunctional prodrug of claim 1, wherein the second activatable anticancer agent comprises gemcitabine, floxuridine, cytarabine, cladribine, fludarabine, and nelarabine.

10. The multifunctional prodrug of claim 1, wherein the second activatable anti cancer agent comprisesAttorney Docket No: 206161-0078-00WOwhereinrepresents a connection to the platinum(IV).

11. The multifunctional prodrug of claim 1, wherein the multifunctional prodrug comprises a structure of Formula (V) or Formula (IV)Formula (V),Attorney Docket No: 206161-0078-00WOFormula (VI),wherein:L1, L2, L3, and L4each represent monoanionic or monodentate ligands, or wherein L1and L2together form a bidentate ligand and / or L3and L4together form a bidentate ligand.

12. The multifunctional prodrug of claim 1, wherein the second activatable anticancer agent comprises the platinum(IV).

13. The multifunctional prodrug of claim 1, wherein the second active anticancer agent comprises cisplatin, carboplatin, or oxaliplatin.

14. The multifunctional prodrug of claim 1, wherein the multifunctional prodrug comprises a structure of Formula (VII):Attorney Docket No: 206161-0078-00WOFormula (VII),wherein:represents hydroxide, halide, cyanide, azide, nitrite, thiocyanate, nitrate, formate, and acetate, or a connection to at least one additional activatable anticancer agent.

15. The multifunctional prodrug of claim 1, wherein the multifunctional prodrug is selected from the group consisting of:Attorney Docket No: 206161-0078-00WOand pharmaceutically acceptable salts and solvates thereof.

16. A method of killing a cancer cell, comprising contacting the cancer cell with the multifunctional prodrug of any one of claims 1-15.Attorney Docket No: 206161-0078-00WO17. The method of:a) inducing immunogenic cell death (ICD) in a subject in need thereof; or b) treating cancer in a subject in need thereof;wherein the method comprises administering to the subject the multifunctional prodrug of any one of claims 1-15.

18. A method of treating cancer in a subject in need thereof, comprising administering to the subject the multifunctional prodrug of any one of claims 1-15.

19. The multifunctional prodrug of any one of claims 1-15, for use in a method of:a) killing a cancer cell;b) inducing ICD in a subject in need thereof; orc) treating cancer in a subject in need thereof.

20. Use of the multifunctional prodrug of any one of claims 1-15, in the manufacture of a medicament for:a) inducing ICD in a subject in need thereof; orb) treating cancer in a subject in need thereof.

21. A pharmaceutical composition comprising the multifunctional prodrug of any one of claims 1-15 and a pharmaceutically acceptable carrier.